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Abstract
Background
Melanoma has one of the fastest rising incidence rates of any cancer. It accounts for a small percentage of skin cancer
cases but is responsible for the majority of skin cancer deaths. History-taking and visual inspection of a suspicious lesion by
a clinician is usually the first in a series of ‘tests’ to diagnose skin cancer. Establishing the accuracy of visual inspection alone
is critical to understating the potential contribution of additional tests to assist in the diagnosis of melanoma.
Objectives
To determine the diagnostic accuracy of visual inspection for the detection of cutaneous invasive melanoma and
intraepidermal melanocytic variants in adults with limited prior testing and in those referred for further evaluation of a
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suspicious lesion. Studies were separated according to whether the diagnosis was recorded face-to-face (in-person) or
based on remote (image-based) assessment.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central
Register of Controlled Trials; ; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing Trials
Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International Clinical Trials
Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Test accuracy studies of any design that evaluated visual inspection in adults with lesions suspicious for melanoma,
compared with a reference standard of, either histological confirmation or clinical follow-up. Studies reporting data for ‘clinical
diagnosis’ where dermoscopy may or may not have been used were excluded.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form
(based on QUADAS-2). We contacted authors of included studies where information related to the target condition or
diagnostic threshold were missing. We estimated summary sensitivities and specificities per algorithm and threshold using
the bivariate hierarchical model. We investigated the impact of: in-person test interpretation; use of a purposely developed
algorithm to assist diagnosis; and observer expertise.
Main results
Forty-nine publications reporting on a total of 51 study cohorts with 34,351 lesions (including 2499 cases) were included,
providing 134 datasets for visual inspection. Across almost all study quality domains, insufficient information was provided in
the majority of study reports to allow the risk of bias to be judged, while concerns regarding applicability of study findings
were scored as ‘High’ in three of four domains assessed. Selective participant recruitment, lack of detail regarding the
threshold for deciding on a positive test result, and lack of detail on observer expertise were particularly problematic.
Attempts to analyse studies by degree of prior testing were hampered by a lack of relevant information and by the restricted
inclusion of lesions selected for biopsy or excision. Accuracy was generally much higher for in-person diagnosis compared
to image-based evaluations (relative diagnostic odds ratio of 8.54, 95% CI 2.89, 25.3, P<0.001). Meta-analysis of in-person
evaluations that could be clearly placed on the clinical pathway showed a general trade-off between sensitivity and
specificity, with the highest sensitivity (92.4%, 95% CI 26.2, 99.8%) and lowest specificity (79.7%, 95% CI 73.7, 84.7%)
observed in participants with limited prior testing (n = 3 datasets). Summary sensitivities were lower for those referred for
specialist assessment but with much higher specificities (e.g. sensitivity 76.7% (95% CI 61.7, 87.1%) and specificity 95.7%
(95% CI 89.7, 98.3%) for lesions selected for excision, n = 8 datasets). These differences may be related to differences in
the spectrum of included lesions, differences in the definition of a positive test result, or to variations in observer expertise.
We did not find clear evidence that accuracy is improved by the use of any algorithm to assist diagnosis in all settings.
Attempts to examine the effect of observer expertise in melanoma diagnosis were hindered due to poor reporting.
Authors' conclusions
Visual inspection is a fundamental component of the assessment of a suspicious skin lesion; however, the evidence
suggests that melanomas will be missed if visual inspection is used on its own. The evidence to support its accuracy in the
range of settings in which it is used is flawed and very poorly reported. Although published algorithms do not appear to
improve accuracy, there is insufficient evidence to suggest that the ‘no algorithm’ approach should be preferred in all
settings. Despite the volume of research evaluating visual inspection, further prospective evaluation of the potential added
value of using established algorithms according to the prior testing or diagnostic difficulty of lesions may be warranted.
Plain language summary
What is the diagnostic accuracy of visual inspection of skin lesions with the naked eye for diagnosis of
melanoma in adults?
What is the aim of the review?
Melanoma is one of the most dangerous forms of skin cancer. The aim of this Cochrane Review was to find out the accuracy
of visual inspection of suspicious skin lesions with the naked eye to diagnose melanoma. The Review also investigated
whether diagnostic accuracy using visual inspection of suspicious skin lesions on a patient in-person differed to diagnostic
accuracy of visual inspection of images of suspicious skin lesions. Researchers in Cochrane included 19 studies to answer
this question.
Why is the diagnostic accuracy of visual examination of skin lesions suspected to be melanomas important?
Not recognising a melanoma when it is present (a false negative test result) delays surgery to remove it, risking cancer
spreading to other organs in the body and possibly death. Diagnosing a skin lesion as a melanoma when it is not (a false
positive result) may result in unnecessary surgery, further investigations, and patient anxiety. Visual inspection of suspicious
skin lesions by a clinician using the naked eye is usually the first of a series of ‘tests’ to diagnose melanoma. Knowing the
diagnostic accuracy of visual inspection alone is important to decide whether additional tests are needed to improve
accuracy to an acceptable level.
What was studied in the review?
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Researchers sought to find out the diagnostic accuracy of visual inspection of suspicious skin lesions on a patient in-person
and the diagnostic accuracy of visual inspection of images of suspicious skin lesions. Researchers also sought to find out
whether diagnostic accuracy was improved by use of a visual inspection checklist or by an increase in level of clinical
expertise; they considered the diagnostic accuracy of the first visual inspection of a lesion, for example, by a GP, and of
lesions which had been referred for further evaluation, for example, by a dermatologist.
What are the main results of the review?
Only 19 studies (17 in-person studies and 2 image-based studies) were clear whether the test was the first visual inspection
of a lesion or was a visual inspection following referral (for example, when patients are referred by a general practitioner to
skin specialists for visual inspection).
First visual inspection in-person (3 studies)
The results of 3 studies of 1339 suspicious skin lesions suggest that in a group of 1000 lesions, of which 90 (9%) actually are
melanoma:
- An estimated 268 will have a visual inspection result indicating melanoma is present. Of these, 185 will not be melanoma
and will result in an unnecessary biopsy (false positive results).
- An estimated 732 will have a visual inspection result indicating that melanoma is not present. Of these, 7 will actually have
melanoma and would not be sent for biopsy (false negative results).
Two further studies restricted to 4228 suspicious skin lesions that were all selected to be excised found similar results.
Visual inspection in-person after referral, all lesions selected to be excised (8 studies)
The results of eight studies of 5331 suspicious skin lesions suggest that in a group of 1000 lesions, of which 90 (9%) actually
are melanoma:
- An estimated 108 will have a visual inspection result indicating melanoma is present, and of these, 39 will not be melanoma
and will result in an unnecessary biopsy (false positive results).
- Of the 892 lesions with a visual inspection result indicating that melanoma is not present, 21 will actually be melanoma and
would not be sent for biopsy (false negative results).
Overall, the number of false positive results (diagnosing a skin lesion as a melanoma when it is not) was observed to be
higher and the number of false negative results (not recognising a melanoma when it is present) lower for first visual
inspections of suspicious skin lesions compared to visual inspection following referral.
Visual inspection of images of suspicious skin lesions (2 studies)
Accuracy was much lower for visual inspection of images of lesions compared to visual inspection in-person.
Value of visual inspection checklists
There was no evidence that use of a visual inspection checklist or the level of clinical expertise changed diagnostic accuracy.
How reliable are the results of the studies of this review?
In the majority of included studies, the diagnosis of melanoma was made by lesion biopsy and the absence of melanoma
was confirmed by biopsy or by follow up over time to make sure the skin lesion remained negative for melanoma*. Biopsy or
follow-up are likely to have been reliable methods for deciding whether patients really had melanoma. In a few studies, the
absence of melanoma was made by expert diagnosis, which is less likely to have been a reliable method for deciding
whether patients really had melanoma. There was lots of variation in the results of the studies in this review. Poor reporting
of study conduct made assessment of the reliability of studies difficult. Selective inclusion of particular types of skin lesion,
lack of detail about how the diagnosis of melanoma was made, and lack of detail on the expertise of the doctor doing the
visual inspection were particularly problematic.
Who do the results of this review apply to?
Thirteen studies were undertaken in Europe (68%), with the remainder undertaken in Asia (n = 1), Oceania (n = 4), North
America (n = 1). Mean age ranged from 30 to 73.6 years (reported in 10 studies). The percentage of individuals with
melanoma ranged between 4% and 20% in first visualised lesions and between 1% and 50% in studies of referred lesions. In
the majority of studies, the lesions were unlikely to be representative of the range of those seen in practice, for example, only
including skin lesions of a certain size or with a specific appearance. In addition, variation in the expertise of clinicians
performing visual inspection and in the definition used to decide whether or not melanoma was present across studies makes
it unclear as to how visual inspection should be carried out and by whom in order to achieve the accuracy observed in
studies.
What are the implications of this review?
Error rates from visual inspection are too high for it to be relied upon alone. Although not evaluated in this review, other
technologies need to be used to ensure accurate diagnosis of skin cancer. There is considerable variation and uncertainty
about the diagnostic accuracy of visual inspection alone for the diagnosis of melanoma. There is no evidence to suggest that
visual inspection checklists reliably improve the diagnostic accuracy of visual inspection, so recommendations cannot be
made about when they should be used. Despite the existence of numerous research studies, further, well-reported studies
assessing the diagnostic accuracy of visual inspection with and without visual inspection checklists and by clinicians with
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different levels of expertise are needed.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies, biopsy, clinical follow up, or specialist clinician diagnosis were the reference standards.
Background 
This review is one of a series of Cochrane Diagnostic Test Accuracy (DTA) reviews on the diagnosis and staging of
melanoma and keratinocyte skin cancers conducted for the National Institute for Health Research (NIHR) Cochrane
Systematic Reviews Programme. Appendix 1 shows the content and structure of the programme. Appendix 2 provides a
glossary of terms used, and a table of acronyms used is provided in Appendix 3.
Target condition being diagnosed
Melanoma is one of the most aggressive forms of skin cancer, with the potential to metastasise to other parts of the
body via the lymphatic system and blood stream. It accounts for a small percentage of skin cancer cases but is
responsible for up to 75% of skin cancer deaths (Boring 1994; Cancer Research UK 2017).
Melanoma arises from uncontrolled proliferation of melanocytes - the epidermal cells that produce pigment or melanin. It
most commonly arises in the skin but can occur in any organ that contains melanocytes, including mucosal surfaces, the
back of the eye, and lining around the spinal cord and brain. Cutaneous melanoma refers to a skin lesion with malignant
melanocytes present in the dermis, and includes superficial spreading, nodular, acral lentiginous, and lentigo maligna
melanoma variants (see Figure 1). Melanoma in situ refers to malignant melanocytes that are contained within the
epidermis and have not yet invaded the dermis, but are at risk of progression to melanoma if left untreated. Lentigo
maligna, a subtype of melanoma-in-situ in chronically sun-damaged skin, denotes another form of proliferation of
abnormal melanocytes. Lentigo maligna can progress to invasive melanoma if its growth breaches the dermo-
epidermal junction during a vertical growth phase (when it becomes known as 'lentigo maligna melanoma');
however, its rate of malignant transformation is both lower and slower than for melanoma in situ (Kasprzak 2015). Melanoma
in situ and lentigo maligna are both atypical intraepidermal melanocytic variants.
The incidence of melanoma rose to over 200,000 newly diagnosed cases worldwide in 2012 (Erdmann 2013; Ferlay 2015
), with an estimated 55,000 deaths (Ferlay 2015). In the UK, melanoma has one of the fastest rising incidence rates of
any cancer and has the biggest projected increase in incidence between 2007 and 2030 (Mistry 2011
). In the decade leading up to 2013, age standardised incidence increased by 46%, with
14,500 new cases in 2013 and 2,459 deaths in 2014 (http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/skin-cancer/incidence). While overall incidence rates are higher in women than in
men, the rate of incidence in the latter is increasing faster than in women (Arnold 2014).
The rising incidence in melanoma is thought to be primarily related to an increase in recreational sun exposure and
tanning bed use and an increasingly ageing population with higher lifetime ultraviolet (UV) exposure, in conjunction with
possible earlier detection (Linos 2009; Belbasis 2016). Putative risk factors are reviewed in detail elsewhere (Belbasis 2016
), but can be broadly divided into host or environmental factors. Host factors include fair skin and light hair or eye
colour; older age (Geller 2002); male sex (Geller 2002); previous skin cancer (Tucker 1985); predisposing skin
lesions, e.g. high melanocytic naevus counts (Gandini 2005), clinically atypical naevi (Gandini 2005), or large
congenital naevi (Swerdlow 1995); genetically inherited skin disorders e.g. xeroderma pigmentosum (Lehmann 2011
); and a family history of melanoma (Gandini 2005). Environmental factors include recreational, occupational, and
work-related exposure to sunlight (both cumulative and episodic burning) (Gandini 2005; Armstrong 2017); artificial
tanning (Boniol 2012); and immunosuppression, e.g. in organ transplant recipients or human immunodeficiency virus
(HIV)-positive individuals (DePry 2011). Lower socioeconomic class may be associated with delayed presentation
and thus more advanced disease at diagnosis (Reyes-Ortiz 2006).
A database of over 40,000 US patients from 1998 onwards which assisted the development of the eighth
American Joint Committee on Cancer (AJCC) Staging System indicated a five-year survival of 99% for stage IA
melanoma (melanoma <=1mm thick without ulceration, mitosis or involvement of the lymph nodes), dropping to
anything between 32% and 93% in stage III disease (melanoma of any thickness with metastasis to the lymph
nodes) depending on tumour thickness, the presence of ulceration and number of involved nodes (Gershenwald 2017).
Before the advent of targeted and immuno-therapies, stage IV melanoma (melanoma disseminated to distant sites /
visceral organs) was associated with median survival of six to nine months, one year survival rate of 25%, and three
year survival of 15% (Balch 2009; Korn 2008).
Between 1975 and 2010, five year relative survival for melanoma (i.e. not including deaths from other causes) in the US
increased from 80% to 94%, with survival for localised, regional, and distant disease estimated at 99%, 70%, and 18%,
respectively in 2010 (Cho 2014). Overall, mortality rates however showed little change, at 2.1 per 100,000 deaths in
1975 and 2.7 per 100,000 in 2010 (Cho 2014). Increasing incidence in localised disease over the same period (from 5.7
to 21 per 100,000) suggests that much of the observed improvement in survival may be due to earlier detection and
heightened vigilance (Cho 2014). New targeted therapies for stage IV melanoma (e.g. BRAF inhibitors) have
improved survival and immunotherapies are evolving such that long term survival is being documented (Pasquali 2018
). No new data regarding the survival prospects for patients with stage IV disease were analysed for the AJCC
8 staging guidelines due to lack of contemporary data (Gershenwald 2017).
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Treatment of melanoma
For primary melanoma, the mainstay of definitive treatment is early detection and excision of the lesion, to remove
both the tumour and any malignant cells that might have spread into the surrounding skin (Garbe 2016; Marsden 2010; 
NICE 2015; SIGN 2017; Sladden 2009). Recommended surgical margins vary according to tumour thickness (Garbe 2016
) and stage of disease at presentation (NICE 2015).
Index test(s)
For the purposes of our series of reviews, each component of the diagnostic process, including visual inspection or clinical
examination, is considered a diagnostic or index ‘test', the accuracy of which can be established in comparison with a
reference standard of diagnosis, either alone or in combination with other available technologies that may assist the
diagnostic process.
Clinical history taking to identify risk factors and visual inspection of the lesion, surrounding skin and comparison
with other lesions on the rest of the body is fundamental to the diagnosis of skin cancer. The strongest common
phenotypic risk factor is the presence of atypical naevi; typically the presence of over a hundred moles or naevi of
abnormal appearance that may pose diagnostic challenges (Goodson 2010; Rademaker 2010; Salerni 2012). In
the UK, clinical examination is typically done at two decision points – first in the general practice (GP) surgery
where a decision is made to refer or not to refer, and then a second time by a dermatologist or other secondary
care clinician where a decision is made to biopsy or not. Specialist advice can also be sought using
teledermatology, where lesion images are forwarded with variable clinical information (such as age, gender, and
location of lesion) to specialist clinics or to commercial organisations for interpretation. The accuracy of these
diagnostic encounters (defined as the proportion of 'correct' diagnoses, i.e. true positive plus true negative
diagnoses out of the total number of diagnoses) is known to vary according to qualifications and experience (Westerhoff
2000; Morton 1998); the accuracy of ‘image-based’ as opposed to face-to-face diagnosis is less clear.
Research into the cognitive processes involved in dermatological diagnoses suggests that two main strategies are
employed simultaneously and iteratively (Elstein 2002; Norman 1989; Norman 2009). Non-analytical pattern
recognition formulates an initial hypothesis; identification is made implicitly, without conscious thought or reference to
specific rules and hidden from the conscious view of the diagnostician (Norman 2009). Analytical pattern recognition
using more explicit rules based on conscious analytical reasoning is then employed to test the initial hypothesis.
Analytical pattern recognition has been described as the “careful and systematic gathering of data and weighing the
elicited information against mental rules” (Norman 2009). The balance between non-analytical and analytical reasoning
varies between clinicians, according to factors such as experience and familiarity with the diagnostic question.
Various attempts have been made to formalise the “mental rules” involved in analytical pattern recognition for melanoma,
ranging from setting out criteria that should be considered (e.g. ‘pattern analysis’; Sober 1979; Friedman 1985) to
formal scoring systems with explicit numerical thresholds (MacKie 1985; MacKie 1990). The most commonly used algorithms
are described in detail in Appendix 4.
The ABCD (asymmetry, border irregularity, colour variegation, diameter > 6 mm) algorithm of clinical warning signs
was developed in 1985 to help distinguish melanoma from a benign naevus (Friedman 1985), and then extended to
include an E for 'enlargement' criterion (Thomas 1998). As a result of its simplicity, ABCD(E) is now widely
advocated for use by non-experts or lay persons (American Academy of Dermatology 2015). The approach has been
criticised for its inability to capture nodular and amelanotic melanomas, which account for a relatively small proportion
(~15% to 20%) of incident melanomas but a large proportion (~50%) of melanoma-related deaths (Moreau 2013; Shaikh
2012). In addition, up to a third of melanomas may be < 6 mm in diameter (Maley 2014), a proportion which is likely to
increase due to improved skin surveillance. The validity of ABCD(E) as a useful tool for the lay public has also been
called into question (Girardi 2006, Liu 2005, Aldridge 2011). Subsequent modifications have been suggested,
including altering the meaning of the ABCD acronym for use in paediatric populations (Cordoro 2013); changing 'D'
to 'dark' (Goldsmith 2014)); or changing the acronym altogether (e.g. CCC for colour, contour, and change (Moynihan 1994);
or "Do UC" the melanoma for different, uneven, changing (Yagerman 2014)). To date, the latter three have not been
evaluated in populations with lesions suggestive for melanoma.
The seven-point checklist assessing change in size, shape, colour, inflammation, crusting or bleeding, sensory
change, or diameter ≥ 7 mm was developed by UK researchers as a guide to help non-dermatologists detect possible
melanoma (MacKie 1985; MacKie 1990). The revised weighted version (MacKie 1990) is currently recommended for
general practitioner (GP) use in the evaluation of pigmented lesions (NICE 2015). A primary care based evaluation
found moderately good performance for the identification of clinically significant lesions (including malignant and
premalignant lesions as disease positive) in primary care (sensitivity and specificity for the presence of ≥ 3 features
were 62.7% and 65.0%, respectively), with higher sensitivity for the detection of melanoma (80.6%) at the expense of
low specificity (61.7%) (Walter 2013).
Unlike most formalised rules, the 'ugly duckling' sign is based on differential pattern recognition where abnormal lesion
identification is achieved by noticing the odd one out, i.e. a melanoma will be the pigmented lesion that does not match
the rest of a person's naevi, for example a very dark or pale/pink lesion that is different in colour compared to the rest of
the pigmented naevi (Grob 1998). Although ugly duckling is inherently a form of subjective pattern recognition,
sensitivity has been reported to be 100% for pigmented-lesion experts and 85% for non-clinicians (Scope 2008).
The assumption that an individual has a "normal" naevus phenotype is debatable, however. Many individuals have
multiple 'atypical' pigmented lesions which, although very similar morphologically, allow malignancy to easily
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disguise itself amidst an abnormal complex of pigmented lesions (also referred to as ‘The Little Red Riding Hood’
phenomenon) (Mascaro 1998).
Clinical Pathway 
The diagnosis of melanoma can take place in primary, secondary, and tertiary care settings by both generalist and
specialist healthcare providers. In the UK, people with concerns about a new or changing lesion will usually present
first to their general practitioner or less commonly directly to a specialist in secondary care, which could include a
dermatologist, plastic surgeon, general surgeon or other specialist surgeon (such as an ear, nose, and throat (ENT)
specialist or maxillofacial surgeon), or ophthalmologist (Figure 2). Current UK guidelines recommend that all
suspicious pigmented lesions presenting in primary care should be assessed by taking a clinical history and visual
inspection using the seven-point checklist (MacKie 1990); lesions suspected to be melanoma should be referred
urgently for appropriate specialist assessment within two weeks (Chao 2013; Marsden 2010; NICE 2015c; SIGN 2017).
Teledermatology consultations can aid more appropriate triage of lesions into urgent referral; non-urgent secondary care
referral (e.g. for suspected basal cell carcinoma); or where available, referral to an intermediate care setting, e.g. clinics run
by GPs with a special interest in dermatology. The distinction between setting and examiner qualifications and experience is
important as specialist clinicians might work in primary care settings (for example, in the UK, general practitioners (GPs) with
a special interest in dermatology and skin surgery who have undergone appropriate training), and generalists might practice
in secondary care settings (for example, plastic surgeons who do not specialise in skin cancer). The level of skill and
experience in skin cancer diagnosis will vary for both generalist and specialist care providers and will also impact on test
accuracy.
The specialist clinician will also use history-taking and visual inspection of the lesion (in comparison with other lesions on the
skin), usually in conjunction with dermoscopic examination, to inform a clinical decision. If melanoma is suspected, then
urgent excision biopsy is recommended; for suspected cutaneous squamous cell carcinoma (cSCC) urgent excision with
predetermined surgical margins. Other lesions such as basal cell carcinoma (BCC) or pre-malignant lesions such as lentigo
maligna may also be referred for a diagnostic biopsy, followed by appropriate treatment or further surveillance or
reassurance and discharge.
Prior test(s)
Although smartphone applications and community-based teledermatology services can increasingly be directly
accessed by people who have concerns about a skin lesion (Chuchu 2018), visual inspection of a suspicious lesion by
a clinician is usually the first in a series of tests to diagnose skin cancer. In the UK first visual inspection of a suspicious
lesion usually takes place in primary care; however, in some countries, people with suspicious lesions can present
directly to a secondary care setting. Considering the degree of prior testing that study participants have undergone is
key to interpretation of resulting test accuracy indices, which are known to vary according to the spectrum or case-mix
of included participants (Lachs 1992; Moons 1997; Leeflang 2013; Usher-Smith 2016). Studies of people with suspicious
lesions at the initial clinical presentation stage ('test naïve') are likely to have a wider range of differential diagnoses and
include a higher proportion of people with benign diagnoses compared with studies of participants who have been referred
for a specialist opinion on the basis of visual inspection (with or without dermoscopy) by a generalist practitioner.
Furthermore, studies in more specialist settings may focus on equivocal or difficult to diagnose lesions rather than lesions
with a more general level of clinical suspicion. A simple categorisation of studies according to primary, secondary, or
specialist setting may not always adequately reflect differences in spectrum.
Role of index test(s)
Visual inspection and history-taking are key to diagnosing skin cancer and are always undertaken as part of a clinical
examination regardless of examiner experience and whatever additional technologies are available. For the generalist
practitioner, the key is to minimise the proportion of people who are referred unnecessarily and identify those lesions that
require urgent referral. For the specialist, the aim is not only to identify those in need of urgent excision due to invasive
cancer, but also to identify high risk lesions with considerable potential to progress to invasive disease, such as those with
severe dysplasia or in situ disease e.g. lentigo maligna, for example. Given differences in setting, prior testing, observer
qualifications, experience and training, the anticipated performance in terms of accuracy is likely to vary.
When diagnosing potentially life-threatening conditions such as melanoma, the consequences of falsely reassuring a person
that they do not have skin cancer can be serious and potentially fatal, as the resulting delay to diagnosis means that the
window for successful early treatment may be missed. To minimise these false-negative diagnoses, a good diagnostic test
will demonstrate high sensitivity and a high negative predictive value (NPV), where very few of those with a negative test
result will actually have a melanoma. Giving falsely positive test results (meaning the test has poor specificity and a high
false-positive rate) resulting in the removal of lesions that turn out to be benign is arguably less of an error than missing a
potentially fatal melanoma, but is not cost free. False-positive diagnoses not only cause unnecessary scarring from the
biopsy or excision procedure, but also increase patient anxiety whilst they await the definite histology results and increase
healthcare costs as the number needed to remove to yield one melanoma diagnosis increases.
Alternative test(s)
A number of other tests have been reviewed as part of our series of Cochrane DTA reviews on the diagnosis of
melanoma. In particular, dermoscopy has become an essential tool for the specialist clinician and is increasingly being
taken up in primary care settings. Dermoscopy (also referred to as dermatoscopy or epiluminescence microscopy or
ELM) uses a hand-held microscope and incident light (with or without oil immersion) to reveal subsurface images of the
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
6 / 256
skin at increased magnification of x 10 to x 100 (Kittler 2011). Used alongside clinical examination, dermoscopy has
been shown in some studies to increase the sensitivity of clinical diagnosis of melanoma from around 60% to as much
as 90% (Kittler 1999; Carli 2002; Bono 2006; Stanganelli 2000) with much smaller effects in others (Benelli 1999; Bono
2002). The accuracy of dermoscopy depends on the experience of the examiner (Kittler 2011), with accuracy when
used by untrained or less experienced examiners potentially no better than clinical inspection alone (Binder 1997; Kittler
2002).
Pattern analysis (Steiner 1987; Pehamberger 1993) is thought to be the most specific and reliable technique to aid
dermoscopy interpretation when used by specialists (Maley 2014); however, dermoscopic histological correlations
have been established and diagnostic algorithms developed based on colour, aspect, pigmentation pattern, and skin
vessels (e.g. the ABCD rule for dermoscopy (Nachbar 1994; Stolz 1994), the Menzies (Menzies 1996) and the
seven-point dermoscopy checklist (Annessi 2007; Argenziano 1998; Argenziano 2001; Gereli 2010; amongst others).
Dermoscopy used in addition to visual inspection (in-person evaluations) or used alone (dermoscopic image
interpretation remotely from the patient concerned) are the subject of a separate systematic review (Dinnes 2018).
A number of other tests which may have a role for the diagnosis of melanoma in a specialist setting have been
reviewed as part of our series of systematic reviews, including teledermatology, mobile phone applications,
reflectance confocal microscopy, optical coherence tomography, computer-aided diagnosis or artificial intelligence-
based techniques, and high frequency ultrasound (Dinnes 2015). Evidence permitting, the accuracy of available tests will be
compared in an overview review, exploiting within-study comparisons of tests and allowing the analysis and comparison of
commonly used diagnostic strategies where tests may be used singly or in combination.
We also considered and excluded a number of tests from review including tests used in the context of monitoring people,
such as total body photography of those with large numbers of typical or atypical naevi, and finally histopathological
confirmation following lesion excision. The latter is the established reference standard for melanoma diagnosis and will be
one of the standards against which the index tests are evaluated in these reviews.
Rationale
Our series of reviews of diagnostic tests used to assist clinical diagnosis in either clinical practice or in a research setting
aims to identify the most accurate approaches to diagnosis and provide clinical and policy decision-makers with the
highest possible standard of evidence on which to base diagnostic and treatment decisions. With increasing rates of
melanoma and a trend to adopt the use of dermoscopy and other high-resolution image analysis in primary care, the
anxiety around missing early cases needs to be balanced against the risk of over referrals, to avoid sending too many
people with benign lesions for a specialist opinion. It is questionable whether all skin cancers picked up by sophisticated
techniques contribute to morbidity and mortality or whether newer technologies run the risk of increasing false-positive
diagnoses. It is also possible that use of some technologies, e.g. widespread use of dermoscopy in primary care with no
training, could actually result in harm by missing melanomas if they are used as replacement technologies for traditional
history-taking and clinical examination of the entire skin. Many branches of medicine have noted the danger of such
"gizmo idolatry" amongst doctors (Leff 2008). The trend toward remote interpretation of dermatology images (whether clinical
or dermoscopic images) and the use of remote technologies that do not involve clinicians without substantive evidence could
further disrupt clinical pathways and healthcare payments as they may attract custom from the worried well, leaving an ever
decreasing pool of qualified doctors to pick up any resulting problems.
There are few available systematic reviews in the field. The literature searches for the most comprehensive
systematic reviews of visual inspection were carried out up to 2007 (Vestergaard 2008) or are focused on specific
clinical questions, for example, specific healthcare professionals (Corbo 2012 including only direct comparisons of the
accuracy of primary care physicians versus dermatologists, and Loescher 2011 reviewing the skin cancer
detection skills of advanced practice nurses) or settings (Herschorn 2012 including direct comparisons of visual
inspection versus dermoscopy in primary care). More recently, Harrington and colleagues (Harrington 2017) published a
systematic review of clinical prediction rules (or published algorithms) used to assist the diagnosis of melanoma; however,
the requirement for a clinical prediction rule does not allow comparison of accuracy with and without the use of an algorithm.
The critical question about the accuracy of visual inspection alone and the impact of examiner, prior patient testing,
underlying risk status, and the use of images for diagnosis needs to be answered before the potential contribution of
additional diagnostic tests can be set in context and appropriately placed in the diagnostic pathway.
This review follows a generic protocol which covers the full series of Cochrane DTA reviews for the diagnosis of
melanoma (Dinnes 2015). The Background and Methods sections of this review therefore use some text that was
originally published in the protocol (Dinnes 2015) and text that overlaps some of our other reviews (Dinnes 2018).
Objectives 
To determine the diagnostic accuracy of visual inspection for the detection of cutaneous invasive melanoma and atypical
intraepidermal melanocytic variants in adults.
Accuracy was estimated separately according to the prior testing undergone by study participants:
i. those with limited prior testing, i.e. primary presentation
ii. those referred for further evaluation of a suspicious lesion, i.e. referred participants
Accuracy was also estimated separately according to whether the diagnosis was recorded based on a face-to-face (in-
person) encounter or based on remote (image-based) assessment.
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Secondary objectives
For the identification of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants:
i. To determine the diagnostic accuracy of individual algorithms used to assist visual inspection; and
ii. To determine the effect of observer experience on diagnostic accuracy
For the alternative definitions of the target condition:
iii. To determine the diagnostic accuracy of visual inspection for the detection of invasive melanoma alone in adults.
iv. To determine the diagnostic accuracy of visual inspection for the detection of any skin cancer or skin lesion with a high
risk of progression to melanoma in adults (i.e. requiring excision).
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity for investigation across our series of reviews, as
outlined in our generic protocol (Dinnes 2015) and described in Appendix 5; however, our ability to investigate these was
necessarily limited by the available data on each individual test reviewed.
The sources of heterogeneity that were investigated for visual inspection were:
In-person versus image-based evaluations;
study setting: primary, community or private care versus secondary versus specialist clinics;
use of a diagnostic algorithm: no algorithm reported versus any named algorithm used;
type of reference standard: histology alone versus histology plus clinical follow-up or other reference standard; and
disease prevalence: <=10% versus >10%. The 10% cut-off was chosen based on advice from clinical co-authors (RB,
HW).
Methods 
Criteria for considering studies for this review
Types of studies 
We included test accuracy studies that allow comparison of the result of the index test with that of a reference standard,
including the following:
studies where all participants receive a single index test and a reference standard;
studies where all participants receive more than one index test(s) and reference standard;
studies where participants are allocated (by any method) to receive different index tests or combinations of index tests
and all receive a reference standard (between-person comparative studies (BPC));
studies that recruit series' of participants unselected by true disease status (referred to as case series for the purposes of
this review);
diagnostic case-control studies that separately recruit diseased and non-diseased groups (see Rutjes 2005); however, we
did not include studies that compared results for malignant lesions to those for healthy skin (i.e. with no lesion present).
both prospective and retrospective studies; and
studies where previously acquired clinical or dermoscopic images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2x2 contingency data or if they included less than five melanoma cases
or less than five benign lesions. The size threshold of five is arbitrary. However, such small studies are unlikely to add
precision to the estimate of accuracy.
Participants
We included studies in adults with pigmented skin lesions or lesions suspicious for melanoma or those at high risk of
developing melanoma, including those with a family history or previous history of melanoma skin cancer, atypical or
dysplastic naevus syndrome, or genetic cancer syndromes.
We excluded studies that recruited only participants with malignant or benign diagnoses.
We excluded studies conducted in children or which clearly reported inclusion of more than 50% of participants aged 16 and
under.
Index tests
Studies reporting accuracy data for visual inspection alone, with either image-based or in-person diagnosis, were eligible for
inclusion. For in-person visual inspection, diagnosis is undertaken in a clinic setting with the patient present (face-to-face
diagnosis). For these studies we assumed that patient history-taking would have taken place and is likely to have contributed
to lesion diagnosis; however, we did not specifically extract details of patient history-taking due to anticipated poor reporting
in the primary studies. For image-based studies, diagnosis is based on clinical or ‘macro’ images (photographs), remotely
from the study participant. For these studies, any additional patient information that was provided to assist diagnosis was
extracted.
All established algorithms or checklists to assist diagnosis by visual inspection were included. Studies developing new
algorithms or methods of diagnosis (i.e. derivation studies) were included if they:
used a separate independent 'test set' of participants or images to evaluate the new approach, or
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investigated lesion characteristics that had previously been suggested as associated with melanoma and the study
reported accuracy based on the presence or absence of particular combinations of characteristics.
Studies were excluded if they:
used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no
separate test set.
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983)
evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no
overall diagnosis of malignancy
reported accuracy data for ‘clinical diagnosis’ with no clear description as to whether the reported data related to visual
inspection alone
were based on the experience of a particular skin cancer clinic, where dermoscopy may or may not have been used on an
individual patient basis.
Although primary care clinicians can in practice be specialists in skin cancer, we considered primary care physicians as
generalist practitioners and dermatologists as specialists. Within each group, we extracted any reporting of special interest or
accreditation in skin cancer.
Target conditions
The primary target condition was defined as the detection of:
any form of invasive cutaneous melanoma or atypical intraepidermal melanocytic variants (i.e. including melanoma in situ,
or lentigo maligna, which has a risk of progression to invasive melanoma).
Two additional definitions of the target condition were considered in secondary analyses, namely the detection of:
any form of invasive cutaneous melanoma alone;
any skin lesion requiring excision. This latter definition includes melanoma plus other forms of skin cancer, such as basal
cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), as well as melanoma in situ, lentigo maligna, and
lesions with severe melanocytic dysplasia.
The diagnosis of the keratinocyte skin cancers, basal cell carcinoma, and squamous cell carcinoma as primary target
conditions are the subject of a separate series of reviews (Dinnes 2015a).
Reference standards
The ideal reference standard is histopathological diagnosis in all eligible lesions. A qualified pathologist or
dermatopathologist should perform histopathology. Ideally, reporting should be standardised detailing a minimum dataset to
include the histopathological features of melanoma to determine the American Joint Committee on Cancer (AJCC) Staging
System (e.g. Slater 2014). We did not apply reporting of a minimum dataset as a necessary inclusion criterion, but extracted
any pertinent information.
Partial verification (applying the reference test only to a subset of those undergoing the index test) was of concern given that
lesion excision or biopsy are unlikely to be carried out for all benign-appearing lesions within a representative population
sample. Therefore, to reflect what happens in reality, we accepted clinical follow-up of benign-appearing lesions as an
eligible reference standard, whilst recognising the risk of differential verification bias (as misclassification rates of
histopathology and follow-up will differ).
Additional eligible reference standards included cancer registry follow-up and 'expert opinion' with no histology or clinical
follow-up. Cancer registry follow-up is considered less desirable than active clinical follow-up, as follow-up is not carried out
within the control of the study investigators. Furthermore, if participant-based analyses as opposed to lesion-based analyses
are presented, it may be difficult to determine whether the detection of a malignant lesion during follow-up is the same lesion
that originally tested negative on the index test.
All of the above were considered eligible reference standards with the following caveats:
all study participants with a final diagnosis of the target disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical follow-up, and
at least 50% of all participants with benign lesions must have either a histological diagnosis or clinical follow-up to confirm
benignity.
Search methods for identification of studies 
Electronic searches 
The Information Specialist (SB) carried out a comprehensive search for published and unpublished studies. A single large
literature search was conducted to cover all topics in the programme grant (see Appendix 1 for a summary of
reviews included in the programme grant). This allowed for the screening of search results for potentially relevant
papers for all reviews at the same time. A search combining disease-related terms with terms related to the test
names, using both text words and subject headings was formulated. The search strategy was designed to capture
studies evaluating tests for the diagnosis or staging of skin cancer. As the majority of records were related to the
searches for tests for staging of disease, a filter using terms related to cancer staging and to accuracy indices was
applied to the staging test search, to try to eliminate irrelevant studies, for example, those using imaging tests to
assess treatment effectiveness. A sample of 300 records that would be missed by applying this filter was screened
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and the filter adjusted to include potentially relevant studies. When piloted on MEDLINE, inclusion of the filter for
the staging tests reduced the overall numbers by around 6000. The final search strategy, incorporating the filter (Appendix
6), was subsequently applied to all bibliographic databases as listed below. The final search result was cross-checked
against the list of studies included in five systematic reviews; our search identified all but one of the studies, and this study is
not indexed on MEDLINE. The Information Specialist devised the search strategy, with input from the Information Specialist
from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August 2016 for relevant published studies:
MEDLINE via OVID (from 1946);
MEDLINE In-Process & Other Non-Indexed Citations via OVID; and
EMBASE via OVID (from 1980).
We searched the following bibliographic databases to 30 August 2016 for relevant published studies:
the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 7, 2016, in the Cochrane Library;
the Cochrane Database of Systematic Reviews (CDSR) Issue 8, 2016 in the Cochrane Library;
Cochrane Database of Abstracts of Reviews of Effects (DARE) Issue 2, 2015;
CRD HTA (Health Technology Assessment) database Issue 3, 2016;
CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO from 1960).
We searched the following databases for relevant unpublished studies:
CPCI (Conference Proceedings Citation Index) via Web of Science™ (from 1990);
Zetoc (from 1993)
SCI Science Citation Index Expanded™ via Web of Science™ (from 1900, using the "Proceedings and Meetings
Abstracts" Limit function).
We searched the following trials registers:
The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov);
NIHR Clinical Research Network Portfolio Database (http://www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/);
The World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/).
We aimed to identify all relevant studies regardless of language or publication status (published, unpublished, in press, or in
progress). No date limits were applied.
Searching other resources 
We have included information about potentially relevant ongoing studies in the 'Characteristics of ongoing studies' tables. We
have screened relevant systematic reviews identified by the searches for their included primary studies, and included any
missed by our searches. We have checked the reference lists of all included papers, and subject experts within the author
team have reviewed the final list of included studies. No citation searching has been conducted.
Data collection and analysis 
Selection of studies 
Titles and abstracts were screened by at least one author (JDi or NC), with any queries discussed and resolved by
consensus. A pilot screen of 539 MEDLINE references showed good agreement (89% with a kappa of 0.77)
between screeners. Primary test accuracy studies and test accuracy reviews (for scanning of reference lists) of any
test used to investigate suspected melanoma, BCC, or cSCC were included at initial screening. Inclusion criteria (Appendix
7) were applied independently by both a clinical reviewer (from one of a team of twelve clinician reviewers) and a
methodologist reviewer (JDi or NC) to all full text articles, disagreements were resolved by consensus or by a third party
(JDe, CD, HW, and RM). Authors of eligible studies were contacted when insufficient data were presented to allow for the
construction of 2x2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently extracted data concerning
details of the study design, participants, index test(s) or test combinations and criteria for index test positivity, reference
standards, and data required to populate a 2x2 diagnostic contingency table for each index test using a piloted data
extraction form. Data were extracted at all available index test thresholds. Disagreements were resolved by consensus or by
a third party (JDe, CD, HW, and RM).
Authors of included studies were contacted where information related to final lesion diagnoses or diagnostic threshold were
missing. In particular, invasive cSCC (included as disease positive for one of our secondary objectives) is not always
differentiated from ‘in situ’ variants such as Bowen’s disease (which we did not consider as disease positive for any of our
definitions of the target condition). Authors of conference abstracts published from 2013 to 2015 were contacted to ask
whether full data were available. If no full paper was identified, we marked conference abstracts as 'pending' and will revisit
them in a future review update.
Dealing with multiple publications and companion papers
Where multiple reports of a primary study were identified, we maximised yield of information by collating all available data.
Where there were inconsistencies in reporting or overlapping study populations, we contacted study authors for clarification
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in the first instance. If this contact with authors was unsuccessful, we used the most complete and up-to-date data source
where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using the QUADAS-2 checklist (Whiting 2011), tailored to the
review topic (see Appendix 8). The modified QUADAS-2 tool was piloted on a small number of included full text articles. One
clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently assessed quality for the
remaining studies; any disagreement was resolved by consensus or by a third party where necessary (JDe, CD, HW, and
RM).
Statistical analysis and data synthesis
Separate analyses were conducted according to the point that study participants have reached in the clinical pathway
(numbered from 1 to 7 in Figure 3), the clarity with which the pathway could be determined (clear or unclear), and the
evaluation of in-person versus image-based diagnosis.
Our unit of analysis was the lesion rather than the patient. This is because (i) in skin cancer initial treatment is directed to the
lesion rather than systemically (thus it is important to be able to correctly identify cancerous lesions for each person), and (ii)
it is the most common way in which the primary studies reported data. Although there is a theoretical possibility of
correlations of test errors when the same people contribute data for multiple lesions, most studies include very few people
with multiple lesions and any potential impact on findings is likely to be very small, particularly in comparison with other
concerns regarding risk of bias and applicability. Where multiple algorithms were assessed in an individual study, datasets
were selected on the following preferential basis:
i. ‘no algorithm’ reported; data presented for clinician’s overall diagnosis or management decision
ii. pattern analysis or pattern recognition
iii. ABCD algorithm (or derivatives of)
iv. 7-point checklist (also referred to as Glasgow/MacKie checklist)
Where multiple thresholds per algorithm were reported, we included the standard or most commonly used threshold.
If data for multiple observers was reported, we used data for the most experienced observer, using single observer
diagnosis in preference to a consensus or average across observers. If we were unable to choose a dataset based on
the above ‘rules’, a random selection of one dataset per study was made. Data on the accuracy of dermoscopy, to
allow comparisons of tests, was included in a separate review in our series (Dinnes 2018).
For each analysis, estimates of sensitivity and specificity were plotted on coupled forest plots and in receiver operating
characteristic (ROC) space. For tests where commonly used thresholds were reported we estimated summary operating
points (summary sensitivities and specificities) with 95% confidence and prediction regions using the bivariate
hierarchical model (Chu 2006; Reitsma 2005). Where inadequate data were available for the model to converge
the model was simplified, first by assuming no correlation between estimates of sensitivity and specificity and
secondly by setting estimates of near zero variance terms to zero (Takwoingi 2015). Where all studies reported 100%
sensitivity (or 100% specificity) the number with disease (or no disease) was summed across studies and used to compute a
binomial exact 95% confidence interval.
For computation of likely numbers of true positive, false positive, false negative and true negative findings in the summary of
findings tables, these indicative values were applied to lower quartile, median and upper quartiles of the prevalence observed
in the study groups. In summary of findings tables we report these numbers for the average operating point on the SROC
curve.
Investigations of heterogeneity
Investigations of heterogeneity, comparisons between algorithms and according to observer experience were made by
comparing summary ROC curves using the hierarchical summary receiver-operator curves (HSROC) model (Rutter 2001).
HSROC curves allow incorporation of data at different thresholds and from different algorithms or checklists. We used an
HSROC model that assumed a constant SROC shape between tests and subgroups, but allowed for differences in threshold
and accuracy by addition of covariates. The significance of the differences between tests or subgroups was assessed by the
likelihood ratio test assessing differences in both accuracy and threshold, and by a Wald test on the parameter estimate
testing for differences in accuracy alone. Simpler models were fitted when convergence was not achieved due to small
numbers of studies, first assuming symmetric SROC curves (setting the shape term to zero), and then setting random effects
variance estimates to zero. Estimates of accuracy from HSROC models are presented as diagnostic odds ratios (DORs)
(estimated where the SROC curve crosses the sensitivity=specificity line) with 95% confidence intervals. Differences
between tests and subgroups from HSROC analyses are presented as relative diagnostic odds ratios (RDORs) with 95%
confidence intervals.
Bivariate models were fitted using the xtmelogit command in STATA 15 and HSROC models fitted using the NLMIXED
procedure in the SAS statistical software package (SAS 2012, version 9.3; SAS Institute, Cary, NC, USA) and the
metadas macro (Takwoingi 2010).
Sensitivity analyses
Sensitivity analyses, restricting analyses to studies at least risk of bias were planned; however, these were not conducted
due to insufficient study numbers.
Assessment of reporting bias
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Because of uncertainty about the determinants of publication bias for diagnostic accuracy studies and the inadequacy
of tests for detecting funnel plot asymmetry (Deeks 2005), we did not perform tests to detect publication bias.
Results 
Results of the search
A total of 34,347 unique references were identified and screened for inclusion. Of these, 1051 full text papers were reviewed
for eligibility for any one of the suite of reviews of tests to assist in the diagnosis of melanoma or keratinocyte skin cancer. Of
the 1051 full text papers assessed, 848 were excluded from all reviews in our series (see Figure 4 PRISMA flow diagram of
search and eligibility results).
Of the 232 studies tagged as potentially eligible for this review of visual inspection, 49 publications were included reporting
49 individual studies. Exclusions were mainly due to the inability to construct a 2x2 contingency table based on the data
presented (n = 54); the use of ineligible index tests (n = 39) (for example: reporting of data for visual inspection and
dermoscopy only (n = 12), reporting of data for ‘clinical diagnosis’ (n = 11), or for serial use of the index test in a follow-up
context (n = 7)); or not meeting our requirements for an eligible reference standard (n = 23). Other reasons for exclusion
included ineligible study populations (n = 20) (for example, recruiting only malignant or only benign lesions (n = 18)),
inadequate sample size (n = 14), ineligible definition of the target condition (n = 14) or with test interpretation by medical
students or laypersons (n = 6). A list of the 183 publications excluded from this review with reasons for exclusion is provided
in Characteristics of excluded studies, with a list of all studies excluded from the full series of reviews available as a separate
pdf.
The authors of 14 publications were contacted for the purposes of this review of visual inspection and, to date,
responses have been received with regard to 7 publications. One response allowed the inclusion of the study in the
review (Walter 2012), five provided clarifications on methods used on studies included (Bono 2006; Bourne 2012; 
Rosendahl 2011; Stanganelli 2000; Walter 2012); one replied with the information needed but the two studies could not
be included due to the evaluation of ‘clinical diagnosis’ (Youl 2007; Youl 2007a); and five replied but were not able to
provide the information requested in relation to eight study publications, one which could still be included (Menzies 2009
) and seven which could not (Fabbrocini 2008; Freeman 1963; Heal 2008; Menzies 2009; Warshaw 2009; Warshaw 2009a; 
Warshaw 2010).
The 49 included study publications report on a total of 51 cohorts of lesions and 134 datasets with 34,351 lesions and 2499
malignancies. The total number of study participants with suspicious lesions cannot be estimated due to lack of reporting in
study publications. Two thirds of studies (n = 32; 65%) also reported accuracy data for diagnosis using dermoscopy; these
comparisons are reported in Dinnes 2018. Seven studies reported data for additional tests including: teledermatology (n = 1)
and computer-assisted diagnosis techniques (n = 6).
Methodological quality of included studies
The overall methodological quality of all included studies (n = 49) is summarised in Figure 5 and Figure 6.
Across almost all study quality domains, insufficient information was provided in the majority of study reports to allow the risk
of bias to be judged, while applicability of study findings were scored as of ‘High’ concern in three of four domains assessed.
For participant selection, only 22% of studies (n = 11) were judged at low risk of bias and 27% (n = 13) were considered
high risk. Ten studies (20%) either used a case-control type design with separate selection of melanoma cases and
lesions with benign diagnoses (n = 6) or did not clearly describe the study design used (n = 5). Over half (55%; n = 27)
reported random or consecutive participant recruitment reported; the remaining 45% did not describe recruitment
methods. Over half of studies (53%) did not describe whether any exclusion criteria were applied and were judged as at
unclear risk of bias. Seven studies (14%) applied inappropriate participant exclusions, excluding ‘difficult to diagnose’
lesions such as awkwardly located lesions (Bono 2002; Morales Callaghan 2008; Unlu 2014); those with disagreement on
histopathology (de Giorgi 2012; Ek 2005; Zaumseil 1983); or dermoscopically ‘peculiar’ lesions (Carli 2003b).
Almost all cohorts (96%; n = 47) were considered at high concern for applicability of participants. In the majority of
cases (n = 41), high concern was due to restricted study populations: inclusion of only melanocytic (n = 10) or
amelanotic (n = 1) lesions; restriction by lesion diameter (Bono 2002b; Bono 2006; Steiner 1987); or, most
commonly, inclusion of lesions selected for excision based on the clinical or dermoscopic diagnosis or selected
retrospectively from histopathology databases (n = 37). Only four cohorts were judged to have included a
representative patient population (Grimaldi 2009; Menzies 2009; Stanganelli 2000; Walter 2012). Fourteen cohorts also
included multiple lesions per participant, with only 8 clearly including similar number of participants and lesions (Bono 2002; 
Bono 2002b; Bono 2006; Bourne 2012; Collas 1999; Krahn 1998; Pizzichetta 2004; Unlu 2014).
For the index test domain, studies were considered separately according to whether they reported in-person
evaluations of visual inspection (n = 33) or evaluations based on interpretation of clinical images (image-based
evaluations; n = 16). For the in-person evaluations, 24% (n = 8) were considered at low risk of bias, and 9% (n =
3) were judged high risk; 22 (67%) did not provide sufficient information to allow the risk of bias to be fully judged.
All studies were considered to have made the diagnosis blinded to the reference standard result: 24% (n = 8) also
clearly reported pre-specification of the diagnostic threshold (5 of the 8 using named algorithms (Argenziano 2006; 
Cristofolini 1994; Stanganelli 2000; Walter 2012; Zaumseil 1983 and three by the same author team (Bono 2002; Bono
2002b; Bono 2006) describing the process by which the diagnosis was reached. Three studies developed new
algorithms (Thomas 1998) or evaluated multiple thresholds for test positivity (Benelli 2001; McGovern 1992).
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Reporting was poorer for the image-based evaluations, with over three quarters of studies (n = 13) not providing
sufficient information to allow the risk of bias to be fully judged, one study (6%) judged at low risk of bias and two
(12%) at high risk. All studies were again considered to have made the diagnosis blinded to the reference standard
result, with one prospectively testing two pre-specified diagnostic thresholds (Benelli 2001) and two (de Giorgi 2012; Scope
2008) testing multiple diagnostic thresholds.
High concern for the applicability of the index tests was recorded for 85% (n = 28) of in-person evaluations. High
concern was primarily due to a lack of description of the diagnostic thresholds used (n = 24), but also as a result
of presentation of average (Argenziano 2006) or consensus diagnoses (Barzegari 2005; Benelli 1999; Carli 2002; Cristofolini
1997; Morales Callaghan 2008; Steiner 1987) as opposed to the diagnosis of a single observer. Two studies were
also judged to have reported diagnosis by non-expert observers (Menzies 2009; Walter 2012), both of which reported
diagnoses by large groups of primary care practitioners. In reality, specific expertise in diagnosing pigmented lesions does
vary amongst examiners, for example Menzies 2009 requiring a history of excision or referral of at least 10 pigmented skin
lesions over the previous 12-month period but excluding those already using dermoscopy or digital monitoring of lesions, and
Walter 2012 excluding those with specialist dermatology training but reporting some training in dermatology for almost a
quarter of participating GPs. Almost three quarters of studies (n = 24) were judged to have applied and interpreted the ‘test’
in a clinically applicable manner, nine (27%) provided sufficient detail of the threshold used and 11 (33%) described the
observers as expert or experienced. All image-based studies were of high concern for applicability, due to the image-based
nature of interpretation limiting the clinical applicability of findings but also the lack of detail on the thresholds used (n = 13).
A higher proportion (62%; n = 10) described the observers as expert or experienced.
Of the 49 included cohorts, 85% were judged at low risk of bias for the reference standard due to the use of an
acceptable reference standard (n = 42). Six did not meet our criteria for an acceptable reference standard, with more
than 20% of the benign lesions having only expert diagnosis with no clinical follow-up (Bono 1996; Green 1991; Grimaldi
2009; Menzies 2009; Stanganelli 2000; Walter 2012), three of which were primary care based studies (Grimaldi 2009; 
Menzies 2009; Walter 2012). Blinding of the reference standard to the index test (in this case the pathology referral
diagnosis) was recorded but did not contribute to the overall risk of bias for the reference standard domain. No
blinding of the reference standard was implemented in three studies (Menzies 2009 and Walter 2012 referring patients for
excision under standard practice and Thomas 1998 describing a form recording the presence or absence of each ABCDE
criterion to the usual pathology form) and blinding was not described in the remaining 46 studies (94%). The applicability of
the reference standard was of low concern in 9 studies (18%), high in 7 (14%), and unclear for 33 (67%). In all cases, high
concern was due to the use of expert opinion for classifying the final diagnosis of some lesions. The majority of studies (40;
82%) did not report histopathology interpretation by an experienced histopathologist or by a dermatopathologist.
In terms of flow and timing, 20 cohorts were judged at high risk of bias, 7 at low risk and 22 did not provide enough
information on which to judge this domain. Of those at high risk, 11 cohorts did not use the same reference standard for all
participants (differential verification), and 15 did not include all participants in the analysis either due to incomplete
information (n = 7; Argenziano 2006; Bono 1996; Ek 2005; McGovern 1992; Menzies 2009; Pizzichetta 2004; Walter 2012
); inadequate images (Chang 2013; Dolianitis 2005; Green 1994; Lorentzen 1999; Pizzichetta 2004; Rosendahl 2011; 
Scope 2008); and exclusion of particular lesion groups following recruitment (Bourne 2012; Dummer 1993; Menzies 2009). A
further 37 cohorts were unclear on the interval between the application of the index test and excision for histology with 12
reporting consecutive diagnosis and excision or biopsy.
Findings
1. Target condition: invasive melanoma and melanocytic intra-epidermal variants
Thirty-seven studies reported accuracy data for the detection of invasive melanoma and melanocytic intra-epidermal
variants, one of which reported data for three different sets of lesions (Morton 1998a; Morton 1998b; Morton 1998c) giving a
total of 39 datasets; 28 evaluations were conducted in-person and 11 were image-based.
Summary details of the in-person studies are summarised in Appendix 9, with quality assessments in Appendix 10. Summary
details of the image-based studies are summarised in Appendix 11 with quality assessments in Appendix 12. Details of
established algorithms used to assist diagnosis are described in detail in Appendix 4. Results for the primary analyses are
presented in Table 1. Forest plots of study data for each analysis in Table 1 are given for each analysis in Figure 7 and
Figure 8; summary estimates are depicted in Figure 9 and Figure 10. Table 2 reports heterogeneity investigations, Table 3
compares test algorithms and Table 4 compares observers.
In-person evaluations
Of the 28 evaluations conducted on an in-person basis, 17 contained enough information to describe where on the
clinical pathway participants were assessed (coded as ‘clear’ on pathway), and 11 were considered not to have
provided sufficient information to allow the pathway to be identified (coded ‘unclear’ on pathway). These evaluations
are considered according to position on the pathway and clear versus unclear pathway classification (Table 1). Figure 7
presents the results of the individual studies grouped by their position on the pathway; Figure 9 depicts the summary
estimates at each point on the pathway.
Studies in participants with limited prior testing
Six in-person evaluations of visual inspection recruited series of participants with pigmented lesions who were
presenting for a first structured clinical assessment of a suspicious lesion (Grimaldi 2009; Menzies 2009; Walter 2012; 
Collas 1999; Gachon 2005; McGovern 1992) (Appendix 9; Appendix 10). All studies included participants with pigmented
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lesions; Gachon 2005 restricted inclusion to melanocytic lesions only. The prevalence of disease ranged from 4 to 6% in four
studies, with Collas 1999 (11%) and Grimaldi 2009 (20%) reporting higher prevalence of melanoma.
Three studies prospectively included all participants presenting in primary care within a given time frame and were clearly
positioned on the clinical pathway (Pathway 2-c in Figure 9):
summary sensitivity was 92.4% (95% CI: 26.2, 99.8%) and specificity 79.7% (95% CI: 73.7, 84.7%) [1339 lesions
and 55 melanomas (Grimaldi 2009; Menzies 2009; Walter 2012)].
Histological diagnosis was supplemented with clinical follow-up of at least 3 months for lesions considered benign
(all three studies) and expert clinical diagnosis only without follow-up for some benign lesions (Menzies 2009; Walter 2012).
Three studies included only participants with lesions selected for excision (Pathway 3-c and 3-u in Figure 9): two were
conducted in private dermatology clinics (Collas 1999; Gachon 2005) and one at an open access veterans’
dermatology clinic (McGovern 1992) (Appendix 9):
summary sensitivity was 90.1% (95% CI: 70.0, 97.3%) and specificity 81.3% (95% CI: 67.5, 90.0%) for two studies
clearly positioned on the clinical pathway(Pathway 3-c) [4228 lesions and 160 melanomas (Gachon 2005; McGovern
1992)].
sensitivity was 78.9% (95% CI: 62.7, 90.4%) and specificity 94.0% (95% CI: 90.7, 96.3%) [353 lesions and 38
melanomas (Collas 1999)] in the single study that could not be clearly positioned on the clinical pathway (Pathway 3-u).
Diagnosis was recorded by primary care physicians with a range of experience (Grimaldi 2009; Menzies 2009; Walter 2012
) or by dermatologists (Collas 1999; Gachon 2005; McGovern 1992) with no obvious differences in sensitivity or
specificity. No formal algorithm to assist diagnosis was reported in four studies; two of which classified lesions
‘suspicious for malignancy’ as test positive (Grimaldi 2009; Gachon 2005) and two reported data for ‘correct’ or
‘primary’ diagnosis of melanoma’ (Menzies 2009; Collas 1999). Walter 2012 reported data for MacKie's revised 7-
point checklist (MacKie 1990) at a threshold of >= 3, and McGovern 1992 used the BCD algorithm at >=2 characteristics
present (this study also reported data using the original 7-point checklist, see Analyses by algorithm reported below).
Studies in referred participants
Twenty-two in-person evaluations of visual inspection were conducted in participants referred for specialist
assessment; 12 could be clearly positioned on the clinical pathway (three evaluations from a single study) and 10 did
not provide sufficient information for a clear assessment to be made (Figure 7; Appendix 9; Appendix 10).
Two studies were judged to include all participants referred for further assessment (Pathway 4-c in Figure 9) and both were
clearly positioned on the clinical pathway:
summary sensitivity was 74.6% (95% CI: 48.9, 90.0%) and specificity 98.6% (95% CI: 94.7, 99.6%) [3494
lesions and 61 melanomas; (Barzegari 2005; Stanganelli 2000)].
Fifteen studies providing 17 datasets included only those with any lesion selected for excision (Pathway 5-c and 5-u in
Figure 9):
summary sensitivity was 76.7% (95% CI: 61.7, 87.1%) and specificity 95.7% (95% CI: 89.7, 98.3%) (5331 lesions
and 258 melanomas) for six studies (with 8 datasets) clearly positioned on the clinical pathway (Pathway 5-c) (Bono 2002;
Bono 2002b; Bono 2006; Ek 2005; Green 1991; Morton 1998a; Morton 1998b; Morton 1998c).
summary sensitivity was 82.8% (95% CI: 74.4, 88.9%) and specificity 89.2% (95% CI: 71.1, 96.5%) (9611 lesions
and 1015 melanomas) for nine studies that could not be clearly positioned on the clinical pathway (Pathway 5-u) (Benelli
1999; Carli 2002; Cristofolini 1994; Cristofolini 1997; Langley 2001; Morales Callaghan 2008; Thomas 1998; Unlu 2014; 
Zaumseil 1983).
Three studies were considered to report data only for those participants with equivocal or difficult to diagnose lesions
selected for excision (Pathway 5*-c and 5*-u in Figure 7 and Figure 9):
summary sensitivity was 84.7% (95% CI: 55.5, 96.1%) and specificity 89.5% (95% CI: 79.5, 95.0%) (930 lesions
and 88 melanomas) for two studies clearly positioned on the clinical pathway (Pathway 5*-c) (Dummer 1993; Soyer 1995).
sensitivity was 61.4% (95% CI: 49.0, 72.9%) and specificity 87.3% (95% CI: 82.5, 91.2%) (318 lesions and 73
melanomas) in one study not clearly positioned on the clinical pathway (Pathway 5*-u) (Steiner 1987).
Studies included pigmented lesions referred for further evaluation at a dermatology or pigmented lesion clinic, two
restricting to melanocytic lesions only (Morales Callaghan 2008; Unlu 2014) and four restricting by lesion diameter (<= 3
mm (Bono 2006), <= 6 mm (Bono 2002b), < 10 mm (Steiner 1987), or <= 15 mm (Barzegari 2005)). The prevalence of
disease ranged from 1% (Ek 2005) to 41% (Soyer 1995). Disease prevalence was generally lower in studies clearly
positioned on the clinical pathway (11% or less in 7 of 10 datasets) compared to those that could not be clearly
positioned (7 of 9 datasets reporting disease prevalence of 15% or over (Appendix 9). The prevalence of melanoma
in studies of equivocal lesions was 3% (Dummer 1993), 23% (Steiner 1987) and 41% (Soyer 1995).
Diagnoses were recorded by dermatologists or dermatology residents (or were assumed to be by dermatologists
based on authors’ institutions or study settings), by surgical oncologists or by plastic surgeons (Appendix 9). Observer
experience was poorly reported, with only 7 studies referring to ‘experienced’ or ‘expert’ observers; three studies were
clearly positioned on the pathway and 4 not clearly positioned. Observer diagnosis with no formal algorithm was
reported in all studies apart from five using ABCD or ABCDE algorithms (Benelli 1999; Cristofolini 1994; Cristofolini 1997; 
Thomas 1998; Stanganelli 2000). Diagnosis was more often based on the opinion of a single observer as
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
14 / 256
opposed to a consensus or average decision in studies clearly positioned on the pathway (10/12 datasets) (Stanganelli 2000;
Bono 2002; Bono 2002b; Bono 2006; Green 1991; Morton 1998a; Morton 1998b; Morton 1998c; Dummer 1993; Soyer 1995
) compared to those not clearly positioned (3/10) (Thomas 1998; Unlu 2014; Zaumseil 1983).
Image-based evaluations
Of the 11 image-based evaluations, two contained enough information to describe where on the clinical pathway
participants were assessed (coded as ‘clear’ on pathway), and 9 were considered not to have provided sufficient
information to allow the pathway to be identified (coded ‘unclear’ on pathway) (Appendix 11 and Appendix 12). Results are
present in Table 1. Figure 8 presents the results of the individual studies grouped by their position on the pathway; Figure 10
depicts the summary estimates at each point on the pathway.
Studies in participants with limited prior testing
Two studies retrospectively reviewed clinical images from participants with lesions excised in primary care settings (Pathway
3-c and 3-u in Figure 10):
sensitivity was 22.2% (95% CI: 2.8, 60.0%) and specificity 70.7% (95% CI: 54.4, 83.9%) (50 lesions and 9 melanomas) in
one study clearly positioned on the clinical pathway (Pathway 3-c) ( Bourne 2012).
sensitivity was 20.7% (95% CI: 8.0, 39.7%) and specificity 96.8% (95% CI: 94.6, 98.2%) (463 lesions and 29
melanomas) in the study not be clearly positioned on the clinical pathway (Pathway 3-u) (Rosendahl 2011). The study
report was unclear as to whether the excisions were undertaken at the primary care practice or in a referral setting.
The prevalence of melanoma was 6% (Rosendahl 2011) and 20% (Bourne 2012) and both studies included a range
of different types of lesions. Lesion images were reviewed by three GPs and a clinical nurse with varying levels of
dermoscopy experience (Bourne 2012) and by an expert dermatologist (Rosendahl 2011). Diagnosis was made without the
aid of a published algorithm.
Studies in referred participants
Nine evaluations of clinical images were conducted in participants referred for specialist assessment; one could be clearly
positioned on the clinical pathway and eight did not provide sufficient information for a clear assessment to be made.
One study clearly positioned on the clinical pathway was considered to have included all participants referred for further
assessment (Pathway 4-c in Figure 10):
sensitivity was 74.2% (95% CI: 55.4, 88.1%) and specificity 82.5% (95% CI: 73.8, 89.3%) (134 lesions and 31
melanomas (Stanganelli 2005)).
The remaining 8 studies did not provide sufficient information to clearly position them on the clinical pathway but were
assumed to have obtained lesion images from referral settings (Pathway 5-u and 5*u in Figure 10):
summary sensitivity was 60.3% (95% CI: 49.2, 70.5%) and specificity 77.0% (95% CI: 63.9, 86.4%) (293 lesions
and 96 melanomas) for six studies that included all lesions selected for excision (Pathway 5-u) (Benelli 2001; Carli 2002b; 
Dolianitis 2005; Pizzichetta 2004; Stanganelli 1998; Winkelmann 2016).
summary sensitivity was 61.9% (95% CI: 46.7, 75.0%) and specificity 81.8% (95% CI: 75.2, 87.0%) (303 lesions and
98 melanomas) across two studies that included participants with equivocal lesions selected for excision (Pathway
5*u) (Carli 2003b; de Giorgi 2012).
Studies were retrospective case series apart from two case control type studies (Winkelmann 2016; Dolianitis 2005)
and one with an unclear design (Benelli 2001). Three studies (Benelli 2001; Dolianitis 2005; Stanganelli 1998)
evaluated observer accuracy before and after dermoscopy training. Images of pigmented or melanocytic lesions
were reviewed in all studies apart from one focused on hypomelanotic (<=30% pigmentation) or amelanotic
lesions (Pizzichetta 2004). The prevalence of melanoma ranged from 19% (Carli 2002b) to 50% (Dolianitis 2005); four
studies included only melanomas (including in situ) and benign naevi (Carli 2003b; de Giorgi 2012; Stanganelli 2005; 
Winkelmann 2016).
Lesion diagnosis was undertaken by dermatologists or by observers with mixed qualifications; observer experience
was poorly reported (Appendix 11). Stanganelli 2005 also provided accuracy data for the average of three GPs (data
reported in section 1.3.2). Most studies presented average accuracy across observers; only two reported accuracy for
a single observer (Benelli 2001; Pizzichetta 2004). Diagnoses were made without the use of diagnostic algorithms in all
studies except Benelli 2001 (ABCDE algorithm) and de Giorgi 2012 (ABCD).
Secondary analyses
Secondary analyses were conducted for the detection of invasive melanoma and melanocytic intra-epidermal variants
regardless of classification by clinical pathway.
Covariate investigations
A preliminary analysis across the 39 datasets contributing to the primary analyses described above found a large difference
in accuracy for in-person evaluations compared to those based on the assessment of clinical images (relative
diagnostic odds ratio (RDOR) 8.54, 95% CI 2.89, 25.3, P < 0.001) (Table 2; Figure 11). The magnitude and importance of the
observed difference is so large, raising serious concerns about the applicability of visual inspection studies done via image
observation only, that we elected to undertake all subsequent covariate investigations based on in-person evaluations only (n
= 28).
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For the 28 in-person evaluations, only one of the four covariate investigations approached statistical significance (Table 2);
observed accuracy was lower in studies where disease prevalence of melanoma (percentage of cases in the study which
tested positive for the reference standard) was over 10% compared to those with disease prevalence of 10% or less (RDOR
0.31, 95% CI 0.09, 1.00; P = 0.05). The RDOR for study setting (secondary care or specialist clinic compared to primary
care) was 1.51 (95% CI 0.32, 7.09; P = 0.59; Figure 12), for use of a named algorithm to aid diagnosis compared to no
algorithm reported was 1.03 (95% CI 0.25, 4.34; P = 0.96; Figure 13), and for use of histology plus clinical follow-up or other
reference standard compared to histology alone was 0.76 (95% CI 0.14, 4.02; P = 0.74; Figure 14).
Analyses by algorithms used to assist visual inspection
Of the 28 in-person evaluations only seven reported using an algorithm to assist visual inspection, limiting the ability of
meaningful comparisons between algorithms to be made (Table 3). Observer diagnosis without the use of a formal
algorithm (n = 21 datasets) had the highest diagnostic accuracy (DOR 46.2, 95% CI 21.9, 97.5), with an average
sensitivity of 78% (95% CI 68, 85%) and average specificity 93% (95% CI 88, 96%). Pooled sensitivity was slightly
higher and specificity slightly lower for variations on the (A)BCD(E) algorithm (n = 6 datasets), but with overlapping
confidence intervals (summary sensitivity 83% (95% CI 75, 88%); summary specificity 88% (95% CI 64, 97%)).
Two datasets reported data for either the original seven point checklist at a number of thresholds (McGovern 1992) or
for the revised 7 point checklist (Walter 2012). At the standard threshold of >=3 for both algorithms, the highest
observed sensitivity and specificity was 94% (95% CI 73, 100) and 80% (95% CI 77, 83%) for the revised version (Walter
2012).
The image-based evaluations reported data for either no algorithm or for variations of ABCD(E); a similar pattern was
observed with much lower levels of overall accuracy (Table 3).
Analyses by observer experience
Analyses by observer expertise were restricted by the limited amount of information provided in the study reports (Table 4; 
Appendix 9 and Appendix 11). Our analyses are therefore based primarily on study subgroups by observer
qualifications (consultant/registrar/mixed qualifications/primary care practitioners), with the ‘consultant’ category
separated into ‘Expert consultant’ (for any study describing observers as expert or experienced) and ‘Consultant’ where
experience or expertise was not otherwise reported (for example, for those that described observers as dermatologists)
(Table 4; Figure 15).
No clear pattern according to observer experience could be discerned for in-person evaluations. Relative DORs in
comparison to the ‘Expert consultant’ group (9 studies) ranged from 0.45 (95% CI 0.05, 3.67; P=0.44) for observers at
resident/registrar level (2 studies) to 7.28 (95% CI 0.69, 76.3; P=0.09) for GPs (3 studies).
For image-based evaluations, accuracy was highest for the ‘Expert consultant’ group (DOR 20.5 (95% CI 4.82, 86.9); relative
DORs in comparison to the ‘expert’ group ranged from 0.18 (95% CI 0.04, 0.90; P=0.04) for observers described as
‘dermatologists’ (4 studies) to 0.56 (95% CI 0.04, 7.51; P=0.63) for mixed secondary and primary care observers (1 study).
Across all definitions of the target condition, 7 studies provided comparative data according to observer qualifications or
experience (Table 5). Most were image-based assessments, using no prescribed algorithm to aid diagnosis and reporting
average results across groups of observers. Some evidence of increased sensitivity and smaller increases in specificity were
observed with increasing experience; however, wide variations in accuracy remained with sensitivity ranging from 58% to
91% for expert dermatologists and specificities from 53% to 99%.
2. Target condition: invasive melanoma only
In this section, we present the results for studies of visual inspection for the identification of invasive melanoma, according to
the approach taken for diagnosis: in-person or image-based evaluations. Summary characteristics of studies are presented
in Appendix 13 and results of meta-analyses in Table 6, and Figure 16. Table 7 compares results in studies reporting data for
invasive melanoma alone and for invasive melanoma plus atypical intraepidermal melanocytic variants.
Seven datasets evaluated the accuracy of in-person visual inspection for the detection of invasive melanoma (Bono 1996; 
Green 1994; Kopf 1975; Krahn 1998; McGovern 1992; Viglizzo 2004; Walter 2012), only two of which also
reported data for the primary target condition (McGovern 1992; Walter 2012). All studies were based in secondary care or
specialist units apart from Walter 2012 (primary care) and McGovern 1992 (army medical centre dermatology
clinic). Studies used a modified version of the ABCD checklist (McGovern 1992), the revised 7-point-checklist (Walter 2012
), or no algorithm (n = 5; 71%) to assist diagnosis. The prevalence of melanoma ranged from 2% (Kopf 1975; Walter 2012
) to 49% (Krahn 1998). Two studies supplemented a histological reference standard with clinical follow-up (Walter 2012
) and expert diagnosis of some benign lesions (Walter 2012; Bono 1996).
Sensitivities ranged from 67% to 100% and specificities ranged from 76% to 100%. In meta-analysis the DOR was 62.4
(95% CI 17.6, 222) (6857 lesions and 208 melanoma cases). Sensitivity and specificity at the average operating point
on the SROC curve were 86% (95% CI: 68, 94%) and 91% (95% CI: 81, 96%) respectively. For the two in-person
evaluations which also reported data for the primary target condition (Table 7), specificity estimates were hardly affected due
to small numbers of included melanoma in situ lesions (5 in McGovern 1992 and 2 in Walter 2012). Sensitivity however, was
higher for detection of invasive melanoma alone in McGovern 1992 (100% versus 73% for detection of invasive melanoma or
atypical intraepidermal melanocytic variants) due to correct diagnosis of only two of five in situ melanomas, and was
marginally lower in Walter 2012 (93.8% versus 94.4% for detection of invasive melanoma or atypical intraepidermal
melanocytic variants) due to correct identification of both in situ melanomas with one invasive melanoma missed.
Five datasets reported the accuracy of image-based visual inspection for the detection of invasive melanoma (Lorentzen
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
16 / 256
1999; Rao 1997; Scope 2008; Troyanova 2003; Westerhoff 2000), but none of which reported data for the primary
target condition. Only two studies used images from normal practice settings (Lorentzen 1999; Rao 1997); one
obtained images from a teledermatology company (Scope 2008) and two selected images of melanoma cases
and controls for use in dermoscopy training studies (Troyanova 2003; Westerhoff 2000). The prevalence of melanoma
ranged from 3% (Scope 2008) to 50% (Troyanova 2003; Westerhoff 2000). The ABCD checklist (Rao 1997), the ugly
duckling approach (Scope 2008), or no algorithm (n = 3) was used to assist diagnosis. Four evaluations clearly
presented only the clinical image with no further patient information (80%), and one (Rao 1997) may have presented
observers with a concurrent dermoscopic image of the lesion as blinding between images was not clearly described.
Sensitivities ranged from 62% to 86%; specificities ranged from 54% to 95%. In meta-analysis the DOR was 14.8 (95% CI
3.56, 61.9) [599 lesions and 150 melanoma cases]. Sensitivity and specificity at the average operating point on the SROC
curve were 76% (95% CI: 50, 91%) and 83% (95% CI: 62, 93%) respectively.
Accuracy was non-significantly higher for in-person compared to image-based evaluations (RDOR 4.21; 95% CI 0.62, 28.6;
P = 0.13).
3. Target condition: any skin lesion requiring excision
In this section, we present the results for studies of visual inspection for the identification of any skin lesion requiring excision
(for each study, data could only be extracted for the detection of any skin cancer), according to the approach taken for
diagnosis: in-person or image-based evaluations. Summary characteristics of studies are presented in Appendix 14 and
results of meta-analyses in Table 6 and Figure 17. Table 7 compares results in studies reporting data for invasive melanoma
alone and for invasive melanoma plus atypical intraepidermal melanocytic variants.
Seven datasets evaluated the accuracy of in-person visual inspection for the detection of any skin lesion requiring
excision (Argenziano 2006; Chang 2013; Ek 2005; McGovern 1992; Stanganelli 2000; Steiner 1987; Walter 2012), five of
which also reported data for the primary target condition (Ek 2005; McGovern 1992; Stanganelli 2000; Steiner 1987; Walter
2012). Three studies were based in primary care (Argenziano 2006; Walter 2012) or community dermatology
clinics (McGovern 1992), the others were based in secondary care or specialist referral clinics. The prevalence of skin
cancer ranged from 3% (Walter 2012) to 68% (Ek 2005). Studies used the ABCD algorithm (Argenziano 2006; McGovern
1992; Stanganelli 2000), the revised 7-point-checklist (Walter 2012), or no algorithm (n = 3) to assist diagnosis.
Two studies supplemented a histological reference standard with clinical follow-up (Stanganelli 2000; Walter 2012)
and expert diagnosis of some benign lesions (Walter 2012).
Sensitivities ranged from 57% to 98%; specificities ranged from 13% to 99%. In meta-analysis the DOR was 20.5 (95%
CI 7.11, 59.3) (8091 lesions and 2187 skin cancer cases). Sensitivity and specificity at the average operating point on
the SROC curve were 81% (95% CI: 68, 90%) and 81% (95% CI: 56, 93%) respectively. For the in-person evaluations
which also reported data for the primary target condition (Table 7), specificity estimates were not affected in four of the five
studies due to the relatively small percentage of other skin cancers in the study populations (BCCs making up 2% of all
lesions in McGovern 1992; 1% in Stanganelli 2000 and Walter 2012; and 6% in Steiner 1987). Sensitivities
increased in two studies due to a majority of BCCs correctly identified (Stanganelli 2000; Steiner 1987); sensitivity fell in
Walter 2012 due to 3 of 4 BCCs not picked up by the revised seven point checklist; and remained the same in McGovern
1992. A large increase in sensitivity and fall in specificity was observed in Ek 2005, however, as BCCs made up 47% of the
total study population and invasive SCCs comprised 20%. When these two lesion groups were considered as disease
positive, sensitivity increased from 48% to 98% and specificity fell from 99% to 13% due to the largely correct identification of
BCC and SCC as malignant and high false positives in the remaining group of lesions considered disease negative (including
large proportions with Bowens disease, solar keratoses, or seborrhoeic keratoses).
Three datasets reported the accuracy of image-based visual inspection for the detection of any skin lesion requiring
excision (Carli 2002b; Rosendahl 2011; Stanganelli 1998), all of which also reported data for the primary condition. All
studies selected images from normal practice settings, two in secondary care (Carli 2002b; Stanganelli 1998) and
one from a primary care practice (Rosendahl 2011). The prevalence of lesions suitable for excision ranged from
22% (Rosendahl 2011) to 47% (Stanganelli 1998); the latter selecting images for use in a dermoscopy training
study. Data were presented for a single dermatologist (Rosendahl 2011), a consensus of two dermatologists (Carli 2002b
), or the average across 20 dermatologists (Stanganelli 1998). No algorithm was used to assist diagnosis (n = 3) and no
further patient information was presented to assist diagnosis.
Sensitivities ranged from 64% to 80%; specificities ranged from 74% to 85%. In meta-analysis the DOR was 11.9 (95%
CI 2.22, 65.3) (547 lesions and 138 skin cancer cases). Sensitivity and specificity at the average operating point on the
SROC curve were 75% (95% CI: 49, 90%) and 79% (95% CI: 38, 96%) respectively. For the three studies which also
reported data for the primary target condition (Table 7), sensitivities increased in two due to correct identification of
BCCs (Rosendahl 2011; Stanganelli 1998). Specificity decreased in Carli 2002b due to small sample size and high
prevalence of malignancy (20/53; 38%) and decreased in Rosendahl 2011 due to the use of a different threshold for the
primary target condition 'is this lesion a melanoma?' compared to ‘should this lesion be excised?’ for the target condition of
any lesion requiring excision.
No significant difference in accuracy between in-person and image-based evaluations was identified (RDOR 1.70; 95% CI
0.24, 12.3; P=0.55).
Discussion 
Summary of main results
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Summary of main results
Visual inspection has been evaluated in a range of study populations, on an in-person basis and using clinical images, and
both with and without the use of published algorithms to assist diagnosis. Wide variations in sensitivity and specificity were
observed for all definitions of the target condition.
There are five main findings from our review:
1) There is an almost universal problem with poor reporting in the primary studies, hindering attempts to analyse studies
according to their position on the clinical pathway and to fully assess sources of heterogeneity and methodological quality.
Less than two thirds of in-person evaluations of visual inspection contained enough information to describe where on the
clinical pathway participants were assessed. This was particularly the case for studies apparently conducted in referred
populations, where almost half of studies neither described participants as ‘referred’, nor provided any description of
participants’ prior testing or pathway followed prior to presentation for specialist review. Observer experience and expertise in
pigmented lesion diagnosis is likely to impact on test accuracy; however, this information was rarely provided in any detail
making it difficult to assess any differences in accuracy according to clinician experience. Analyses by reported observer
qualifications and descriptions of observers as ‘expert’ or ‘experienced’ showed no significant differences between groups.
In terms of methodological quality, studies were at unclear risk of bias due to poor reporting of key items around participant
selection, pre-specification of thresholds used, and timing of diagnosis in relation to reference standard diagnosis. Concern
around applicability of studies was almost universally poor due to restricted inclusion of lesions and lack of reproducibility of
diagnostic thresholds. Given these limitations and the heterogeneity in various aspects of the primary studies, our results
cannot be considered conclusive regarding the accuracy of visual inspection for melanoma diagnosis.
2) Prior testing of participants or study position on the clinical pathway does appear to matter.
Focusing on in-person evaluations that could be clearly positioned on the clinical pathway (Summary of findings table 1), the
highest sensitivity (92.4%, 95% CI 26.2, 99.8%) and lowest specificity (79.7%, 95% CI 73.7, 84.7%) for the primary target
condition of invasive melanoma or atypical intraepidermal melanocytic variants was observed in three datasets from
participants with limited prior testing; however, confidence intervals were wide and heterogeneity high, particularly for
sensitivity. Data for referred participants suggest that summary sensitivities fall to around 75%, but with much higher
specificities (e.g. sensitivity 76.7% (95% CI 61.7, 87.1%) and specificity 95.7% (95% CI 89.7, 98.3%) for lesions selected for
excision, n = 8 datasets). Sensitivity was higher for equivocal lesion populations but with very wide confidence intervals
(84.7%, 95% CI 55.5, 96.1%) with summary specificity of 89.5% (95% CI 79.5, 95.0%) (2 datasets).
The general trade-off between sensitivity and specificity along the pathway could be due to differences in the
spectrum or ‘case mix’ of included lesions, differences in the definition of a positive test result, or may be linked to
variations in observer expertise. Spectrum effects can be observed when tests that are developed further down the
referral pathway have lower sensitivity and higher specificity when applied in settings with participants with limited
prior testing (Usher-Smith 2016). Classic examples include the use of dipstick tests for detection of urinary tract
infection (UTI) (Lachs 1992) and the D-dimer test to detect pulmonary embolism (PE) (Ginsberg 1993). In both studies, as
the prior probability of having UTI or PE increases (and so prevalence of disease increased), test sensitivity increased (from
79% to 93% in Ginsberg 1993, and from 58% to 92% in Lachs 1992) while specificities decreased (from 76% to 45% in
Ginsberg 1993 and from 77% to 42% in Lachs 1992). However, this direction of effect is not consistent across tests and
diseases as Leeflang 2013 clearly demonstrates; the mechanisms in action are often more complex than prevalence alone
and can be difficult to identify.
Using disease prevalence as a proxy for disease spectrum, our classification of studies did result in a somewhat lower
prevalence of disease (suggesting a wider spectrum of lesion types) in limited prior testing studies (median prevalence 5%,
interquartile range (IQR) 3%, 9%) compared to referral settings (median prevalence 15%, IQR 10, 21%), but with overlapping
ranges (2% to 11%, and 1% to 41%, respectively). The lower specificity observed in limited prior testing studies is likely
related to the presence of a wider range of benign lesions with similar characteristics to melanoma leading to more referrals.
Observers in primary care are also likely to have a lower threshold for considering benign lesions as possibly malignant due
to the risk of missing true cases of melanoma, contributing both to higher sensitivity and a higher false positive rate. Referred
populations on the other hand may have a higher proportion of equivocal or ‘difficult to diagnose’ melanomas that are difficult
to identify.
In terms of eligibility criteria, varying degrees of clinical suspicion of malignancy were required for lesion inclusion in limited
prior testing populations ranging from lesions that could not immediately be diagnosed as benign, to there being a
requirement for a teledermatology second opinion. In referral populations, eligibility was frequently based on lesion excision,
the basis or rationale for which was not described. The restriction to lesions deemed to be suitable for excision will decrease
specificity, as more obviously benign lesions would be excluded. The spectrum of lesion types in the disease negative
groups also varied across studies, with a number of studies restricting inclusion only to those with melanocytic lesions (such
that all benign lesions were benign melanocytic naevi) and others reporting high proportions of other types of skin cancers
(BCC or SCC), or of benign keratotic lesions such as seborrhoeic or actinic keratoses, or of Spitz naevi which may be difficult
to differentiate from melanoma.
3) Visual inspection alone is not sufficiently sensitive for the detection of melanoma, and there is no clear evidence that
accuracy is improved by the use of any named or published algorithm to assist diagnosis in all settings.
Test sensitivity was greater than 90% (i.e. less than 1 in 10 melanomas missed) in only 6 of the 28 in-person based
evaluations of the primary target condition and confidence intervals for the pooled estimates were wide, raising the question
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as to whether visual inspection can be relied on to rule out the presence of melanoma. Applying the sensitivity and specificity
estimates for the limited prior testing studies cited above to a hypothetical cohort of 1000 lesions at disease prevalence of
4%, 9%, and 16% (see Summary of findings table 1) shows that visual inspection would on average miss 3, 7 or 12
melanomas, with 195, 185 and 171 false positive results (potentially leading to unnecessary excisions or lesion
referral or follow-up depending on the anticipated clinical action following a positive result). The wide confidence
intervals however mean that the number of melanomas missed could range from between 0 and 118, with false
positives from 129 to 252. For a cohort of 1000 lesions in a referred population at prevalence of 4%, 9%, and 16% (
Summary of findings table 1), the pooled sensitivity of 76.7% and specificity 95.7% translate to 9, 21, and 37 melanomas
missed on average (range: 5 to 61) and 41, 39, and 36 false positive results (range: 14 to 99).
The evidence to support the use of available algorithms to assist visual inspection was limited, and results are likely to be
confounded by patient spectrum and observer experience. Considerable variation in definitions of test positivity across
studies that did not report using any algorithm was also observed, i.e. where observer diagnosis was based on observers’
own interpretation of lesion characteristics. Where reported, visual inspection was considered to be positive for observers
‘correct diagnosis of melanoma’, ‘suspicion of malignancy’, or ‘selection for excision’, each of which is likely to result in
varying proportions of test positive or negative for any given population.
Nevertheless, covariate investigations for the primary analysis across all study settings suggested no difference in
accuracy according to the reported use of any named or published algorithm to assist diagnosis. This result was
supported by limited subgroup analysis according to algorithm used. Only one eligible study directly compared the
accuracy of visual inspection with and without the use of an algorithm (Collas 1999); however, the authors developed their
own new algorithm for the study and found sensitivity to be higher without the use of the algorithm. Comparing different
algorithms, McGovern 1992 reported highest sensitivities from the BCD algorithm (any one characteristic present) and
the original seven point checklist (at least two characteristics present). Current guidelines in the UK support the use of
the revised seven point checklist in primary care (NICE 2015). A number of studies assessing the revised seven
point checklist algorithm did not meet the stringent inclusion criteria for our review (Healsmith 1994; Higgins 1992; Osborne
1999; Walter 2013); however, the single eligible study using the revised seven point checklist as part of a large
randomised controlled trial reported high sensitivity (94%) when used by GPs (Walter 2012).
4) The definition of the target condition has an effect on diagnostic accuracy.
Results from studies reporting data for more than one definition of the target condition show that sensitivity in particular is
affected by the inclusion of, and percentage of, melanoma in situ and BCC lesions considered disease positive. The direction
of effect depends on observers’ ability to correctly identify these lesions as malignant. It is likely that similar effects impact on
results observed across all included studies. Clear identification of the target condition was not provided in 11 of the 28
datasets included in our primary analyses so that the inclusion of melanoma in situ lesions as disease positive was assumed
on the basis that the disease positive group was described as ‘melanoma’ and not as ‘invasive melanoma’ or ‘malignant
melanoma’. Of those studies that clearly reported including in situ lesions, the percentage of the disease positive group
(invasive melanoma and atypical intraepidermal melanocytic variants) described as being in situ ranged from 10% to 50%.
Where studies included other invasive skin cancers (mainly BCCs or SCCs) in the study population (lesions considered
disease negative for detection of the primary target), we attempted to class any that were correctly identified by observers as
malignant as ‘true negative’ results as opposed to ‘false positives’ (thereby increasing observed specificities), on the basis
that removal of any skin cancer in the attempt to identify melanomas would not be a negative consequence of the test. Our
ability to reclassify lesions relied on studies providing a disaggregation of test results according to final lesion classification
and was not always possible, particularly when invasive SCCs were not separated from ‘in situ’ lesions such as Bowen’s
disease.
5) There are substantial differences in diagnostic accuracy between in-person and image-based assessments.
Accuracy was much lower and reporting was poorer for evaluations of a diagnosis based on the interpretation of clinical
images as opposed to in-person evaluations. Other than possible differences in patient spectrum between in-person
and image-based studies, one possible explanation for the observed difference is that even using the highest quality
clinical image, a remote assessment is not equivalent to a physical, face-to-face patient to clinician interaction, which
will include patient history-taking as well as a total body examination. We were unable to examine any impact from
history-taking over and above inspection of the lesion itself; however, history-taking and in particular, assessment of
and knowledge of patients’ other lesions could have a significant impact on the decision as to whether or not a patient
has melanoma (Grob 1998; Aldridge 2013). Subtle differences in assessing the lesion shape and colour can be done in an
in–person consultation, e.g. by stretching the lesion in the axis perpendicular to the skin creases, which may distort the lesion
shape, and by altering the light intensity and direction used during lesion inspection. Palpation of the lesion (and regional
lymph nodes) is also possible during in-person examination. The fact that image quality is likely to vary between studies, the
time taken to review each image is likely to vary, and the considerable variation in supplementary information provided to
observers (ranging from no clinical information, to clinical details regarding patient age, gender or lesion site and information
on lesion change over time) will have further contributed to variation in accuracy and lower accuracy estimates in comparison
to in-person evaluations. Furthermore, the diagnostic context may have a key influence on observer decisions. In a face-to-
face diagnostic encounter and for the examination of lesion images for a teledermatology consultation, the clinicians
concerned know that their assessment has a direct consequence on patient management and potentially on patient
outcomes. The image-based evaluations included in our primary analysis however were not conducted for teledermatology
purposes, but were studies using lesion images to compare accuracy between clinical image diagnosis and dermoscopic
image diagnosis, or to compare observer or algorithm performance, for example. Observers would have been aware that
their assessment of the lesion image was done in an experimental setting, and would not impact on patients; this could
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potentially have affected interpretation.
Strengths and weaknesses of the review
The strengths of our review include an in-depth and comprehensive electronic literature search, systematic review methods
including double extraction of papers by both clinicians and methodologists, and contact with authors to allow study inclusion
or clarify data. A clear analysis structure according to approach to diagnosis, the definition of the target condition, and the
patient pathway was adopted to estimate test accuracy in different study populations. A detailed and replicable analysis of
methodologic quality was undertaken.
In comparison to other available systematic reviews, our review extends the time period searched for eligible studies to
August 2016 (from 2007 in Vestergaard 2008 and from March 2015 in Harrington 2017), and we include all eligible studies
regardless of availability of a direct comparison with dermoscopic examination (as required in Vestergaard 2008)
or requirement for an algorithm or clinical prediction rule to be included (Harrington 2017). Our stringent application of review
inclusion criteria meant that several otherwise eligible studies were excluded. For example, those reporting accuracy data for
‘clinical diagnosis’ where dermoscopy may or may not have been used to assist diagnosis were excluded on the basis that
the contribution of visual inspection of the lesion could not be discerned.
Studies evaluating eligible algorithms (that were included in Harrington 2017) were excluded from our review, due to lack of
data to construct a 2x2 contingency table, the serial use of the algorithm in the context of lesion follow-up, or use of
inadequate reference standards. Without these restrictions, the observed data would likely have been considerably more
heterogeneous and of poorer methodological quality. At the same time, our inclusion of all studies reporting data for visual
inspection means that an overall assessment of observer accuracy could be made regardless of the use of a named
algorithm. Harrington and colleagues rightly point out that lower sensitivity associated with the use of a clinical prediction rule
“should not prevent [its] use unless usual decisions, made without the rule, are demonstrably better”; however, unless the
accuracy of ‘usual decisions’ is examined, any benefit from the use of an algorithm cannot be established.
The main concerns for the review are a result of the poor reporting of primary studies, in particular forcing some
assumptions to be made to allow studies to be split by pathway and in separating studies by the different definitions of
the target condition. Our inability to clearly separate studies by pathway is of real concern given the evidence for the
effect on accuracy according to the spectrum or case-mix of included participants (Lachs 1992; Moons 1997; Leeflang 2013).
Finally, observer expertise is key for any diagnostic process based on visual inspection, with both non-analytical
pattern recognition (implicit identification) and analytical pattern recognition (using more explicit ‘rules’ based on
conscious analytical reasoning) employed to varying extents between clinicians, according to factors such as
experience and familiarity with the diagnostic question (Norman 2009). A lack of clear reporting of observer training and
experience made analysis difficult.
Applicability of findings to the review question
Varying definitions of the eligible study populations and lack of clarity regarding the patient pathway and any prior testing
may restrict the applicability of our findings to the clinical setting. Varying definitions of test positivity and lack of
reproducibility of diagnostic thresholds, variability in the use of published algorithms, and in observer qualifications and
experience, further restrict the transferability of results to a clinical setting.
Authors' conclusions 
Implications for practice 
Visual inspection is an essential, fundamental component of the assessment of a suspicious skin lesion; however, the
evidence suggests that melanomas will be missed if visual inspection is used on its own. The evidence to support its
accuracy in the range of settings in which it is used is both flawed and poorly reported, resulting in an inability to produce
meaningful summary results and clear pointers as to where visual inspection is most useful. Overall, the use of published
algorithms to assist diagnosis does not appear to improve accuracy; however, neither is there sufficient evidence to suggest
that the ‘no algorithm’ approach should be preferred in all settings, e.g. for training junior staff. Further investigation may lend
support to the theory that expert observers are more reliant on non-analytical pattern recognition, while attempts to assist
analytical pattern recognition are of more benefit for less experienced or more generalist observers.
Implications for research 
Despite the vast volume of research that has been funded to evaluate visual inspection, further prospective
evaluation of the added value of established algorithms according to the prior testing or diagnostic difficulty of lesions
may be warranted. Prospective recruitment of consecutive series of participants and with systematic follow-up of
non-excised lesions to avoid over-reliance on a histological reference standard would allow results to be more
generalisable to routine practice. A clear identification of the level of training and experience required to achieve
good results is also required. Any future research study needs to be clear about the diagnostic pathway followed by
study participants prior to study enrolment, and should conform to the updated Standards for Reporting of Diagnostic
Accuracy (STARD) guideline (Bossuyt 2015).
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Differences between protocol and review 
We set out to review visual inspection and dermoscopy for the detection of melanoma in a single review; however, due to the
volume of evidence identified, two separate reviews were prepared: one for visual inspection alone and one for dermoscopy,
the latter including direct comparisons with visual inspection where both tests were evaluated in the same studies.
Primary objectives and primary target condition have been changed from detection of invasive melanoma alone, to the
detection of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants, as the latter is more clinically
relevant to the practicing clinician.
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Secondary objectives have been tailored to the individual test, with two objectives added: to determine the diagnostic
accuracy of individual algorithms for visual inspection; and to determine the effect of observer experience.
Sources of heterogeneity that could be investigated (as listed under Secondary objectives) were restricted due to lack of
data.
Studies using cross-validation, such as 'leave-one-out' cross-validation were excluded rather than included as these methods
are not sufficiently robust and are likely to produce unrealistic estimates of test accuracy.
To improve clarity of methods, this text from the protocol "we will include studies developing new algorithms or methods
of diagnosis (i.e. derivation studies) if they use a separate independent ’test set’ of participants or images to evaluate
the new approach.We will also include studies using other forms of cross validation, such as ’leave-one-out’ cross-
validation (Efron 1983). We will note for future reference (but not extract) any data on the accuracy of lesion characteristics
individually, e.g. the presence or absence of a pigment network or detection of asymmetry" has been replaced with "studies
developing new algorithms or methods of diagnosis (i.e. derivation studies) were included if they:
used a separate independent 'test set' of participants or images to evaluate the new approach, or
investigated lesion characteristics that had previously been suggested as associated with melanoma and the study
reported accuracy based on the presence or absence of particular combinations of characteristics.
Studies were excluded if they:
used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no
separate test set.
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983)
evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no
overall diagnosis of malignancy
reported accuracy data for ‘clinical diagnosis’ with no clear description as to whether the reported data related to visual
inspection alone
were based on the experience of a particular skin cancer clinic, where dermoscopy may or may not have been used on an
individual patient basis.”
Although we extracted any reporting of special interest or accreditation in skin cancer according to observer expertise, we
were unable to analyse the effect on accuracy.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g.
British Association of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European
Academy of Dermatology and Venereology Meeting, Society for Melanoma Research Congress, World Congress of
Dermatology, European Association of Dermato Oncology), however due to volume of evidence retrieved from database
searches and time restrictions we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic. In terms of analysis, restriction
to analysis of per patient data was not performed due to lack of data. Sensitivity analyses were not performed as planned
due to lack of data.
Published notes 
Characteristics of studies
Characteristics of included studies 
Argenziano 2006
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Randomised controlled trial
allocating primary care physicians to use
either visual inspection alone or visual
inspection plus dermoscopy (only excised
lesions can be included for each arm).
Data collection: Prospective
Period of data collection May 2003 to Sept
2004
Country Italy and Spain
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients asking for screening or
exhibiting one or more skin tumours as seen during
routine physical examination (patient-finding
screening) were considered for inclusion; those
undergoing excision were included in this review (i.e.
those deemed sufficiently suspicious by the Expert
evaluation). PCPs were invited to participate in the
trial; only those who attended the training sessions
and who then screened patients and referred them
to the Pigmented Lesion Clinics were randomised.
Setting: Primary
Prior testing: No prior testing
Setting for prior testing: N/A
Exclusion criteria: NR
Sample size (patients): No. eligible: 3271 patients
screened; 1325 patients allocated to Naked Eye
observation and 1197 patients allocated to
dermoscopy observation; No. included: 162 received
histology after Expert evaluation at the PLC
Sample size (lesions): 85 in VI arm and 77 in
Dermoscopy arm underwent excision
Participant characteristics: Based on full sample:
mean age 40, range 2-90 (visual inspection group)/
41, range 3-94 (dermoscopy group). Male 498
(38%): VI group / 451 (38%) dermoscopy
Lesion characteristics NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) ABCD (control arm of RCT comparing naked eye examination to naked eye plus
dermoscopy)
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Qualitative NR; Described in Intro as: simple morphologic features summarized
by the asymmetry, border irregularity, color variegation, and diameter 5 mm (ABCD)
Diagnosis based on: Average (n=37)
Observer qualifications: Primary care physicians
Experience in practice: Not described
Experience with index test: Not described
Other detail: Pre-randomisation all participating PCPs underwent training in ABCD rule for clinical
diagnosis and 3-point checklist for dermoscopy.
Dermoscopy: evaluated in intervention arm of trial only.
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: All lesions considered suggestive of skin cancer at
the PLC were excised and subsequently diagnosed
histopathologically. Equivocal lesions by histopathologic
examination were reviewed by a second independent
pathologist and a final diagnosis made.
Disease positive: 92 malignant tumours; Disease negative:
70 benign tumours
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 12; BCC:
66; cSCC: 14
Sebhorrheic keratosis: 13; Melanocytic nevi 51; Other: 6
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Data can only be
extracted for those with histology (i.e. patients
considered to have lesions suggestive of skin
cancer); remainder had expert diagnosis (not
included in the final 2x2 data extracted)
Time interval to reference test: Not reported
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
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Barzegari 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection NR
Country Iran
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions with a clinical
diagnosis of melanocytic lesion <=15mm diameter referred
to dermatology clinic for diagnostic evaluation or cosmetic
reasons
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion; Patient request for
evaluation/excision
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 91
Sample size (lesions): No. included: 122
Participant characteristics: Mean age 32.3 (6-94y); Male:
30; 33%
Lesion characteristics NR
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Qualitative Melanoma likely (i.e. melanoma first in list of considered diagnoses)/
Melanoma possible (melanoma one of a number of diagnoses)
Diagnosis based on: Consensus (2 observers); n=2
Observer qualifications: Dermatology registrar (Dermatology resident (3rd year)); Dermatologist
Experience in practice: Mixed experience (low and high experience combined)
Experience with index test: Mixed (low and high experience combined)
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 6; Disease negative: 116
Target condition (Final diagnoses) 
Melanoma (invasive): 3; Melanoma (in situ):
3
Sebhorrheic keratosis: 2; Benign naevus:
104; Dysplastic naevus 7 DF 1 AK
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None;
Time interval between index and reference:
Unclear
Time interval between index test(s):
Consecutive
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less? No
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Benelli 1999
Patient Selection
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
26 / 256
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection 01/09/1997 to
30/09/1998
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All pigmented skin lesions
observed and excised at the Dermatologic Surgery
Department
Setting: Dermatologic Surgery Department
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Dermatologic Surgery
Department
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. included: 401
Participant characteristics: NR
Lesion characteristics: Thickness 42 < 0.75 mm
thick, 80.76-1.5 mm thick. 4 1.5-4 mm thick (mean
0.60 mm, median 0.55 mm. max 1.9 mm, min 0.10
mm, SD 0.45).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) ABCDE
Method of diagnosis: In person diagnosis
Prior test data: Lesions assessed by both dermatologists clinically and dermoscopically
Diagnostic threshold: Data given for accuracy of each potential score (1-5); score estimation described
in detail
Diagnosis based on: Consensus (2 observers); n= 2
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Dermoscopy 7FFM also assessed by same observers
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 60 (15%) lesions; Disease
negative: 340 (non melanoma) + 1 BCC
Target condition (Final diagnoses) 
Melanoma (invasive): 54 (13.5%); Melanoma
(in situ): 6 (1.5%); BCC: 1 (0.4%)
Sebhorrheic keratosis: 1 (0.4%); Melanocytic
nevi: 316; Epithelioid and/or spindle cell nevi:
18 (4.5%); Lentigo simplex: 5 (1.2%)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: NR;
Time interval to reference test: same day
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Benelli 2001
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Unclear
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection Not reported - only
dates of training course and agreement study
given (April-May 1999)
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Slides of pigmented skin tumours
were selected for evaluation during a training course
on dermoscopy. Lesions not located on head, palms
or soles histological slide available
Setting: Training images; Authors institution.
Institute of Dermatologic Sciences, University of
Milan
Prior testing: Slides of pigmented skin tumours were
selected for evaluation during a training course on
dermoscopy
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 49 (paper
reports 50 but only 49 accounted for in text)
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) ABCDE
Method of diagnosis: Clinical photographs
Prior test data: No further information used
Diagnostic threshold: ABCDE Score >/=2; presence of 2 criteria; ABCDE Score >/=3; presence of 3
criteria. All criteria described in full
Diagnosis based on: Single (n=1); Average (n=65; attending one of three courses in dermoscopy held
to inform dermatologists about a new dermatoscopic diagnostic method (7FFM))
Observer qualifications: Dermatologists
Experience in practice: Expert author; Not described for participating dermatologists
Experience with dermoscopy: Expert author; Prior experience not described for participating
dermatologists; all underwent dermoscopy training for study purposes
Dermoscopy: 7FFM; ABCDE also evaluated in study
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 12/49 melanomas (paper reports
50 but only 49 accounted for in text)
Target condition (Final diagnoses) 
Melanoma (invasive): 10; Melanoma (in situ): 2;
BCC: 2 pigmented BCC
3 seborrhoeic keratoses, 2 pigmented basal cell
carcinoma, 1 blue nevus, 2 angiokeratoma, 5 Spitz
nevus, 5 junctional nevi, 9 compound nevi, 10 nevi
undergoing regression.
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: Unclear
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Bono 1996
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Unclear
Data collection: Not reported
Period of data collection between March
1993 and Oct 1994
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions at the Instituto
Nazionale Tumori of Milan.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) Instituto Nazionale Tumori of Milan
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. eligible: 45
Sample size (lesions): No. eligible: 54/ No. included: 43
Participant characteristics: NR
Lesion characteristics: Site - Face/Ears: 3 (6%)/ Trunk:
39 (72%)/ Limbs: 12(22%); 10 MM ≤1mm depth; median
size: 10mm (4 to 40mm)
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Not reported; 'clinical diagnosis'
Diagnosis based on: Single observer; n= NR
Observer qualifications: treating surgeon
Experience in practice: Not described
Experience with index test: Not described
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
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A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
Histological diagnosis Disease positive: 18;
Disease negative: 25
Expert opinion - Disease negative: 11
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not reported):
18
Mild/moderate dysplasia: 8 dysplactic nevi
Benign naevus: 17 common melanocytic nevi
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: only 43 lesions had
complete clinical and histological
information. 11 lesions not surgically
removed had only clinical diagnosis
(benign) and were not included in the final
accuracy analysis
Time interval to reference test: not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Yes
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Bono 2002
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection June 1998-March
2000
Country Italy
Test set derived A training set was
separately derived using data
obtained from 237 previously studies
lesions (Farina 2000)
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Cutaneous pigmented lesions with
clinical and/or dermatoscopic features that suggested a
more or less important suspicion for CM
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Location/site of lesion - Awkwardly
situated lesions eg interdigital space, ears, nose or
eyelids. Lesions on scalp excluded due to hair
interference with reflectance - lesion size obvious large,
thick melanomas
Sample size (patients): No. included: 298
Sample size (lesions): No. included: 313
Participant characteristics: Mean age: 40y (10-86y);
Male: 122; 41%
Lesion characteristics: Lesion site: Head/Neck: 3%;
Trunk: 61%; Limbs: 36%; Thickness ≤1mm: 70%
(46/66); for 55 invasive MM: median thickness 0.64mm,
range 0.17-3.24mm. Median diameter: 11mm (3-31mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm (Training in the unit is based on ABCD but subjective experience of
the clinician used for diagnosis)
Method of diagnosis: In person diagnosis
Prior test data: Same clinician undertook clinical diagnosis and diagnosis using dermoscopy
Diagnostic threshold: Clinical diagnostic criteria based on subjective experience; emphasise lesion
colour over dimensions. Diagnosis of suspect CM made when the level of suspicion was 'roughly 50%
or more'. ABCD (asymmetry, border, colour, dimension) criteria have been the basis of training at the
unit, but is not implemented in diagnosis; preferred emphasis on colour rather than dimensional
character
Diagnosis based on: Single observer; (n=1)
Observer qualifications: Surgical oncologists
Experience in practice: High experience or ‘Expert’; over 5 years
Dermoscopy: also evaluated in same study (no algorithm)
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Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
TARGET CONDITION (Final diagnoses)
Melanoma (invasive): 55; Melanoma (in situ):
11; BCC: 6
'Benign' diagnoses: 241;151 compound
naevus, 24 junctional naevus, 12 dermal
naevus, 12 lentigo simplex, 10 dysplastic
naevus, 8 spindle-cell naevus, 8 sebhorrheic
keratosis, 5 blue naevus, 3 spitz naevus, 8
other.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: NR
Interval between index and reference: NR
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
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Notes -
 
Bono 2002b
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Dec 2000 and Aug
2001
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive cutaneous pigmented
lesions that were <=6mm in diameter and required
surgical biopsy for diagnosis based on clinical or
dermoscopic suspicion of CMM
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Not reported
Exclusion criteria: lesion size >6mm; non-pigmented
Sample size (patients): No. eligible: 349/ No. included:
157
Sample size (lesions): No. eligible: 375/ No. included:
161
Participant characteristics: Mean age 38y (14-82); Male:
61 (39%)
Lesion characteristics: Site: head/Neck: 14 (9%); trunk:
88 (55%); limbs: 59 (36%)
Lesion size: median: 5mm (1mm to 6mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Visual inspection (VI). No algorithm (ABCD (asymmetry, border, colour, dimension) criteria have been
the basis of training at the unit, but is not implemented in diagnosis; preferred emphasis on colour
rather than dimensional character)
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: Dermoscopy evaluated in same study by same observer(s)
Diagnostic threshold: A diagnosis of suspect CM is made when the level of suspicion is roughly 50%
or more; lesions at a lower index of suspicion were considered benign for the purposes of this study.
Diagnosis based on: Single observer diagnostic criteria based on the subjective experience of the
single clinician examining the pigmented lesion (n=2)
Observer qualifications: Surgical oncologists
Experience in practice: High experience or ‘Expert’; observers described as “expert in the recognition
of pigmented lesions"
Other detail: Diagnostic criteria were based on the subjective experience of the single clinician
examining the pigmented lesion, although the ABCD criteria have been the basis of training at the unit,
they did not consider the ABCD mnemonic an essential formula for diagnosis of CM. They did not take
into consideration the dimensional character and attributed great importance to the colour of a given
lesion.
Dermoscopy: performed by the same two clinicians who firstly made and registered the clinical
diagnosis
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 13 CM; Disease negative: 148
Target condition (Final diagnoses) 
Melanoma (invasive): 10; Melanoma (in situ): 3;
BCC: 2 (1.2%)
Mild/moderate dysplasia: 26 (16.1%);
Sebhorrheic keratosis: 4 (2.5%); Benign naevus:
compound nevus 57 (35.4%), junctional nevus 38
(23.6%), spindle-cell nevus 6 (3.7%), spitz nevus
5 (3.1%), blue nevus 2 (1.2%), other 6 (3.7%),
Lentigo simplex 2 (1.2%)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
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B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Bono 2006
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection: Jan 2003 - Dec 2004
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive patients with pigmented
skin lesions with a maximum diameter of <=3mm
undergoing excision. The decision for diagnostic
excision was based on clinical and/or dermoscopic
features suggesting a more or less important suspicion
for CM
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) Istituto NazionaleTumori of Milan
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: - lesion size >3mm
Sample size (patients): No. eligible: 204/ No. included:
204
Sample size (lesions): No. eligible: 206/ No. included:
206
Participant characteristics: Median age: 40 (6-74); Male:
71 (35%)
Lesion characteristics Head/Neck: 8 (4%); Trunk: 84
(41%); Limbs: 114 (55%). Median size: 2mm (1 to 3mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: Dermoscopy evaluated in same study by same observer(s)
Diagnostic threshold: A diagnosis of suspicious CM is made when the level of suspicion is roughly
50% or more; lesions at a lower index of suspicion were considered not CM
Diagnosis based on: Single observer; n= 1
Observer qualifications: Not reported (assumed Oncologist as per Bono 2002 and Bono 2002b);
"single clinician examining the pigmented lesion"
Experience in practice: Not described
Experience with dermoscopy: Not described
Dermoscopy: evaluated in same study; Menzies criteria
Any other detail: ABCD (asymmetry, border, colour, dimension) criteria have been the basis of training
at the unit, but is not implemented in diagnosis; preferred emphasis on colour rather than dimensional
character
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
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Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: The slides were evaluated according to widely
accepted criteria for the histopathological diagnosis of
the various pigmented lesions.
Disease positive: 23; Disease negative: 183
Target condition (Final diagnoses) 
Melanoma (invasive): 19 (9.2%); Melanoma (in situ): 4
(2.0%)
Mild/moderate dysplasia: dysplastic naevus 10 (4.9%);
junctional naevus 76 (36.9%); compound naevus 50
(24.3%); dermal naevus 12 (5.8%); blue naevus 11
(5.3%); reed naevus 7 (3.4%); spitz naevus 3 (1.5%);
halo naevus 3 (1.5%); lentigo simplex 7 (3.4%); other
4 (1.9%)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Bourne 2012
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection June 1 - July 6 2009
Country Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All skin lesions consecutively excised
at a skin cancer practice to exclude skin cancer and
common lesions assessed as clearly benign and not
biopsied were included
Setting: Primary
Prior testing: Clinical and/or dermatoscopic suspicion.
Prior testing to assemble the test set occurs in
secondary care by an experienced skin cancer doctor,
then the images are tested on primary care
professionals
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Clinically obvious basal cell
carcinomas which could be easily diagnosed without
dermoscopy were not included in the collection set.
Sample size (patients): No. eligible: 46/ No. included: 46
Sample size (lesions): No. eligible: 50/No. included: 50
Participant characteristics: Mean age: 58 (30 to 60);
Male: 22
Lesion characteristics: Face = 8; Neck = 1; Chest = 3;
Back = 21; Shoulder = 2; Arm = 3; Thigh = 4; Leg = 7;
Foot plantar = 1
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used; Image assessments were done on four occasions, each
time using a different diagnostic approach.
Diagnostic threshold: Not reported clinicians provided with Excel answer sheets for each method
listing the various criteria used in that algorithm but no algorithm was cited for VI
Diagnosis based on: Average (n=4)
Observer qualifications: 3 GPs and 1 clinical nurse
Experience in practice: Mixed; described as varying levels of dermatoscopic experience
Dermoscopy: evaluated in same study; 3-point rule; Menzies criteria
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis plus other
Histopathological examination (n=46);
Expert diagnosis as benign (n=3); Digital follow up
(n=1)
Target condition (Final diagnoses) 
Melanoma (invasive): 1; Melanoma (in situ): 7; BCC: 6;
Lentigo maligna 1
Sebhorrheic keratosis: 5; 'Benign' diagnoses: Banal
nevus 10, Blue naevus 1, Nevus and seborrhoeic
keratosis/solar lentigo collison 3, Solar lentigo 4, LPLK
4, Dermatofibroma 1, Psoriasis 1, Solar keratosis 2,
Intraepidermal carcinoma 3, Regressed
keratoacanthoma 1
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: As two of the methods
(Menzies and 3 point checklist) related to only
pigmented lesions, the 5 non-pigmented
specimens in the set of 50 were excluded from
the contingency tables for these methods.
Time interval to reference test: "all skin lesions
consecutively excised to exclude skin cancer
were recorded"
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Unclear
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Carli 2002
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective for clinical
examination and in-vivo dermoscopy;
Retrospective image selection / Prospective
interpretation for ex-vivo dermoscopic evaluation
Period of data collection: June 1997 - December
1998
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinically equivocal and suspicious
pigmented skin lesions subjected to excisional
biopsy at the Institute of Dermatology
Setting: Secondary (not further specified)
Prior testing: Clinical and/or dermatoscopic
suspicion
Setting for prior testing: Secondary
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): 256
Participant characteristics: None reported
Lesion characteristics Of the cutaneous melanomas,
14 (25.9%) were in situ melanoma (Clark level I), 18
(33.3%) were invasive with less than 0.75 mm
thickness, 19 (35.3%) were of intermediate
thickness (0.76–1.50 mm) and three (5.5%) were
thicker than 1.5 mm. The median thickness of
invasive melanomas was 0.94 mm ± 0.5 (SD) (range
0.2–2.6).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Other test data: clinical examination and in vivo dermoscopy were performed before excision by two
trained dermatologists and diagnosis reached
Diagnostic threshold: Not reported
Diagnosis based on: Consensus (2 observers); final clinical diagnosis was based on agreement
between the two observers. In case of disagreement, the opinion of a third observer (B.G.) was
considered to be the judge for the diagnosis
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; described as “dermatologists with extensive
experience in both clinical and dermoscopic diagnosis of pigmented skin lesions”
Dermoscopy: evaluated in same study; pattern analysis
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
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B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Target condition (Final diagnoses) 
Melanoma (invasive): 40; Melanoma (in situ):
14
BCC: 5
Sebhorrheic keratosis: 4; Benign naevus: 90
common melanocytic naevi; 78 melanocytic
naevi; 9 blue naevi; 16 Spitz reed naevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Carli 2002b
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection: NR
Country: Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinically suspicious or equivocal
pigmented skin lesions undergoing excision for
diagnostic purposes; only lesions with a diameter of
14 mm or less were included
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: None reported
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 57
Participant characteristics: None reported
Lesion characteristics: thickness ≤1mm: 11 cases (5
in situ 6 invasive); All <=14mm diameter
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs; Fixed focus distance of 10cm; images observed using a
viewer in two separate diagnostic sessions
Prior test data: No further information used; Contact (dermoscopic) images viewed first and then
distant images (clinical), without knowing the classification of the contact image of the individual
lesions.
Diagnostic threshold: Not reported
Diagnosis based on: Consensus (2 observers); n=2
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; States 'with experience in the field of PSL'
Other detail: Used an AF micro Nikkor 60 lens objective mounted on a NIKON f50 camera, with a fixed
focus distance of 10cm
Dermoscopy: evaluated in same study; no algorithm
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histology (not further
described) 
Disease positive: 21; Disease negative: 36
Target condition (Final diagnoses) 
Melanoma (invasive): 6; Melanoma (in
situ): 5; BCC: 10
'Benign' diagnoses: 36
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results
of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: No exclusions reported
Time interval to reference test: Photographic
procedures performed consecutively prior to
surgery
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Carli 2003b
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: 1999-2001
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinically difficult to diagnose or
equivocal melanocytic lesions randomly selected
from image database; all melanomas less than 1mm
thickness.
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: >/=1mm thick melanomas,
dermoscopically peculiar lesions (eg Blue nevi or
Spitz nevi)
Sample size (patients): NR
Sample size (lesions): No. included: 200
Participant characteristics: None reported
Lesion characteristics: Diameter <6mm 58, 6-10mm
87, >=10mm 55 (results reported per subgroup).
Lesions ≤1mm thickness: 64; median thickness
0.3mm, 25th-75th centile 0.00-0.58mm; Mean
diameter 7.4 (SD2.79) mm; Median: 7mm (2-16mm)
Any other detail: Same lesions appear to be reported
in De Giorgi 2011 but with a different set of 8
observers (De Giorgi 2011 excluded from review on
this basis)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used; dermoscopic images interpreted subsequent to clinical
images
Diagnostic threshold: Not reported
Diagnosis based on: Average; n= 8
Observer qualifications: Dermatology registrar; 2 final year residents. Dermatologist 6
Experience in practice: Mixed - 2 senior experts, 4 practicing dermatologists, 2 last year resident
dermatologists. Classified as 'high' due to expertise/training in dermoscopy use
Other detail: Clinical photos using Nikon F40 with macro lens at 15cm.
Dermoscopy: evaluated in same study; no algorithm (own choice)
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 64; Disease negative: 136
Target condition (Final diagnoses)
Melanoma (invasive): 40; Melanoma (in
situ): 24
Other: 136 melanocytic nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: No exclusions reported
Time interval to reference test: Interval not
described
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Chang 2013
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection: Jan 2006 to Jul 2009
Country: Taiwan
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Potentially malignant biopsied or
excised skin lesions (non-tumour specimens
excluded)
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: prior surgery; image mis-
registered or poor quality images (unfocused or
containing a motion artefact) (considered under Flow
and Timing)
Sample size (patients): No. eligible: 3964; No.
included: 676
Sample size (lesions): No. eligible: 4192; No.
included: 769
Participant characteristics: Mean age: 47.6 (SD
21.0); Male: 296; 43.8%
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Not reported; clinicians’ impressions prior to biopsy were classified as ‘‘benign’’,
‘‘malignant’’, or ‘‘indeterminate’’. When the clinicians were not confident enough to make a definite
benign or malignant diagnosis, the clinical impression was considered as ‘‘indeterminate’’ data
extracted for malignant vs rest and malignant/indeterminate vs rest
Diagnosis based on: Single observer; board-certified staff dermatologists from institute; n= 25
Observer qualifications: Dermatologist
Experience in practice: Board certified; High
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
49 / 256
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histology (not further
described) 
Disease positive: 174; Disease negative:
595
Target condition (Final diagnoses) 
Melanoma (invasive): 4; Melanoma (in
situ): 4; BCC: 110; cSCC: 20
'Benign' diagnoses: 595
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results
of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: mis-registered or poor
quality images (unfocused or containing a
motion artifact) as a study inclusion criterion
Time interval to reference test: Not described
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Collas 1999
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection January 1996 and
August 1997
Country: France
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions undergoing
excision by dermatologists in private practice, and
by hospital dermatologists
Setting: Secondary (general dermatology); Private
care
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Secondary (general
dermatology); Private care
Exclusion criteria: None reported
Sample size (patients): No. included: 353
Sample size (lesions): No. included: 353
Participant characteristics: Male: 46%; 162
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm. Own new algorithm;
Diagnosis based on features from ABCD and 7-point checklist but neither one specifically followed.
Authors' select own combination of lesion characteristics based on observed data
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Diagnostic threshold: Data can be extracted at a number of thresholds
1. Primary diagnosis of melanoma; 2. Certainty of melanoma diagnosis; 3. Various combinations of
assessed features (based on logistic regression)
Recorded: Most likely clinical diagnosis; degree of melanoma suspicion and clinical sign(s)
that led to the removal decision based on ABCD rule (McCarthy 1995) and the seven-point
checklist (Healsmith 1994).
Diagnosis based on: Single observer; n= NR
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Other detail: Most predictive features derived by logistic regression from the following list: 1) irregular
contours , 2) abnormal pigmentation, 3) blurred, 4) frank tumor appearance, 5) erosion, ulceration or
bleeding, 6) regression signs. 7) lesion recently amended, 8) lesion appeared recentl , 9) pruritic
lesion, 10) other
Visual Inspection - in-person
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others? No
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histology (not further
described) 
Disease positive: 38; Disease negative:
315
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 38
Other: 160
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results
of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: No exclusions reported
Time interval to reference test: Consecutive;
"When the dermatologist decided to resection a
pigmented lesion, he fulfilled a pre-printed
sheet"
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? Low risk
Notes
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
52 / 256
Notes -
 
Cristofolini 1994
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: October 1990-
June 1991
Country: Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with pigmented lesions
presenting during a campaign for the early diagnosis
of cutaneous melanoma at the Dermatology
Department in Trento
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Lesions that were not taken into
consideration included benign lesions, naevi of Unna
and Miescher types and naevi that showed no
inclusion criteria at the ABCDE clinical examination
Sample size (patients): No. eligible: 700 people; No.
included: not reported
Sample size (lesions): No. eligible: 220; No.
included: 220
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
53 / 256
Index tests
Visual inspection (VI) ABCDE
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: Dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: lesions showing at least two of the ABCDE criteria all of which were shown the
same diagnostic importance, were considered positive.
Diagnosis based on: Unclear; n=4
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; all trained in the recognition of pigmented lesions
during a training course about the clinical diagnosis of naevi and melanomas; all working in a
department where the early diagnosis of melanoma had been dealt with for over 10 years.
Experience with dermoscopy: High experience /‘Expert’ users
Other detail: ABCDE criteria are (asymmetry in shape, border irregular and notched, colour mottled-
haphazard display, dimension >6mm, evolution changes in pigmentation)
Dermoscopy: evaluated in same study; Pattern analysis
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported):
33
Mild//moderate dysplasia: 23 dysplastic naevi;
Sebhorrheic keratosis: 4; Benign naevus: 158
common naevus
Other: 2 thrombosed angiomas
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: No exclusions reported
Time interval to reference test: Not described
Time interval between index tests: clinical
evaluation directly followed by dermoscopy
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Cristofolini 1997
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Nov 1992 to Sept
1993
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with small and flat
common and atypical pigmented skin lesions
recruited during a health campaign for the early
diagnosis of CM underwent clinical diagnosis,
computerised analysis by SVS and subsequent skin
biopsy.
Setting: Secondary (general dermatology)
Prior testing: No prior testing
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: None reported
Sample size (patients): 176
Sample size (lesions): 176
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI) ABCD
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Not reported; examined individual ABCD characteristics but no 'rule' as to when
to diagnose melanoma; appears to be subjective dx
Diagnosis based on: Consensus (3 observers) (n=3)
Observer qualifications: Dermatologist
Experience in practice: Not described in paper but judged as 'High'; States that “All lesions were
examined by three dermatologists according to the ABCD system, if they disagreed a fourth
dermatologist an expert in the diagnosis of pigmented lesions was consulted.” Cristofolini 1994
describes four dermatologists "trained in the recognition of pigmented lesions", three of the four are in
common with Cristofolini 1997.
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not
reported): 35
Other: 141 melanocytic nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: not reported
Time interval to reference test: 'subsequent
skin biopsy'
Time interval between index test(s): not
reported-appears to be simultaneous
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
de Giorgi 2012
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection between Oct 2006 and
Sept 2010
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented melanocytic skin
lesions with a maximum diameter of 6mm excised at
Dept Dermatology
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Location/site of lesion - palmar
and plantar regions, mucosal lesions and pigmented
melanocytic lesions of the nails excluded
Sample size (patients): NR
Sample size (lesions): No. included: 103
Participant characteristics: Mean age: Melanoma
group male (50.4yrs) female (48.4 yrs); Benign
group male (36yrs) female (36.8yrs)
Lesion characteristics: Head/Neck: 3; Trunk: 21;
Upper limbs/shoulder: 16; Lower limbs/hip: 26;
back= 34; dorsal acral =3. Thickness: <= 1mm 15;
>1mm= 1 MM
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) ABCD
Method of diagnosis: Clinical photographs
Prior test data: Unclear
Other test data: Dermoscopic images also presented separately to observer (only presence/absence
of particular dermoscopic features recorded; not an overall diagnostic assessment)
Diagnostic threshold: ABCD criteria =>2 criteria present
Diagnosis based on: Consensus (3 observers); n= 3
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; “the four dermatologists had the same level of
training and experience in dermatology, with more than 5 years of practice in dermoscopy”
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 34; Disease negative: 69
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 34
'Benign' diagnoses: 69 benign melanocytic
nevus
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported;
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Dolianitis 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection July 2001 to June 2002
Country Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Dermoscopy training study using a
CD with five test sets of images, each with 40 images
of melanocytic skin lesions. Only good-quality
macroscopic and dermoscopic images were
included.
Setting: Training images; author inst Dept
Dermatology, University of Melbourne
Prior testing: unclear
Setting for prior testing: Not reported
Exclusion criteria: Nonmelanocytic lesions; poor
quality index test image - only good-quality
macroscopic and dermoscopic images were
included, where the whole lesion was visible,
including the entire periphery (considered under
flow/timing)
Sample size (patients): Not reported
Sample size (lesions): No. eligible: 40; No. included:
40
Participant characteristics: None reported
Lesion characteristics: ≤1mm thickness: 14 invasive
melanomas; median 0.50 mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: Clinical photographs alone
Prior test data: No further information used
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone.
Diagnostic threshold: Not reported
Diagnosis based on: Average; 61 participants (invited to participate in a study comparing dermoscopic
algorithms; advertised at several medical meetings and on a Web site for primary care physicians).
Observer qualifications: 10 dermatologists, 16 dermatology trainees, 35 GPs
Experience in practice: Mixed. Participant (volunteers) "had a range of experience levels with
assessment of skin lesions [outlined in detail in the paper].. and a significant number were novices in
dermoscopy”. Paper reports 82% of participants responded that they assessed at least 2-4 PSL per
week. Participants were given explanatory written material and CDs containing educational material on
dermoscopy and test images.
Dermoscopy: evaluated in same study based on dermoscopic images alone; pattern analysis; 7-point
checklist; ABCD; Menzies criteria
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
plus other (one lesion described as having
no biopsy performed)
Histology (not further described) Disease
positive: 20; Disease negative: 19
Expert dx: 1
Target condition (Final diagnoses) 
Melanoma (invasive): 18; Lentigo maligna 2
Benign naevus: 7 dysplactic nevi; 3 spitz
nevi; 3 junctional nevi; 2 compound nevi; 4
other (ink-spot lentigo, blue nevus, solar
lentigo, ephelis)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
Unclear
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Dummer 1993
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Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: 12 month period
(year/dates NR)
Country: Germany
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with skin lesions difficult to
diagnose clinically
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic) a type of specialist
care- dermatology based clinic
Exclusion criteria: Patients who had excisions performed
in individual practices or where there was no histology or
cases that were so obvious they didn't need to have
further investigation (clearly benign)
Sample size (patients): Not reported
Sample size (lesions): No. eligible: 824; No. included:
771
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection: No algorithm
Method of diagnosis: In person
Prior test data: In person
Other test data: Dermoscopic images viewed separately
Diagnostic threshold: NR
Diagnosis based on: Single observer; (n=2 or 3)
Observer qualifications: Unclear; clinician based in Dermatology clinic
Experience in practice: Unclear
Experience with index test: Unclear
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 23MM; Disease negative:
748 benign
Target condition (Final diagnoses) 
Invasive melanoma: 23
Benign naevus 706; Sebhorrheic keratosis 4;
Benign non-melanocytic naevus 32
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 53 non-melanocytic
lesions not included in the final analysis (no
melanomas present in this group)
Time interval to reference test: Not reported
Time interval between index test(s): Not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Ek 2005
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection January 2001 to
December 2002
Country Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Lesions excised at tertiary referral
centre for the management of cancers; only those
lesions in which malignancy could not be excluded were
included
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Punch, shave or incisional biopsies
and palliative excisions. Equivocal pathology report
(n=56).
Sample size (patients): No. eligible: 1302; No. included:
1223
Sample size (lesions): No. eligible: 2678; No. included:
2582
Participant characteristics: Mean age: 73.6y (16–102y).
Male: 784 (64.1%); History of melanoma/skin cancer (%)
224; 8.7% recurrent lesions
Lesion characteristics: Head/Neck: 61%; Trunk: 14.4%;
Limbs: 24.6%
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Not reported pre-operative diagnosis
Diagnosis based on: Unclear; Likely single (n= 5).
Observer qualifications: Three consultants, a plastic surgery trainee and a clinical assistant.
Experience in practice: Mixed (low and high experience combined); Plastic surgery trainee usually 1st
year, on 6 month rotation; clinical assistant described as having “many years of experience”.
Other detail: Some results are presented for consultant, senior registrar and registrar but underlying
patient numbers are not provided per observer to allow separate 2x2 estimation. The discussion does
describe the “six MM misdiagnosed as benign … as .. assessed by non-consultants”.
Visual Inspection - in-person
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 23
BCC: 1214; cSCC: 517
'Benign' diagnoses: 188 (7.3%) SCC in situ
(Bowen’s disease), 330 (12.8%) solar
keratoses, 63 (2.4%) seborrhoeic keratoses
247 (9.6%) were other benign lesions
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Lesions with incomplete
or incorrectly entered proformas were
excluded (n=40).
Index to reference interval: Consecutive; used
pre-operative clinical diagnosis of lesions
undergoing biopsy
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
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Notes
Notes  
Gachon 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series (dermatologists recruited
and asked to use standardized questionnaire form
whenever he or she decided to remove a nevus or
MM for any reason, e.g., suspicion of MM,
aesthetics,comfort, prevention).
Data collection: Prospective
Period of data collection NR
Country France
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic skin lesions removed for any
reason (e.g. suspicion of melanoma, aesthetics, comfort,
prevention) by volunteer dermatologists.
Setting: Secondary (general dermatology) and private care;
mostly "community dermatologists working in a private
setting, and only 2 were academic dermatologists"
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion / Patient request for
evaluation/excision; 1199 (29.7%) excised because they
were considered suspicious by the dermatologist, and 869
(21.5%) because they were considered as precursors by
the dermatologist; 1634 (40.7%) removed due to aesthetic
or functional reasons, and 535 (13.3%) “only to reassure
the patient"
Setting for prior testing: N/A
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 4036
Participant characteristics: None reported
Lesion characteristics: 36 (24.1%) of 149 melanoma were
in situ or other invasive lesions with a median Breslow
thickness of 0.60 mm
Are the included patients and chosen study setting
appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Visual inspection (VI); No algorithm Accuracy presented only for clinician's first clinical impression of
lesions; after recording likelihood of melanoma, assessments were made as to the contributions of
pattern recognition, ABCD criteria and ugly duckling (differential recognition)
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: 'considered suspicious' by dermatologist
Diagnosis based on: Single observer; (n= 135 of 200 volunteers)
Observer qualifications: Dermatologist
Experience in practice: Not described; Most were community dermatologists working in a private
setting, and 2 were academic dermatologists.
Experience with index test: Not described
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 149; Disease negative:
3887
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 149 (36 were in situ or other
invasive lesions with a median Breslow
thickness of 0.60 mm)
'Benign' diagnoses: 3629 nevi (89.9%); 4
uncertain MMs/nevi (0.1%); and 254 non-
melanocytic lesions clinically considered to
be nevi or MMs (6.3%).
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: NR
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Green 1991
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Feb 1989 - Aug
1990
Country Australia
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented lesions with complete
clinical and histological data
Setting: Secondary (referred from surgery,
dermatology, casualty)
Prior testing: Not reported
Setting for prior testing: Depts surgery, dermatology,
casualty
Exclusion criteria: None reported
Sample size (patients): No. eligible: 81 / No.
included: unclear
Sample size (lesions): No. eligible: 89; No. included:
70
Participant characteristics: Median age 32 yrs; Male
36 (44%)
Lesion characteristics: site Trunk: 80%; - Limbs:
10%; - face and neck 10%
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI); No algorithm
Method of diagnosis: In person diagnosis
Prior test data: In person
Diagnostic threshold: Not reported clinical diagnosis recorded plus assessment of diameter, colour,
regularity of outline, diffuseness of edge and palpability
Diagnosis based on: Single observer; (n= NR)
Observer qualifications: Mixed; "in the majority of cases a surgeon or a dermatologist"
Experience in practice: Not described
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard; Histological diagnosis
and Expert diagnosis
Histology: 62/70 lesions
Expert diagnosis: 8/70 lesions; Eight lesions
had clinical diagnoses assigned (all benign)
in the absence of available histology reports
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 5
BCC: 2; Sebhorrheic keratosis: 7; Benign
naevus: 53 Other: 2 skin tags, 1 'lentigo'
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: 19/89 lesions
excludedue to incomplete clinical and
histology records.
Time interval to reference test: Assumed
consecutive; pathology referral form used to
ascertain clinical diagnosis
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Green 1994
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported; appears to use
previously acquired images to develop a new
CAD classifier (not included as derivation), and
compare results to clinical Dx of clinicians as
recorded in notes. Unclear whether set up
prospectively or was retrospective assessment.
Period of data collection August 1990 to April
1992
Country Australia
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented lesions for excision
Setting: Secondary (Dept Surgery)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 129
Sample size (lesions): No. eligible: 204; No.
included: 164
Participant characteristics: Mean age 36y, range 6 to
87y; Male: 42.6%
Lesion characteristics: site - Face/Neck: 10% Trunk:
66%- Limbs: 24%
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: In person diagnosis
Prior test data: No further information used
Diagnostic threshold: Not reported; clinical diagnosis recorded plus assessment of diameter, colour,
regularity of outline, diffuseness of edge and palpability (same as for Green 1991)
Diagnosis based on: Single observer; (n= NR)
Observer qualifications: Not reported
Experience in practice: Not described
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histology (not further
described) 
Disease positive: 18; Disease negative: 146
Target condition (Final diagnoses) 
Melanoma (invasive): 18; Melanoma (in situ): 3
128 melanocytic nevi; 15 miscellaneous
pigmented lesions including seborrhoeic
keratoses, basal cell carcinomas, and lentigines
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 33 lesions excluded due to
problems using the images with the CAD software,
e.g. lesion 'too big'; image 'obscured by hairs or
surgeons pen marks' or 'software was unable to
contend with the lesion characteristics, mainly
because the lesion was too light or too fragmented'
or 'avoidable operator error'
Time interval to reference test: NR
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application
of index test(s) of at least: 3 months for melanoma or cSCC or 6 months
for BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Grimaldi 2009
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Oct 2005 - Mar
2006
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Cutaneous pigmented lesions with
digital images forwarded by primary care physicians
to a referral centre for confirmation of diagnosis.
Setting: Primary; Lesions selected for referral by
GPs; accuracy of GP diagnosis assessed
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Lesions whose removal had been
explicitly demanded by the patients for aesthetic
reasons, as well as those irritated or subjected to
trauma
Sample size (patients): No. included: 197
Sample size (lesions): No. included: 235
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI); No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: "two-step judgment (before and after dermoscopy) formulated by the sending
physician, who labelled each lesion as ‘benign’ or ‘suspicious for malignancy’."
Diagnostic threshold: Not reported "Each physician was asked to formulate a written first judgment of
every lesion before digital acquisition and to re-evaluate it after dermoscopy"
Diagnosis based on: Single observer; (n= 13)
Observer qualifications: GP; From approximately 250 primary care clinicians attending a conference,
13 volunteered to participate
Experience in practice: Not clearly described; assumed to be Low experience with pigmented lesions
Experience in dermoscopy: Unclear; classified as 'trained' - “simple protocols for diagnosis were made
up and given to the participants via e-learning courses, direct meetings, and involving self assessment
procedures”
Dermoscopy: evaluated in same study; no algorithm (ABCD used for telediagnosis at reference centre)
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
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Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis plus follow
up (Reference is expert diagnosis for Teledermatology
component of study)
Histology (not further described): n=16; Disease
positive: 5; Disease negative: 11
Clinical FU (6 months) plus histology of suspicious
lesions: n=219; Disease positive: 0; Disease negative:
208
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 5
Other: 230 benign
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: NR
Time interval to reference test: NR
Time interval between index test(s): NR
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
Yes
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Kopf 1975
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection: 1955 to 1967
Country: US
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All lesions subject to biopsy at the
Oncology Section of the Skin and Cancer Unit.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 5538
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI); No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Diagnostic threshold: Not reported; clinical diagnosis
Diagnosis based on: Single observer; in clinic diagnosis (n= NR)
Observer qualifications: Oncologist
Experience in practice: Not described
Experience with index test: Not described
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 99; Disease negative: 5439
Target condition (Final diagnoses) 
Melanoma (invasive): 99 (described as 'malignant
melanoma')
Diagnoses listed only for false positives; included: 3
pigmented BCC, 3 dermatofibromas, 2 junction nevi, 2
compound nevi, and 1 each of: Kaposi sarcoma,
hemangioma, seborrheic keratosis, leiomyoma, cellular
blue nevus, sclerosing hemangioma, SCC, verrucous
nevus, and intradermal nevus FNs included: 6 clinically
diagnosed as pigmented BCC; 2 "other forms" of BCC;
3 junction nevi; 3 pyogenic granulomas; 2 compound
nevi; 2 squamous cell carcinomas; 2 halo nevi; 1
Bowen disease; 1 seborrheic keratosis; and 1 lentigo.
Seventeen of these lesions were pigmented and six
were not.
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: Not reported
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Krahn 1998
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: NR
Country: Germany
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Excised pigmented skin lesions
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 80
Sample size (lesions): No. included: 80
Participant characteristics: None reported
Lesion characteristics range in thickness
(melanomas) 0.18-1.9mm; 29/39 <0.76mm; 7/39
0.76-1.5mm; 3/39 >1.5mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm reported
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Other test data: Dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: Not reported; no details
Diagnosis based on: Single observer (n=1)
Observer qualifications: Not reported likely Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Dermoscopy: evaluated in same study; no algorithm
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
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A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone including histometrics
Disease positive: 39; Disease negative: 41
Target condition (Final diagnoses) 
Melanoma (invasive): 39 (SSM, lentigo MM,
nodular M)
Benign naevus: 37 common nevus; 3
dysplastic nevus, 1 Spitz nevus
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Langley 2001
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Not reported
Country: USA
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with lesions scheduled for
excision at the pigmented lesion clinic to either remove
atypical nevi or to rule out melanoma or for cosmetic
reasons
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Selected for excision; to remove atypical
nevi or rule out melanoma or for cosmetic reasons
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 29
Sample size (lesions): No. eligible: 40; No. included: 38
Participant characteristics: Mean age 39 yrs, range 19 to
95 years; Male: 14 (48%)
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Not reported NR; clinical diagnosis
Diagnosis based on: Unclear likely in clinic diagnoses (n= NR)
Observer qualifications: Not reported likely dermatologists
Experience in practice: Not described
Experience with index test: Not described
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard - Histological diagnosis plus other
Histology details (n=38): "After excision, the samples were
processed in paraffin and stained with H&E for routine light
microscopy. Correlation was performed by examining the
confocal images and the pathology sections to compare
nuclear, cellular, and morphologic detail and to identify
potential significance of the in vivo CSLM observations.
For the histologic diagnosis of dysplastic nevi, we used the
criteria that are defined in the World HealthOrganization
consensus study."
Expert diagnosis (n=2): Two lesions did not undergo
histology; expert diagnosis only (both benign)
Target condition (Final diagnoses) 
Melanoma (invasive): 3; Melanoma (in situ): 1; Lentigo
maligna 2
Dysplastic nevi: 17; Benign naevus: 15
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Lorentzen 1999
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Between 1994 and
1997
Country: Denmark
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with lesions suspicious for
CMM referred to outpatients clinic
Excluded participants: none reported
Time interval to reference test: not reported
Setting: Not reported
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion
Setting for prior testing: Not reported
Exclusion criteria: Poor quality index test image
(considered under flow/timing)
Sample size (patients): No. eligible: 242; No.
included: 232
Sample size (lesions): No. eligible: 242; No.
included: 232*
Participant characteristics: None reported
Lesion characteristics: None reported
*NB Not all cases were assessed by all observers;
2x2 are based on presented sensitivity and
specificity estimates for full dataset of lesions; "the
dermatoscopy experts assessed almost all cases
(98 ± 100%), whereas the non-expert group
completed fewer assessments, from 76 to 98%.
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used; no option to change clinical diagnosis after viewing
dermoscopic image
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone; clinical images presented before dermoscopic images
Diagnostic threshold: Not reported; clinical diagnosis
Diagnosis based on: Average; n= 9
Observer qualifications: Dermatologist
Experience in practice: High; Moderate; Mixed (average reported); 4 'experienced dermatologists' (4-5
years daily experience) & 5 'non-expert dermatology residents' (1-2 years interest and formal training
in dermatoscopy]
Experience with index test: High; Moderate; Mixed
Visual Inspection - in-person
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A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 65 ; Disease negative: 167
Target condition (Final diagnoses)
Melanoma (invasive): 49 'malignant melanoma'
BCC: 16
Sebhorrheic keratosis: 12; Benign naevus: 137
(pigmented nevi=116; blue nevi=16; atypical
nevi=5); Other: 18 (spitz nevi, Bowen's disease,
sarcoid, nevus spilus, hemangioma, and others)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 10 cases were "considered unfit
for evaluation" due to poor quality image
Reference interval: "biopsy specimens...were obtained
after the clinical and dermatoscopic photographs had
been performed"
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-
up following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was
the interval between application of the different algorithms 1 month
or less?
Could the patient flow have introduced bias? High risk
Notes
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McGovern 1992
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Between 1 Nov
1989 and 31 Oct 1990
Country: USA
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented lesions excised to rule
out dysplasia, lentigo maligna or malignant
melanoma
Setting: Secondary (general dermatology); Army
Dermatology clinic - appears to be open access
Prior testing: No prior testing. Multiple reasons given
for seeking dermatological consultation, including (in
descending order): increasing size, "mole check",
inflammation, color change, itch, follow-up,
variegation, cosmetic, referral, irregular border, seen
for other lesion, unknown, large size
Setting for prior testing: N/A
Exclusion criteria: None reported
Sample size (patients): No. eligible: 179; No.
included: Not reported
Sample size (lesions): No. eligible: 237; No.
included: 13 lesions excluded and 32 lesions
unaccounted for.
Participant characteristics: Mean age: 44 (SD 18);
Range: 3 months to 86 years; Male: 89 (49%)
Lesion characteristics: lesion site: head/neck: 71
(30%); trunk: 52 (23%); upper limbs/shoulder: 22
(9%); lower limbs/hip: 33 (14%); back = 58 (24%);
genitalia = 1 (0.4%)
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI) ABCD; Assessed only 'BCD'; also referred to in paper as 3 point checklist;
Glasgow/MacKie original seven-point checklist (Keefe 1990)
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Diagnostic threshold: Described in detail; ABCD excluded Asymmetry' -one half does not match the
other half)
Diagnosis based on: Single observer in clinic diagnoses used (n=NR)
Observer qualifications: Not reported likely dermatologists
Experience in practice: Not described
Any other details: Border irregularity- edges are ragged, notched, or blurred; Color irregularity-
pigmentation is not uniform; shades of tan, brown and black are present with dashes of red, white, or
blue; Diameter- greater than 6 mm, the size of a pencil eraser
7-point: Increasing size, Variegation, Inflammation, Irregular outline,Greater than 1cm diameter, Itch,
Bleeding One point awarded for each feature
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: Shave excision=109; punch biopsy = 64;
excision=47; snip biopsy=17
Disease positive: 16 lesions; Disease negative: 221
Target condition (Final diagnoses) 
Melanoma (invasive): 6; Lentigo maligna 6; BCC: 4;
Dysplastic naevus 28; Sebhorrheic keratosis: 32;
Benign naevus: 110; Lentigo 12; blue naevus 9;
actinic keratosis 6; dermatofibroma 6; atypical
naevus 4; other 14
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: Missing data for the different
algorithms; approximately 32 lesions unaccounted for (13
excluded due to lesion size of 8mm or less). ABCD
evaluated=192/224 lesions; 3 point evaluated =192/224
lesions; 7 point evaluated =205/224 lesions
Time interval to reference test: not reported
Was there an appropriate interval between index test and
reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum
follow-up following application of index test(s) of at least: 3
months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was
the interval between application of the different algorithms 1
month or less?
Unclear
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Menzies 2009
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection December 2005 to
August 2006
Country Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented lesions which, after
routine naked eye examination by the GP, would
have been biopsied or referred, i.e. a SPL
(suspicious pigmented lesion). GPs were recruited
from practices with at least 3 clinicians; excluded if
they already used dermoscopy or SDDI in their
routine practice.
Setting: Primary
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion
Setting for prior testing: Primary
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. included: 374
Participant characteristics: None reported
Lesion characteristics None reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: clinical diagnosis and placed in a sealed envelope before proceeding to dermoscopy
examination
Diagnostic threshold: Not reported; initial diagnosis recorded along with confidence of diagnosis (scale
1 to 10; 1 not at all confident and 10 extremely confident), certainty of melanoma (scale 0 to 100%; 0
definitely not melanoma and 100 definitely melanoma) and management (biopsy, referral).
Diagnosis based on: Single observer (n=63; 102 GPs initially recruited; 74 (72.5%) completed the
educational intervention and online assessment; 63 GPs from 19 practices finally participated)
Observer qualifications: GP
Experience in practice: Not fully described; assumed to be low experience with pigmented lesions.
GPs must have each excised or referred >=10 PSL in previous 12-month period; excluded if
dermoscopy or SDDI already used in routine practice. During the pretrial period all GPs underwent a
training programme in the use of dermoscopy.
Dermoscopy: evaluated in same study; no algorithm
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
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B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis plus other
Histology (not further described): described as to standard
practice and not necessarily blinded to the GP’s diagnosis;
author confirmed that all melanoma had histological diagnosis
and >50% of benign had histology or follow-up
Total excised or referred: 163. Immediate excision/referral:
110. Excision/referral after SDDI: 48. Excision/examination
after patient self referral 5
Disease positive: 37; Disease negative: total of 126 benign or
unknown were 'excised OR referred' so some would have had
specialist dx only.
Clinical FU plus histology of suspicious lesions: Short term
digital monitoring (SDDI) available as an option for lesions
considered not to be melanoma but that were still considered
suspicious; follow-up imaging occurred initially at 3 months
with any morphological changes to result in biopsy or referral;
some lesions continued SDDI for a further 3 months; Length
of FU: 3-6 months
No. patients: Initially recommended for SDDI: 192; SDDI
continued for further 3 months: 6; Underwent SDDI only (no
excision): 146
Disease positive: 15 (SDDI then histologically confirmed);
Disease negative: 176 benign (incl 1 missed in situ
melanoma); 4 unknown
Expert opinion: GPs could refer for specialist opinion or
lesions could undergo dermoscopy telemedicine (images
reviewed by an expert in dermoscopy and SDDI).
Dermoscopy telemedicine was blinded to the GP’s diagnosis.
Observe for change group, i.e. discharged after dermoscopy:
72 Plus a proportion of those in Excise/refer group will have
had expert dx alone but details not given
Disease positive: 0; Disease negative: 71 benign; 1 unknown
Target condition (Final diagnoses) 
Melanoma (invasive): 33; Melanoma (in situ): 1
BCC: 6
2 Bowen's disease; 323 benign; 9 unknown
Is the reference standards likely to correctly classify the
target condition? No
Were the reference standard results interpreted without
knowledge of the results of the index tests? No
Could the reference standard, its conduct, or its interpretation
have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: nine lesions with unknown
diagnoses, plus BCC and Bowen's excluded from some
analyses
Time interval to reference test: Not reported;
Histopathological and specialist examination occurred
according to standard practice
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-
up following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
Yes
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or
less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Morales Callaghan 2008
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection 1 January 2005 -
31 December 2005
Country Spain
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
88 / 256
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Randomly selected melanocytic
lesions; melanocytic on both clinical and dermoscopic
criteria
Setting: Secondary (general dermatology)
Prior testing: Dermatoscopic suspicion in all cases
Setting for prior testing: Not reported
Exclusion criteria: Location/site of lesion - Palms,
soles, mucous membranes of face, under nails; non-
melanocytic appearance
Sample size (patients): No. included: 166
Sample size (lesions): No. included: 200
Participant characteristics: Mean age 33.7y (SD
14.5), range 8 to 84yrs; Male gender: 64 (38.6%);
Fitzpatrick phototype II (44%); type III (41.5%)
Lesion characteristics: Macular component=181
(90.5%), Papular component=125 (62.5%) Both =
106 (53%), either one or other = 94 (47%).
Asymmetrical 144 (72%). Irregular borders 154
(77%). 4 colours in 40 (20%), 3 colours in 96 (48%), 2
colours in 57 (28.5%), 1 colour in 1 (0.5%). History of
bleeding 7 (3.5%). changes reported by patient 154
(77%). Lesion site: trunk 155 (77.5%), including the
back in 106 (53%). Lesion size: mean long axis
diameter 7.9mm (SD 8.6)mm, mean short axis
diameter 5.1 (SD 5).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Other test data: Appears that dermoscopy was undertaken by same clinician(s) subsequent to clinical
evaluation; clinical history was constructed following a standardised protoco and a presumptive clinical
diagnosis recorded. Each lesion was then photographed and immediately afterwards examined using
a manual
dermatoscope
Diagnostic threshold: Not reported; presumptive clinical diagnosis
Diagnosis based on: Consensus (n=2)
Observer qualifications: Dermatologist
Experience in practice: Not clearly described; assumed to be High - “both dermatologists had
experience in dermoscopy.”
Dermoscopy: evaluated in same study; Pattern analysis
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Details: Lesions described using
terminology proposed by US National Insts
of Health
Disease positive: 6/6 lesions; Disease
negative: 194/194 lesions (assuming the 9
'Other' diagnosis lesions were not
malignant), or 185/185 (removing the 9
'other' diagnosis lesions from dataset)
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 6 (3%)
Other: Atypical mole (104), Common mole
(70), congenital nevus (6), Blue nevus (3),
Spitz/Reed nevus (1), Spilus nevus (1),
Others [unclear whether benign or
malignant] (9)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions: none reported
Time interval to reference test: "Samples for
histologic analysis were taken immediately
after clinical and dermoscopic examination"
Time interval between index test(s): Images
taken at same time
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
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Notes
Notes -
 
Morton 1998a
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection 1992 - 1994
Country Scotland
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All biopsies generated at Pigmented
lesion clinic during time period.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Not reported
Setting for prior testing: N/A
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1999
Sample size (lesions): 763 lesions examined by one of
two consultants
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis referred to as 'clinical diagnosis'; no dermoscopy used
Diagnostic threshold: Not reported NR; clinical diagnosis
Diagnosis based on: Single observer and average data presented; (n= 10 in total)
Observer qualifications: 2 consultant dermatologists,
Experience in practice: High (2 consultants each with >10 years experience in dermatology)
Any other detail: Data from same study for senior registrar and registrar presented in Morton 1998b
and Morton 1998c
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard - Histological diagnosis
alone
Target condition (Final diagnoses) (For full
sample of 1999 biopsies)
Melanoma (invasive): 102 (82 SSM, 11 nodular
melanoma, 4 partially regressed, 2 acral
lentiginous, 2 metastatic CM deposits, 1
desmoplastic melanoma); Melanoma (in situ):
24; Lentigo maligna: 2
Benign: 1871 benign (breakdown by lesion
type not reported)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: Not reported
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Morton 1998b
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection 1992 - 1994
Country Scotland
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias?
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All biopsies generated at Pigmented
lesion clinic during time period.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Not reported
Setting for prior testing: N/A
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1999
Sample size (lesions): 567 lesions examined by senior
registrar
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate?
Did the study avoid including participants with multiple lesions?
Are there concerns that the included patients and setting do not
match the review question?
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis referred to as 'clinical diagnosis'; no dermoscopy used
Diagnostic threshold: Not reported NR; clinical diagnosis
Diagnosis based on: Single observer and average data presented; (n= 10 in total)
Observer qualifications: 2 senior registrars
Experience in practice: Moderate – 2 two senior registrars each with 3-5 years experience
Any other detail: Data from same study for consultants and for registrar presented in Morton 1998a
and Morton 1998c
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner?
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Visual inspection - image-based
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner?
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard - Histological diagnosis
alone
Target condition (Final diagnoses) (For full
sample of 1999 biopsies)
Melanoma (invasive): 102 (82 SSM, 11 nodular
melanoma, 4 partially regressed, 2 acral
lentiginous, 2 metastatic CM deposits, 1
desmoplastic melanoma); Melanoma (in situ):
24; Lentigo maligna: 2
Benign: 1871 benign (breakdown by lesion
type not reported)
Is the reference standards likely to correctly classify the target condition?
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Could the reference standard, its conduct, or its interpretation have
introduced bias?
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist?
Are there concerns that the target condition as defined by the reference standard does not match the question?
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: Not reported
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference standard?
Did all patients receive the same reference standard?
Were all patients included in the analysis?
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias?
Notes
Notes -
 
Morton 1998c
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection 1992 - 1994
Country Scotland
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias?
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All biopsies generated at Pigmented
lesion clinic during time period.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Not reported
Setting for prior testing: N/A
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1999
Sample size (lesions): 669 lesions examined by registrar
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate?
Did the study avoid including participants with multiple lesions?
Are there concerns that the included patients and setting do not
match the review question?
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis referred to as 'clinical diagnosis'; no dermoscopy used
Diagnostic threshold: Not reported NR; clinical diagnosis
Diagnosis based on: Single observer and average data presented; (n= 10 in total)
Observer qualifications: Registrars
Experience in practice: Low – 6 rotating registrars each with 1-2 years experience
Any other detail: Data from same study for consultants and for senior registrars presented in Morton
1998a and Morton 1998b
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner?
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Visual inspection - image-based
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner?
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard - Histological diagnosis
alone
Target condition (Final diagnoses) (For full
sample of 1999 biopsies)
Melanoma (invasive): 102 (82 SSM, 11 nodular
melanoma, 4 partially regressed, 2 acral
lentiginous, 2 metastatic CM deposits, 1
desmoplastic melanoma); Melanoma (in situ):
24; Lentigo maligna: 2
Benign: 1871 benign (breakdown by lesion
type not reported)
Is the reference standards likely to correctly classify the target condition?
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Could the reference standard, its conduct, or its interpretation have
introduced bias?
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist?
Are there concerns that the target condition as defined by the reference standard does not match the question?
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: Not reported
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference standard?
Did all patients receive the same reference standard?
Were all patients included in the analysis?
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias?
Notes
Notes -
 
Pizzichetta 2004
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection Jan 1996 to Dec 2001
Country Participants recruited from 5
participating centres (4 in Italy and 1 in USA)
study conducted in Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinical and/or dermoscopic
hypomelanotic (extent of pigmentation <=30%) and
amelanotic skin lesions seen and excised at the five
participating centres
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic
suspicion
Setting for prior testing: Not reported
Exclusion criteria: Poor quality or unavailable index
test image (considered under Flow and TIming)
Sample size (patients): No. included: 151
Sample size (lesions): No. eligible: 174; No.
included: 151
Participant characteristics: mean age 47 years (±
17.5 SD); male gender: 73 (48%)
Lesion characteristics: Lesion site - head/neck
(5.3%); trunk (20.5%); upper limbs/shoulder (11.9$);
lower limbs/hip (25.2%); back (21.2%); abdomen
(11.3%); hand (3.3%); foot (1.3%). Melanoma
thickness: ≤1mm 85.3% (n=29); >1mm 14.7%
(n=15)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: only the gender, age at diagnosis and the site of the skin lesion were known to the
observer
Other test data: File contained clinical and dermoscopic images; unclear whether both observed at the
same time.
Diagnostic threshold: investigated clinical features such as elevation, ulceration, shape, borders,
colour
Diagnosis based on: Single observer (n=1)
Observer qualifications: Not reported likely dermatologist
Experience in practice: Not described
Experience with index test: Not described
Dermoscopy: evaluated in same study; Pattern analysis
Visual Inspection - in-person
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A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses) 
Melanoma (invasive): 34 (39 in full sample);
Melanoma (in situ): 5;
Other diagnoses reported only for full sample of 151
(only 108 with clinical images for VI evaluation):
55 (40 with clinical images) "amelanotic ⁄
hypomelanotic non melanocytic lesions" (25 BCC, 4
SCC, 10 dermatofibroma, 8 Bowen’s disease, 8
seborrhoeic keratosis)
52 (29 with clinical images) "amelanotic ⁄
hypomelanotic benign melanocytic lesions" (24
compound naevi, 17 dermal naevi, 5 Spitz naevi, 4
congenital naevi and 2 combined naevi).
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: 23 lesions excluded
due to image quality; further 43 lesions were
not available for evaluation by clinical
images ("mainly benign melanocytic
lesions").
Time interval to reference test: Not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Rao 1997
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection not reported
Country USA
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with atypical melanocytic
lesions or suspected early malignant melanoma
Setting: Private care
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Private care
Exclusion criteria: lesions over 13mm in diameter
were excluded as they could not fit entirely within the
standardized photographs
Sample size (patients): No. included: 63
Sample size (lesions): No. included: 72
Participant characteristics: None reported
Lesion characteristics: Melaoma thickness - ≤1mm:
100% of MM (n=21)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection ABCD
Method of diagnosis: Clinical photographs
Prior test data: Unclear
Other test data: Dermoscopic images also presented to observer but unclear whether both viewed at
the same time or not; "Each color transparency was independently analyzed" by observers. The 1)
clinical, 2) ”overall” dermoscopic, and 3) ABCD ”scored dermoscopic diagnoses of either MM or AMN
were recorded for each lesion by the same observers. No indication of blinding between images
Diagnostic threshold: Clinical variables were defined as follows: Asymmetry (A): Both silhouette and
colour distribution were considered. Border irregularity (B): This was judged by the unevenness of the
perimeter. Color (C): Color variegation and number of colours were evaluated. Diameter (D): The
largest in situ diameter in millimetres of each lesion was recorded
Diagnosis based on: Single observer (n=4)
Observer qualifications: Two experienced dermatologists, and two melanoma fellows
Experience in practice: Mixed experience (low and high experience combined)
Experience with index test: Not reported
Dermoscopy: evaluated in same study; ABCD and no algorithm
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: Each of the 72 melanocytic neoplasms was
histopathologically diagnosed as with AMN or an early
MM by a dermapathologist with special expertise in
melanocytic neoplasms. Each lesion was completed
excised and step sectioned.
Disease positive: 21 MMs; Disease negative: 51 AMN
Target condition (Final diagnoses) 
Melanoma (invasive): 21
51 atypical melanocytic nevus
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
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B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Rosendahl 2011
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection 30-month period; dates
NR
Country Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive series of pigmented
lesions submitted for histology from the primary care
skin cancer practice of one author.
Setting: Primary care skin cancer practice
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Primary
Exclusion criteria: Poor image quality (considered
under Flow and Timing); no other exclusion criteria
reported
Sample size (patients): No. included: 389
Sample size (lesions): No. eligible: 466 pigmented
lesions out of 1959 lesions excised or biopsied; No.
included: 463
Participant characteristics: Mean age: 57y (SD 17).
Male gender: 67.4%
Lesion characteristics: (53.1%) melanocytic. Lesion
site: 17.7% head or face; Trunk: 52.1%; 27.6%
extremities; 2.2% palms or soles. Melanoma
thickness: ≤1mm: 1/29 melanoma (3.4%)
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs overview and close up image presented
Prior test data: No further information used
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone.
Diagnostic threshold: Clinical diagnosis/subjective impression. Observers gave a diagnosis with level
of confidence (from 0 for definitely benign to 100 for definitely malignant) after viewing the clinical
images. (NB used authors threshold for detection of any skin cancer which includes lesions clinically
considered to be MM, BCC pigmented epithelial carcinoma including SCC, keratoacanthoma, actinic
keratosis and Bowen's disease as test positive; review only considered histologically confirmed MM,
BCC or invasive SCC to be disease positive)
Diagnosis based on: Single observer (n=NR)
Observer qualifications: Expert dermatologist (based on author communication).
Experience in practice: Expert
Experience with dermoscopy: Expert
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: Excise or biopsy
Disease positive: 138; Disease negative: 325
Target condition (Final diagnoses) 
Melanoma (invasive): 9; Melanoma (in situ): 20; BCC:
72; cSCC: 5 (including 2 keratoacanthoma)
'Benign' diagnoses: 18 Bowen's disease and 14 actinic
keratosis, 217 benign melanocytic plus additional 140
benign non melanocytic
*authors considered Bowen's disease, actinic keratosis
and keratoacanthoma as malignant; all considered
benign for review analysis
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Lesions were excluded due
to poor image quality (n=3)
Time interval to reference test: Unclear; lesions
'routinely photographed' if scheduled for excision
or biopsy but not further described
Time interval between index test(s): consecutive
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application
of index test(s) of at least: 3 months for melanoma or cSCC or 6 months
for BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Scope 2008
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection after January 2003
Country Not reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Images of pigmented skin lesions
selected from a database of standardised patient
images provided by a New Zealand-based
teledermatology company (MoleMap). Images were
selected on the basis that (1) at least 8 clinically
atypical nevi were apparent on the back; (2) most of
the lesions on the back and all of the atypical nevi
had close-up clinical digital images; (3) 1-year follow-
up images (close-up clinical and dermoscopic
images) were available to show that lesions
considered to be benign were in fact biologically
indolent by revealing no change; and (4) the image
quality of both the overview and the close-up images
were acceptable
Setting: New Zealand based teledermatology
company; images were sent electronically to
participants as a powerpoint file.
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: Poor quality index test image
(considered under flow/timing); naevi on any body
site except the back
Sample size (patients): No. eligible: 12; No. included:
12
Sample size (lesions): No. eligible: 145; No. included:
145
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Visual inspection (VI) Ugly duckling
Method of diagnosis: Clinical photographs
Prior test data: No further information used
Diagnostic threshold: For each lesion that was deemed as different, the participants had to mark the
lesion number on the form, identify it as either completely different or somewhat different from the
other moles, give a short qualitative description of how the lesion differs, and report whether they
would like to have a biopsy performed on the lesion
Diagnosis based on: Average (n=34)
Observer qualifications: Four subgroups in terms of clinical expertise: group 1, pigmented lesion
experts (n = 8); group 2, dermatologists who were considered non-experts in pigmented lesion
evaluation (n = 13); group 3, dermatology nurses (n = 5, including 1 dermatology medical
photographer); and group 4, non-clinical medical staff (n = 8).
Experience in practice: Mixed experience (low and high experience combined)
Other detail: The study was sent electronically to participants as a powerpoint file (Microsoft Corp,
Redmond, Washington) that contained the clinical image interface and a word document that
contained questionnaire and response forms. The participants were not shown dermoscopic images.
However, dermoscopic images of lesions (with a 1-year follow-up dermoscopic image) were available
to the investigators to verify that lesions considered benign did not show dermoscopic features
suggestive of malignancy, and the 1-year follow-up images confirmed that the lesions were in fact
biologically indolent by revealing no change.
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis
plus follow up
Details: Unclear; all MMs were excised with
histological confirmation and all benign had 1-
year follow-up images (close-up clinical and
dermoscopic images) to show that lesions
considered to be benign were in fact
biologically indolent by revealing no change,
not clear whether any of the benign group
were excised
Target condition (Final diagnoses) 
Melanoma (invasive): 5 'malignant melanoma'
Benign naevus: 140
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Unclear
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: excluded if unacceptable
image quality of both the overview and the
close-up images
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Yes
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Soyer 1995
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear
Period of data collection Not reported
Country Austria
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesion, difficult to
diagnose on clinical grounds alone
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical suspicion
Setting for prior testing: Secondary (general
dermatology); referred by dermatologists or general
physicians
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. included: 159
Participant characteristics: None reported
Lesion characteristics "23 melanomas with a Breslow
index of </= 0.75mm, 13 melanomas with a Breslow
index >/=0.76mm and </= 1.5mm, 12 melanomas with a
Breslow index >/=1.51mm and </=3.5mm, 2 melanomas
with a Breslow index of >/=3.5mm."
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? Unclear
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: Dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: Not reported
Diagnosis based on: n= 2 (1 or 2 per lesion)
Observer qualifications: Dermatologist
Experience in practice: Not clearly described; assumed to be High; “Each lesion was examined
clinically by .. one of the authors .. and a clinical diagnosis was recorded.” “After application of a drop
of immersion oil, each lesion was examined dermoscopically …; the examination was performed by a
dermatologist expert in dermoscopy and a dermoscopic diagnosis was recorded”
Experience with index test: Not described
Other detail: "Photographic documentation was performed using an incident light stereomicroscope
(Wild M 650) equipped with a Minolta XG-M camera"
Dermoscopy: evaluated in same study; Pattern analysis
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
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A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 65 (41%); Disease negative: 94
(59%)
Target condition (Final diagnoses) 
Melanoma (invasive): 50; Melanoma (in situ): 15
BCC: pigmented basal cell carcinoma (3)
Sebhorrheic keratosis: 18; Clark's nevus of
dysplastic nevus (61 cases); lentigo actinica lentigo
(2), pigmented actinic keratosis (4), angioma (3),
angiokeratoma (2).
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Stanganelli 1998
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection Just states 1997
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Images of pigmented skin lesions
selected from computerised files of the skin cancer
clinic.
Setting: Training study; images selected from skin
cancer clinic
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 30PSLs
Participant characteristics: None reported
Lesion characteristics None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone (images were randomised).
Diagnostic threshold: Not reported
Diagnosis based on: Average; n= 20
Observer qualifications: Dermatologist
Experience in practice: Not described; 30 dermatologists with “experience in ELM but (with) no formal
training” attended a seminar on clinical and ELM diagnosis of PSL; 20 then participated in a test of
their diagnostic accuracy. A second session on ELM was then held.
Other detail: The observers received 2hrs seminar of the principles of clinical diagnosis of NMLsS,
BCC, MN and MM. The participants were then invited to undergo an anonymous test of their
diagnostic accuracy.
Dermoscopy: evaluated in same study; no algorithm
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported):
10
BCC: 4
Mild//moderate dysplasia: 3; Sebhorrheic keratosis:
3; Benign naevus: Melanocytic nevi-7
Other: 1 hemangioma1 subungunal hemorraghe1
plantar intraepidermal hemorraghe
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Stanganelli 2000
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection 1994-1996
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with pigmented skin lesions
referred by dermatologists and general practitioners
either for pre-surgical assessment or consultation
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: patients referred for pre-surgical
assessment or consultation indicating they have had
prior tests
Setting for prior testing: Primary some patients referred
for consultation only; dermoscopy findings are reported
back and management decision remains with referring
clinician; Secondary (general dermatology)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1556
Sample size (lesions): No. eligible: 3372; No. included:
3372
Participant characteristics: Median age 30 years, range
10 to 94; Male: 522 (34%)
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) ABCD
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: Dermoscopic and clinical images subsequently presented separately to observer
subsequent to diagnosis using clinical images alone.
Diagnostic threshold: NR
Diagnosis based on: Single observer; n= 1
Observer qualifications: Not reported; described as one of the co-authors and study based in skin
cancer clinic - likely dermatologist
Experience in practice: Not described
Other detail: A crude clinical image (magn X6 and X10) was recorded in the digital database
Dermoscopy: evaluated in same study (image based); Pattern analysis
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
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B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
plus follow up; histology report of known
surgical excisions (n=262) plus a cancer-
registry based follow up of benign cases
(n=3110)
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 55; BCC: 43
'Benign' diagnoses: 3274
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Time interval between index test(s): not
clearly reported just indicated that D-ELM
was performed soon after clinical
examination
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Yes
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Stanganelli 2005
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Unclear (likely case series)
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection NR
Country Italy
Test set derived A training set of 22 melanomas
and 218 melanocytic nevi was randomised from
the dataset. The test set was formed by the
complement (the remaining 20 melanomas and
217 nevi). A further subset of images from the
original dataset, consisting of 31 melanomas
and 103 nevi, was used for the comparison
between observers and CAD; derivation of the
subset not reported.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic lesions from patients
referred to the Skin Cancer Unit and undergoing clinical
and dermoscopic evaluation; images were 'selected'
from a larger image database. Potential overlap with
Stanganelli 2000 (not possible to determine).
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1556 referred / No.
included: NR
Sample size (lesions): No. eligible: 3274 / No. included:
477 melanocytic lesions; 237 in test set and 134 in
comparison between CAD and human operators
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness 61.2%
<0.75mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: General practitioners evaluated only clinical images; unclear for dermatologists
Other test data: dermatologists examined both clinical and dermoscopic images but unclear whether
clinical diagnosis was made prior to presentation of dermoscopic images
Diagnostic threshold: Not reported
Diagnosis based on: Average (n=6)
Observer qualifications: GP 3; Dermatologist 3
Experience in practice: Assumed Low for GPs; High for dermatologists - described as “dermatologists
with experience in ELM (2 years)”
Other detail: Digital images included melanocytic lesions evaluated in ELM with a fixed x16
magnification
Dermoscopy: evaluated in same study; no algorithm
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
plus cancer registry
All included lesions underwent histology but
some were identified using a cancer-
registry-based follow-up of benign
diagnoses.
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not
reported): 42 in full sample; 31 in CAD vs
human observer interp and 20 in test set
'Benign' diagnoses: 435 melanocytic nevi;
103 in CAD-observer comp and 217 in test
set
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
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B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Unclear
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Steiner 1987
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection not specified
Country Austria
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Small (< 10 mm) pigmented skin
lesions considered diagnostically equivocal in that there
was no absolute agreement on the clinical diagnosis
among investigating clinicians at a pigmented lesions
clinic.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): 318
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
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Index Test
Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A
Other test data: Dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: Not reported
Diagnosis based on: Consensus (3 observers) "All lesions were independently seen and diagnosed by
the three investigators, and the diagnosis that appeared most probable to at least two of the three
investigators was recorded as the clinical"; n= 3
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’ "experienced dermatologists"
Experience with index test: - "experienced dermatologists"
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 73 melanomas, 20 BCCs; Disease negative:
225
Target condition (Final diagnoses) 
Melanoma (invasive): 49; Melanoma (in situ): 15; Lentigo maligna
9 (also includes lentigo maligna melanoma)
BCC: 20
Sebhorrheic keratosis: 20; Junctional naevi 39; Blue naevus 29;
Dysplastic naevus 75; Lentigo simplex and nevoid lentigo 19;
Angioma/angiokeratoma 15
Is the reference standards likely to correctly classify the
target condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its
interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: assumed
consecutive; following diagnosis, lesions
subsequently excised
Time interval between index test(s):
consecutive
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Thomas 1998
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control; separate recruitment
Data collection: Retrospective
Period of data collection NR; appears to be
post-1992
Country France
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Retrospective selection of all 460
cases of melanoma and a nonselected consecutive
group of 680 nonmelanoma pigmented tumours
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
All excised
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 1140
Participant characteristics: None reported
Lesion characteristics: Other test data: Dermoscopy
undertaken by same clinician(s) subsequent to
clinical evaluation
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI): ABCDE
Method of diagnosis: In person diagnosis; dermatologist making referral for excision made the
diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Number of characteristics present (from>=1 to all 5)
Diagnosis based on: Single observer;n= NR
Observer qualifications: Dermatologist
Experience in practice: Assumed to be High; described as 'trained' dermatologists
Other detail: Preliminary meeting held to precisely define each criterion, agree on the significance of
each abnormality and define the appropriate way to fill in the study form. ABCDE: Criterion A was
defined as geometrical asymmetry in two axes of the tumour, criterion B as irregular (unsharp or ill-
defined or angular) borders, criterion C as presence of at least two different colours within the lesion
(with the exception of the usual symmetrical darkening of the lesion in its center), criterion D as
diameter equal or superior to 6mm. Criterion E, the only anamnestic (based on the patient’s
description of the natural history of the lesion) criterion was defined as enlargement of the surface (and
not in height) of the lesion.
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 460; Disease negative: 680
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 460
BCC: BCC
Sebhorrheic keratosis: 19; 576 benign pigmented
naevus; 55 dysplastic naevi; 4 blue naevi; 2 compound
naevi with sutton inflammatory infiltrate; 2 spitz; 1 reeds
naevi; 3 haemangiomas; 9 dermatofibromas; 1
accessory nipple
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? No
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
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B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Troyanova 2003
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection Not reported
Country Not reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Images of pigmented skin lesions
<=13mm in diameter selected for a dermoscopy
training study
Setting: Training study
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): 
Sample size (lesions): No. included: 50 lesions
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness: ≤1mm:
100%
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: Clinical photographs and dermoscopic images
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone.
Prior test data: No further information used
Diagnostic threshold: Not reported
Diagnosis based on: Average; n= 32
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: Low experience / novice users; experienced in PSL field but not ELM
Dermoscopy: evaluated in same study; no algorithm
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 25; Disease negative: 25
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 25
'Benign' diagnoses: 5025 "not melanoma"
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Unlu 2014
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection January 2008-January
2010
Country Turkey
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic lesions excised at Ankara
University Department of Dermatology Pigmented
Lesion Clinic
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) Ankara University Department of Dermatology
Pigmented Lesion Clinic
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Location/site of lesion facial, nail and
volar acral lesions were excluded; non-melanocytic
appearance
Sample size (patients): No. included: 115
Sample size (lesions): No. included: 115
Participant characteristics: Mean age: 38.72y (+/- 18.46
y). Male gender: n=56 (49%).
Lesion characteristics: Lesion site: 100% trunk and
limbs. Melanoma thickness: 10 (41.7%) <0.75mm; 14
(58.3%) >=0.75mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm; Appears to be original clinical diagnosis at time of lesion
presentation
Method of diagnosis: In person diagnosis Appears to be diagnosis on presentation
Prior test data: N/A in-person diagnosis
Other test data: Dermoscopic images presented to different observers
Diagnostic threshold: Not reported
Diagnosis based on: Unclear - for visual inspection appears to be single examiner at time of clinic
diagnosis (n=NR); dermoscopic images "scored by three other experienced dermatoscopists" (n=3)
Observer qualifications: Not reported; assumed dermatologists - described as experienced
dermatoscopists
Experience in practice: Unclear for clinic diagnosis; dermatoscopists described as "experienced"
Experience with index test: Described as "experienced"
Dermoscopy: evaluated in same study by 3 experienced dermoscopists; 3-point rule; 7-point checklist;
ABCD; CASH algorithm (image based)
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
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A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 24; Disease negative: 91
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 24
'Benign' diagnoses: 91 melanocytic benign
lesions; 37 (32.2%) dermal nevi; 15 (13%)
clark's nevi; 14 (12.2%) compound nevi; 13
(11.3%) blue nevi; 6 (5.2%) spitz nevi; 4
(3.5%) congenital melanocytic nevi; 2
(1.7%) junctional nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Time interval between index test(s): Appear to
be consecutively applied
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Viglizzo 2004
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection Not reported
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions
examined at the Dermoscopy Service and
undergoing excision; a modified version of
Kenet's risk stratification approach for
dermoscopy (Ascierto 2000) was used to select high and
very high risk lesions for excision; medium and low risk
lesions were excised based on cosmetic or functional
reasons. (2x2 data have been extracted only for
melanocytic subgroup).
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) Dermoscopy service at a university department
(Department of Endocrinologic and metabolic disease)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 349 patients; No.
included: not reported
Sample size (lesions): No. eligible: 520 lesions; No.
included: 79 lesions excised included in the final
analysis
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI). No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Other test data: Dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: Not reported; correct diagnosis of melanoma
Diagnosis based on: Single observer (n=NR; "All dermoscopic
evaluations were performed by the same operators")
Observer qualifications: Not reported; "each lesion was .. diagnosed clinically and dermoscopically" at
the Dermoscopy service
Experience in practice: Not described
Experience with dermoscopy: Not described; assumed High as diagnosis at 'Dermoscopy service'
Dermoscopy: evaluated in same study; no algorithm
Visual Inspection - in-person
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Target condition (Final diagnoses) 
Melanoma (invasive): 11; Melanoma (in
situ): 1
Melanocytic lesion: 67
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Walter 2012
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Randomised controlled trial
(control group only included)
Data collection: Prospective
Period of data collection March 2008 to May
2010
Country UK
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Adults with any suspicious
pigmented skin lesion, i.e. any lesion presented by a
patient, or opportunistically seen by a family doctor or
practice nurse, that could not immediately be
diagnosed as benign and about which the patient
could not be reassured.
Setting: Primary 15 general practices in eastern
England
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Primary
Exclusion criteria: Those unable to give informed
consent or considered inappropriate to include by
their family doctor.
Sample size (patients): No. eligible: 1297; No.
included: 1293
Sample size (lesions): No. eligible: 1580; No.
included: 1583
Participant characteristics: Mean age: 44.6y (SD
16.8). Male: 465 (36%). Ethnicity: White 1214
(93.9%); Mixed 45 (3.5%); Missing: 34 (2.6%)
Lesion characteristics. Lesion thickness ≤1mm: in
'more than half' of MM
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) Glasgow/MacKie revised seven-point checklist (MacKie 1990)
Method of diagnosis: In person diagnosis
Prior test data: N/A
Diagnostic threshold: Not reported
Diagnosis based on: Single observer (n=30)
Observer qualifications: 28 GPs and 2 nurse practitioners recruited as 'lead clinicians' (2 per practice);
appears though they conducted all skin examinations. Excluded GPs with known dermatological
expertise, e.g. current hospital practitioners, clinical assistants in dermatology, and GPs with a special
interest in dermatology
Experience in practice: Mixed GP experience - median of 15 years experience (range 4 to 27yrs);
assumed low experience with pigmented skin lesions- seven had undergone some training in
dermatology, three had a short dermatology training post, three were on clinical attachment to an out-
patient clinic, and one was unspecified
Visual Inspection - in-person
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
plus FU and Expert opinion
Histology (not further described) 215
(histology result missing in further 4)
Disease positive: 35; Disease negative: 180
Clinical FU plus histology of suspicious
lesions: 22 of the 411 referred patients were
monitored (not further described); 566 of the
1162 not referred underwent expert review
and were then re-assessed at 3-6 months
Disease positive: 1; Disease negative: 588
Expert opinion. Reviewed by two dermatology
experts using the recorded clinical history and
examination, a digital photograph, and
MoleMate image where available.
Disease positive: 0; Disease negative: 725
Target condition (Final diagnoses) 
Melanoma (invasive): 30; Melanoma (in situ):
6; BCC: 10
'Benign' diagnoses: 1306
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the
results of the index tests? No
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: 417 withdrew from control
group after randomisation - 10 did not attend for
dermatology assessment; 19 excluded; 1 died; 4
missing histology (in referred group; included as
benign?); plus 12 with unknown outcome (in non-
referred group, assumed benign and included)
Time interval to reference test: suspicious lesions
referred under 2 week wait system
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Yes
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Westerhoff 2000
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control (for lesion selection;
study was an RCT of dermoscopy training for
PCPs)
Data collection: Retrospective
Period of data collection Not reported
Country: Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinically atypical pigmented skin
lesions; 50 invasive melanomas and 50 nonmelanomas
randomly selected from the Sydney Melanoma Unit
pigmented skin lesions (PSL) image database.
Setting: Specialist unit (lesion selection)
Prior testing: Selected for excision or followed up
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 100
Participant characteristics: None reported
Lesion characteristics: median Breslow thickness 0.6mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
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Index Test
Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: Clinical photographs
Prior test data: Unclear; all participants "were instructed not to look at the surface microscopic image
until they had scored the clinical image"
Diagnostic threshold: Not reported
Diagnosis based on: Average (n=37; 74 practising primary care practitioners randomised to
dermoscopy education intervention or not). (Diagnoses were recorded for both groups of GPs at
baseline (pre-test) and after the training intervention had been administered to the intervention group
(post-test), resulting in 8 sets of 2x2 data based on interpretation of the same set of 100 lesions; post-
test data for the intervention group of GPs was used for the Visual Inspection analysis.)
Observer qualifications: GP
Experience in practice: Considered to be Low; Only practitioners who had had no formal training with
surface microscopy and did not use a surface microscope in their clinical practice were included.
Experience with dermoscopy: Low experience / novice users (non-training arm); 'Trained' for the
intervention arm
Other detail: Camera designed for close-up clinical photography (Elicar Macrolens, Japan)
Dermoscopy: evaluated in same study; Menzies criteria (Intervention arm underwent training in
Menzies criteria)
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis plus follow
up
Histology: All the lesions except two had been excised
after photography and subjected to histopathological
examination. Disease positive: 50 / Disease negative:
48
Clinical FU plus histology of suspicious lesions: The
two benign PSL that had not been excised were
monitored over a longer period of time and had shown
no morphological change.
Length of FU: NR; Disease positive: 0 / Disease
negative: 2
Target condition (Final diagnoses) 
Melanoma (invasive): 50 / 'Benign' diagnoses: 50
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: "All the lesions
except two had been excised after
photography"
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Unclear
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Winkelmann 2016
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection not reported
Country Not reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Images of pigmented skin lesions
previously analysed by a digital classifier MSDSLA;
method of selection of the 12 not reported
Setting: Dermoscopy conference
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 12
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: Unclear
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone.
Diagnostic threshold: Not reported - biopsy decision
Diagnosis based on: Average (n=70)
Observer qualifications: Dermatologist
Experience in practice: Not described; recruited “dermatologists at a dermoscopy conference”; no
further details
Other detail: Authors report that practitioners with a particular interest in skin cancer or technology
may have chosen to attend this conference and/or self-selected to take part in the study.
Dermoscopy: evaluated in same study; no algorithm
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 5 / Disease negative: 7
Target condition (Final diagnoses) 
Melanoma (invasive): 3 / Melanoma (in situ): 2
Mild/moderate dysplasia: 7 low grade dysplastic
nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
Yes
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Zaumseil 1983
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection 1976-1981
Country Germany
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Skin lesions undergoing excision
Setting: Secondary (not further specified)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic) Described as 'skin
clinic'
Exclusion criteria: Disagreement between evaluators on
tumour histological classification Those in which the
histological diagnosis was 'unclear' were excluded
melanoma metastases were excluded
Sample size (patients): Not reported
Sample size (lesions): No. included: 7063
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Primary diagnosis of melanoma (method of Kopf 1975 was cited)
Diagnosis based on: Single observer (n=NR)
Observer qualifications: Not reported
Experience in practice: Not described
Experience with index test: Not described
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
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A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 337 / Disease negative: 6726
Target condition (Final diagnoses)
Melanoma (invasive or in situ): 337
Other diagnoses only listed for the 89 FPs: 23
benign nevi; 13 BCC; 12 blue nevus; 11
angiomatosis; 10 sebhorrheic keratosis; 6
histiocytoma; 4 spitz nevus; 4 lentigo; 3 Bowen's
disease; 1 acrospiroma; 1 keratinizing papilloma
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Footnotes
ABCD(E) - asymmetry, border, colour, differential structures (enlargement); AK - actinic keratosis; AMN – atypical
melanocytic naevi; BCC - basal cell carcinoma; BD – Bowen’s disease; BN – benign naevi; BPC – between person
comparison (of tests); CAD – computer assisted diagnosis; CCS – case control study; CD – compact disc; CM – cutaneous
melanoma; CMM - cutaneous malignant melanoma; CS – case series; CSCC – cutaneous squamous cell carcinoma; DF –
dermatofibroma; Dx – diagnosis; ELM – epiluminescence microscopy; FPs - false positives; FU – follow-up ; GP – general
practitioner; H&E – haematoxylin and eosin stain; LPLK – lichen planus-like keratosis; LS – lentigo simplex; MM – malignant
melanoma; MiS – melanoma in situ (or lentigo maligna); MN – melanocytic naevi; MSDSLA - multispectral digital skin lesion
analysis device; N/A – not applicable; NC – non comparative; NMLs – non melanocytic lesions; NR – not reported; P –
prospective; PCPs – primary care providers; PLC – pigmented lesion clinic; PSL – pigmented skin lesion; R –retrospective;
RCM – reflectance confocal microscopy; RCT – randomised controlled trial; SCC - squamous cell carcinoma; SD – standard
deviation; SDDI - short-term sequential digital dermoscopy imaging; SK – seborrhoeic keratosis; SN – Spitz nevi; SSM –
superficial spreading melanoma; SVS – support vector system; VI – visual inspection; WPC – within person comparison (of
tests).
Characteristics of excluded studies 
Abbasi 2004
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Reason for exclusion EXCLUDE not a primary study
systematic review
 
Aldridge 2011
Reason for exclusion EXCLUDE on test observer
medical students and lay persons
 
Aldridge 2011a
Reason for exclusion EXCLUDE on test observer
 
Aldridge 2013
Reason for exclusion EXCLUDE on 2x2 data
not test accuracy study
 
Alendar 2009
Reason for exclusion EXCLUDE on reference standard
only 7 reported verified histologically
 
Argenziano 1999
Reason for exclusion EXCLUDE on study population
Only includes melanoma
 
Argenziano 2003
Reason for exclusion EXCLUDE on 2x2 data
Table V gives se/sp data for 108 lesions but can't derive the number of melanoma for
this subset of the original 128
Authors contacted 10/5/16; 24/6/16
 
Argenziano 2012
Reason for exclusion EXCLUDE on reference standard
no follow-up of test negatives
 
Argenziano 2014
Reason for exclusion EXCLUDE on 2x2 data
 
Ascierto 2003
Reason for exclusion EXCLUDE not a primary study
 
Badertscher 2015
Reason for exclusion EXCLUDE on 2x2 data
 
Bafounta 2001
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Reason for exclusion EXCLUDE not a primary study
systematic review
 
Banky 2005
Reason for exclusion EXCLUDE on target condition
EXCLUDE on index test
 
Basarab 1996
Reason for exclusion EXCLUDE on study population
not all suspected of skin cancer
EXCLUDE on 2x2 data
 
Bauer 2000
Reason for exclusion EXCLUDE on index test
Does not provide 2x2 data for visual inspection alone
 
Bauer 2005
Reason for exclusion EXCLUDE on index test
follow-up/monitoring study
 
Becker 1954
Reason for exclusion EXCLUDE not a primary study
 
Benelli 2000
Reason for exclusion EXCLUDE on 2x2 data
only inter-rater reliability data given (n=25); authors have published much larger
evaluations of 7FFM and ABCD
 
Blum 2004
Reason for exclusion EXCLUDE not a primary study
comment paper
 
Blum 2004a
Reason for exclusion EXCLUDE not a primary study
letter
EXCLUDE Letter only; limited data presented - evaluates '3-colour' rule as developed
By MacKie 1992 (excluded as assessment of individual lesion features only)
 
Blum 2004b
Reason for exclusion EXCLUDE on index test
Evaluates dermoscopy only
 
Bolognia 1990
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Reason for exclusion EXCLUDE on reference standard
no ref standard diagnosis for index test negatives
 
Bono 2001
Reason for exclusion EXCLUDE on 2x2 data
aim of the study is to determine what features are present in amelanotic cutaneous
melanoma
 
Borsari 2015
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Borve 2012
Reason for exclusion EXCLUDE on study population
includes participants without skin lesions
EXCLUDE on sample size
<5 BCC
 
Brown 2000
Reason for exclusion EXCLUDE not a primary study
systematic review 
 
Brown 2009
Reason for exclusion EXCLUDE on test observer
lay persons
 
Buhl 2012
Reason for exclusion EXCLUDE on index test
folow up/monitoring
EXCLUDE duplicate or related publication
same patients as Haenssle 2010 #191
 
Burki 2015
Reason for exclusion EXCLUDE not a primary study
 
Burr 2015
Reason for exclusion EXCLUDE not a primary study
 
Burton 1998
Reason for exclusion EXCLUDE on reference standard
can only get 2x2 data for referral accuracy
EXCLUDE on 2x2 data
 
Carli 2003
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Reason for exclusion EXCLUDE on reference standard
Only 39/1042 with ref test
 
Carli 2003a
Reason for exclusion EXCLUDE on sample size
 
Carli 2004
Reason for exclusion EXCLUDE on sample size
<5 MM per arm
EXCLUDE on 2x2 data
 
Carli 2004a
Reason for exclusion EXCLUDE on index test
EXCLUDE but contact authors
Author passed away; unable to make contact with co-authors
 
Carli 2004b
Reason for exclusion EXCLUDE on index test
'Clinical diagnosis' - Dataset covers 1997-2001, but dermoscopy routinely introduced
1998; authors contacted but no response. 
 
Carli 2005
Reason for exclusion EXCLUDE on 2x2 data
Only sensitivity data given (% with correct diagnosis); % of benign lesions incorrectly
diagnosed was not reported
EXCLUDE but contact authors
 
Carlos-Ortega 2007
Reason for exclusion EXCLUDE on 2x2 data
Gives se/sp for visual inspection and dermoscopy in the English abstract. 68
patients/70 lesions were included but only 36 seem to have had visual inspection
results and all underwent dermoscopy. Two observers performed each test blinded to
each other. Table I gives 22 with BCC and 11 with melanoma overall (no. D+ not
reported for those with VI results), but using either or both of these numbers with the
se/sp provided does not give the same PPV and NPV as given by the authors
EXCLUDE but contact authors
data not clearly presented for 2x2; translator suggested alternative but still does not
work out to what is in paper; tried contacting authors twice, no reply
 
Chen 2001
Reason for exclusion EXCLUDE not a primary study
Systematic review comparing PCP accuracy with dermatologist accuracy. 
 
Chen 2006
Reason for exclusion EXCLUDE on 2x2 data
only given AUC
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Chiaravalloti 2014
Reason for exclusion EXCLUDE on study population
Includes melanoma only
 
Ciudad-Blanco 2014
Reason for exclusion EXCLUDE on study population
Includes melanoma only
 
Cooper 2002
Reason for exclusion EXCLUDE on target condition
Insufficient data for inclusion in melanoma review
 
Cornell 2015
Reason for exclusion EXCLUDE on test observer
 
Cox 2008
Reason for exclusion EXCLUDE on reference standard
Se and sp estimates for diagnosis of melanoma for both the seven-point checklist and
the revised (10-point) checklist; reference standard not reported for any of the 381
TWR referrals for melanoma
EXCLUDE but contact authors
Author contacted 10/05/16; co-author contacted 24-6-16
 
De Giorgi 2011
Reason for exclusion EXCLUDE Duplicate publication
Study appears to use same lesions as Carli 2003b (included study). Both studies
have the same numbers of melanomas and benign nevi and have common co-
authors (De Giorgi 2011 in particular). Although not explicit, the De Giorgi 2011 paper
appears to have used the same lesions and study design but with different observers.
The original Carli 2003 paper reported using 8 expert observers while the later paper
recruited 8 dermatologists who had undergone a dermoscopy training course but who
reported no experience in assessing pigmented skin lesions.
 
DeCoste 1993
Reason for exclusion EXCLUDE on 2x2 data
Not given the total number of D+/D- or total number of lesions included. Just given the
sensitivity/specificity values 
 
Di Carlo 2014
Reason for exclusion EXCLUDE on index test. Videothermography not relevant for the review and there is
no 2x2 data for dermoscopy EXCLUDE if derivation study. Only includes AK and BCC;
no 2x2 for dermoscopy
 
Di Chiacchio 2010
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Reason for exclusion EXCLUDE on target condition
Excluding nail bed melanoma
EXCLUDE on 2x2 data
There is insufficient data to extract for a 2x2 table
 
Dreiseitl 2009
Reason for exclusion EXCLUDE on index test
Does not evaluate visual inspection alone
 
Duff 2001
Reason for exclusion EXCLUDE on index test
Does not evaluate visual inspection alone
 
Edmondson 1999
Reason for exclusion EXCLUDE on reference standard
It seems that the reference standard here is expert diagnosis. This is not a
teledermatology paper 
 
Emmons 2011
Reason for exclusion EXCLUDE on 2x2 data
not test accuracy study; promoting primary prevention
 
Engelberg 1999
Reason for exclusion EXCLUDE on sample size
only 1 confirmed melanoma and 3 BCC
 
English 2003
Reason for exclusion EXCLUDE on 2x2 data
no accuracy data given 
 
English 2004
Reason for exclusion EXCLUDE on 2x2 data
no accuracy data
 
Fabbrocini 2008
Reason for exclusion EXCLUDE on 2x2 data
there isn't sufficient data provided for each index test to populate 2x2 table 
EXCLUDE but contact authors
Requested cross tabulation of each clinician's diagnosis (e.g. at threshold of >=3 on 7
point checklist) against the histological diagnosis and/or a cross tabulation of the
remote diagnosis against the Face to Face diagnoses. Author responded 30-6-16
cannot access data needed
 
Federman 1995
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Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy
 
Fikrle 2013
Reason for exclusion EXCLUDE on reference standard
Follow up study <50% of study participants have their final diagnosis reached by
histopathology.
 
Freeman 1963
Reason for exclusion EXCLUDE on 2x2 data
Only gives % correct for each lesion type
EXCLUDE but contact authors
Tables 2 and 3 appear to give % correct diagnoses per lesion type, but does not give
data on numbers misclassified as melanoma, or other malignancy, i.e. FPs. Author
responded; paper too old, cannot provide data
 
Friedman 1985
Reason for exclusion EXCLUDE not a primary study
 
Funt 1963
Reason for exclusion EXCLUDE on index test
EXCLUDE on 2x2 data
No 2x2 data
 
Gerbert 1996
Reason for exclusion EXCLUDE on target condition
No breakdown of final diagnoses for included lesions
EXCLUDE on 2x2 data
Only gives % correct for each lesion type; not sensitivity/specificity
 
Gerbert 1998
Reason for exclusion EXCLUDE on 2x2 data
 
Giannotti 2004
Reason for exclusion EXCLUDE not a primary study
a review
 
Grana 2003
Reason for exclusion EXCLUDE on index test
EXCLUDE if individual lesion characteristics
only looking at lesion border
 
Grob 1998
Reason for exclusion EXCLUDE not a primary study
 
Guibert 2000
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Reason for exclusion EXCLUDE on reference standard
Not designed as an accuracy study only observational. Can't get 2x2 data >50% of
study participants did not recieve histology as ref standard. 
 
Gunduz 2003
Reason for exclusion EXCLUDE on sample size
case study
 
Gutierrez 2013
Reason for exclusion EXCLUDE on index test
test to improve histopathology diagnosis
 
Hacioglu 2013
Reason for exclusion EXCLUDE on target condition
Does not provide sufficient data for detection of melanoma
 
Haenssle 2010
Reason for exclusion EXCLUDE on index test
test used for monitoring and not initial diagnosis; no VI data
 
Haenssle 2010a
Reason for exclusion EXCLUDE on 2x2 data
Does not report specificity
EXCLUDE duplicate or related publication
same patients as Haenssle 2010 #191
 
Hallock 1998
Reason for exclusion EXCLUDE on index test
'clinical diagnosis'; dermoscopy used for 3 of 4 years
 
Haniffa 2007
Reason for exclusion EXCLUDE on reference standard
looks like approximately 20% of patients received a final diagnosis by histology. 179
biopsies were performed. Total sample was 881 lesions 
 
Har-Shai 2001
Reason for exclusion EXCLUDE on index test
'clinical diagnosis'
 
Heal 2008
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Reason for exclusion EXCLUDE on 2x2 data
Sensitivities and PPVs are given so theoretically a 2x2 could be worked out but the
numbers do not appear to work out 
Author response; the 2x2 table the Cochrane researchers want to create is not
possible for our results, because sensitivity and PPV are based on different sample
sizes. 
 
Healsmith 1994
Reason for exclusion EXCLUDE on reference standard
Benign lesions described as 'clinically diagnosed' rather than histology/follow-up
 
Higgins 1992
Reason for exclusion EXCLUDE on study population
Includes only benign lesions
EXCLUDE on sample size
No melanomas
EXCLUDE on 2x2 data
No malignant cases
 
Hoorens 2016
Reason for exclusion EXCLUDE on index test
EXCLUDE on reference standard
No info on numbers undergoing histology; and no follow-up reported for benign
appearing lesions
EXCLUDE on 2x2 data
 
Huang 1996
Reason for exclusion EXCLUDE if individual lesion characteristics
Border irregularity not overall dx
EXCLUDE on 2x2 data
 
Jamora 2003
Reason for exclusion EXCLUDE on reference standard
no referene standrd for index test negatives
 
Janda 2014
Reason for exclusion EXCLUDE on sample size
only one case of melanoma, one case of BCC and one of SCC
 
Jensen 2015
Reason for exclusion EXCLUDE not a primary study
comment paper
 
Jolliffe 2001
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Reason for exclusion EXCLUDE on index test
Provides data for clinical diagnosis (including dermoscopy for some cases)
 
Jonna 1998
Reason for exclusion EXCLUDE on 2x2 data
only included index test positives to get PPV, not worth author contact on this one
 
Kaddu 1997
Reason for exclusion EXCLUDE on sample size
Sample size <5; not test accuracy
 
Keefe 1990
Reason for exclusion EXCLUDE on reference standard
Only 28% (60/214) of non melanoma group had excision
 
Kelly 1986
Reason for exclusion EXCLUDE on target condition
Can't disaggregate the severely dysplastic/in situ MM
EXCLUDE on sample size
unclear whether >5 in situ melanoma
 
Koh 1990
Reason for exclusion EXCLUDE on reference standard
screening study; no adequate reference standard
 
Kroemer 2011
Reason for exclusion EXCLUDE on index test
Provides data for clinical diagnosis (including dermoscopy for some cases)
 
Krol 1991
Reason for exclusion EXCLUDE on reference standard
No follow up reported for those who were test negative
 
Kurvers 2015
Reason for exclusion EXCLUDE on index test
Collective intelligence - majority rule and quorum rule applied to large number of test
interpreter decisions
EXCLUDE duplicate or related publication
re-analyses data from 2 previously published studies to determine whether collective
intelligence (i.e. majority rules or quorum rules across a large number of observers)
improves test accuracy. We have excluded one of these studies as the number of
melanomas is not provided ( Argenziano 2003 ) and included the other in dermoscopy
review ( Zalaudek 2006 ).
 
Kvedar 1997
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Reason for exclusion EXCLUDE on study population
Not all suspected of skin cancer
 
Lechner 2015
Reason for exclusion EXCLUDE not a primary study
Erratum
 
Lewis 1999
Reason for exclusion EXCLUDE on 2x2 data
Study appears to meet all eligibility criteria but disease prevalence not given alongside
se/sp
EXCLUDE but contact authors
Authors contacted 10/05/2016; email returned
 
Lindelöf 1994
Reason for exclusion EXCLUDE on study population
only malignant melanoma 
EXCLUDE on 2x2 data
not enough information given to derive a 2x2 table. only given for a sample of 50
patients who had a strong suspicion of melanoma clinically. Do not know what
happened to those with no suspicion clinically 
 
Lorentzen 2000
Reason for exclusion EXCLUDE on index test
Does not provide data for visual inspection alone
 
Luttrell 2012
Reason for exclusion EXCLUDE on test observer
Accuracy data only given for lay-persons not interested in this population of test
observers
 
Machet 2005
Reason for exclusion EXCLUDE on study population
**[Note this is a staging study]
 
MacKenzie-Wood 1998
Reason for exclusion EXCLUDE on study population
only malignant diagnosis
 
MacKie 1990
Reason for exclusion EXCLUDE not a primary study
 
Mackie 1991
Reason for exclusion EXCLUDE not a primary study
letter
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Mackie 2002
Reason for exclusion EXCLUDE if individual lesion characteristics
presence of 3 or more colours on dermoscopy
 
Mahendran 2005
Reason for exclusion EXCLUDE on index test
Face to face is 'clinical diagnosis', i.e. visual inspection +/- use of dermoscopy
 
Mahon 1997
Reason for exclusion EXCLUDE not a primary study
a summary of a comparison of two screening checklists
 
Malvehy 2014
Reason for exclusion EXCLUDE on index test
Does not report data for visual inspection alone
 
Marghoob 1995
Reason for exclusion EXCLUDE not a primary study
letter
 
Marghoob 2007
Reason for exclusion EXCLUDE not a primary study
 
Markowitz 2015
Reason for exclusion EXCLUDE on target condition
Does not report sufficient data for detection of melanoma
 
McCarthy 1995
Reason for exclusion EXCLUDE not a primary study
leaflet
 
McMullan 1956
Reason for exclusion EXCLUDE on 2x2 data
 
Menzies 2008
Reason for exclusion EXCLUDE on index test
evaluates dermoscopy alone 
 
Menzies 2011
Reason for exclusion EXCLUDE on index test
surveillance study; data used to id factors predictive of lesion changes
 
Menzies 2013
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Reason for exclusion EXCLUDE on index test
evaluates dermoscopy only
 
Moffatt 2006
Reason for exclusion EXCLUDE on index test
'clinical diagnosis'
 
Mohammad 2015
Reason for exclusion EXCLUDE on study population
only includes BCC
 
Morrison 2001
Reason for exclusion EXCLUDE on 2x2 data
Study gives % correct diagnosis within each histology group and then gives the %
‘correct’ diagnosis of skin cancer as 22% for FP and 87% for dermatologist. But these
statistics appear to have been reached by taking the mean of the % correct diagnoses
across the malignant groups and do not equate to sensitivity. i.e. If you take the mean
of the FP correct (%) for the 4 malignant groups you get: (40+22+25+0)/4 = 21.75%
and then the same for the dermatologist correct (%) column:
(95+77+75+100)/4=86.75% 
 
Nachbar 1994
Reason for exclusion EXCLUDE on index test
Data for visual inspection alone influenced by use of dermoscopy in most cases
 
Nathansohn 2007
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; follow-up study
 
Nilles 1994
Reason for exclusion EXCLUDE on index test
Does not provide data for visual inspection alone
 
Osborne 1998
Reason for exclusion EXCLUDE on reference standard
not clear what the ref standard is 
EXCLUDE on 2x2 data
 
Osborne 1999
Reason for exclusion EXCLUDE on study population
Only patients with melanoma included
 
Parslew 1997
Reason for exclusion EXCLUDE on study population
Not all suspected of skin cancer
 
Pazzini 1996
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Reason for exclusion EXCLUDE on 2x2 data
 
Perednia 1992
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy
 
Perrinaud 2007
Reason for exclusion EXCLUDE on index test
Does not provide data for visual inspection alone
 
Piccolo 2000
Reason for exclusion EXCLUDE on index test
No data can be extracted for visual inspection alone
 
Piccolo 2002
Reason for exclusion EXCLUDE not a primary study
EXCLUDE on 2x2 data
not enough data to populate 2x2 table. No breakdown of index test results and ref
standard. 
 
Pizzichetta 2001
Reason for exclusion EXCLUDE on 2x2 data
Observer agreement only
 
Provost 1998
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; only reports concordance
 
Quereux 2011
Reason for exclusion EXCLUDE on index test
self-administered questions to patients attending a GP surgery before their
appointment to determine whether they are at high risk of melanoma--which is meant
to highlight to the GP which patient to examine during their consultation
 
Rallan 2006
Reason for exclusion EXCLUDE on index test
No data can be extracted for visual inspection alone
 
Rampen 1988
Reason for exclusion EXCLUDE on study population
Only melanoma included
 
Reeck 1999
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Reason for exclusion EXCLUDE on study population
Only includes index test negatives; i.e. those considered benign by referring clinician
EXCLUDE on target condition
 
Riddell 1961
Reason for exclusion EXCLUDE on study population
All malignant
 
Rigel 1993
Reason for exclusion EXCLUDE not a primary study
 
Robati 2014
Reason for exclusion EXCLUDE on reference standard
no follow-up of patients not referred to dermatology clinics, who did not recieve
histopathology 
 
Robinson 2010
Reason for exclusion EXCLUDE on index test
self examination
 
Rosado 2003
Reason for exclusion EXCLUDE not a primary study
Systematic Review
 
Rossi 2000
Reason for exclusion EXCLUDE on reference standard
Unclear reference standard in disease negative
 
Roush 1986
Reason for exclusion EXCLUDE on target condition
only dysplastic nevus
 
Salvio 2011
Reason for exclusion EXCLUDE not a primary study
EXCLUDE on sample size
 
Schindewolf 1994
Reason for exclusion EXCLUDE on index test
evaluates CAD not VI
 
Schmoeckel 1987
Reason for exclusion EXCLUDE not a primary study
 
Schwartzberg 2005
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Reason for exclusion EXCLUDE on target condition
Does not provide sufficient data for detection of melanoma 
INCLUDE based on full report
 
Seidenari 2006
Reason for exclusion EXCLUDE on study population
assessing best means of follow-in up patients with previous melanoma - total body
exam versus only lesions >2cm. No melanoma identified
 
Seidenari 2006a
Reason for exclusion EXCLUDE if individual lesion characteristics
looks like this study is only looking at asymmetry judgement
 
Shariff 2010
Reason for exclusion EXCLUDE on reference standard
 
Sondak 2015
Reason for exclusion EXCLUDE not a primary study
comment paper 
 
Soyer 2004
Reason for exclusion EXCLUDE on index test
Does not provide data for visual inspection alone
 
Stanganelli 1998a
Reason for exclusion EXCLUDE on 2x2 data
can't derive specificity; only gives 'exact diagnoses for MM and 2 benign categories
and not number benign misdiagnosed as MM
 
Stanley 2003
Reason for exclusion EXCLUDE if individual lesion characteristics
fuzzy histogram is based on the lesion's colour, which is an individual lesion
characteristic
 
Stathopoulos 2015
Reason for exclusion EXCLUDE on 2x2 data
only includes index test positive patients, i.e. no FN or TN results
 
Stratigos 2007
Reason for exclusion EXCLUDE on reference standard
EXCLUDE on 2x2 data
 
Tandjung 2015
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Reason for exclusion EXCLUDE on target condition
'Malignant' includes: AK, Bowen's, dysplastic nevus, lentigo maligna, SCC, BCC, MM,
keratoacanthoma
EXCLUDE on index test
GPs sent images for telederm opinion; then free to send for biopsy or not; results
shown are only for those that wer biopsied, according to TD advice
 
Terrill 2009
Reason for exclusion EXCLUDE on index test
Whole body skin examination after patients referred on for further assessment by a
specialist
EXCLUDE on 2x2 data
 
Terushkin 2010
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy - reports final diagnoses of those excised over a number of time
periods and benign-malignant ratio
 
Terushkin 2010a
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy - reports final diagnoses of those excised over a number of time
periods and benign-malignant ratio
 
Thomson 2005
Reason for exclusion EXCLUDE not a primary study
letter
 
Torrey 1941
Reason for exclusion EXCLUDE on target condition
includes non-cutaneous lesions
 
Ulrich 2015
Reason for exclusion EXCLUDE on target condition
Does not provide sufficient data for evaluation of melanoma
 
van der Rhee 2010
Reason for exclusion EXCLUDE on reference standard
<50% of disease negative have an adequate reference standard
 
van der Rhee 2011
Reason for exclusion EXCLUDE on sample size
<5 cases
 
Vasili 2010
Reason for exclusion EXCLUDE conference abstract
 
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
151 / 256
Wagner 1985
Reason for exclusion EXCLUDE on 2x2 data
 
Walter 2010
Reason for exclusion EXCLUDE not a primary study
clinical trial protocol
 
Walter 2013
Reason for exclusion EXCLUDE on reference standard
Final diagnosis reached by histology or expert opinion; no FU of non-excised lesions
reported in this paper. The Walter 2012 trial report does report follow-up for enough
benign lesions for control arm (weighted 7PCL) data to be included. Authors contacted
and confirmed calculations (02/03/16).
 
Warshaw 2009
Reason for exclusion EXCLUDE on 2x2 data
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in
comparison to histopathology; in order to include in our review, data would need to be
presented as a 2x2 contingency table, either per type of malignancy e.g. tele-dx
classification of melanoma vs not melanoma against histological diagnosis of
melanoma/not melanoma, or with malignant diagnoses grouped together, ie tele-dx of
malignancy vs not malignant against same histological breakdown. 
EXCLUDE but contact authors
Authors contacted: the 2x2 table the Cochrane researchers want to create is not
possible for our results, because sensitivity and PPV are based on different sample
sizes. This can be seen in Table 2 of the paper which actually adds up to 11870 skin
lesions across, as for each histological diagnosis of interest the first lesion with such a
histological diagnosis was considered per patient. Hence, a patient might appear
several times across the columns. Table 1 adds up to 8585 skin lesions – the first skin
lesion in the data set per patient with a clinical diagnosis.
 
Warshaw 2009a
Reason for exclusion EXCLUDE on 2x2 data
As per Warshaw 2009
 
Warshaw 2010
Reason for exclusion EXCLUDE on 2x2 data
As per Warshaw 2009 ; this 2010 paper presents combined data for pigmented and
nonpigmented lesions
 
Westbrook 2006
Reason for exclusion EXCLUDE on 2x2 data
 
Whitaker-Worth 1998
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Reason for exclusion EXCLUDE on study population
EXCLUDE on test observer
mixed medical student/clinicians
EXCLUDE on 2x2 data
not test accuracy study
 
Whited 1998
Reason for exclusion EXCLUDE on sample size
 
Williams 1991
Reason for exclusion EXCLUDE on 2x2 data
 
Winkelmann 2015
Reason for exclusion EXCLUDE duplicate or related publication
 
Winkelmann 2015a
Reason for exclusion EXCLUDE duplicate or related publication
 
Wolf 1998
Reason for exclusion EXCLUDE on index test
clinical diagnosis study; Test clearly described - "concerning the clinical diagnosis, we
were not able to ascertain from the clinical data sheet whether the referring physicians
used additional diagnostics techniques such as dermoscopy"
 
Yoo 2015
Reason for exclusion EXCLUDE conference abstract
 
Youl 2007
Reason for exclusion EXCLUDE on index test
'clinical diagnosis' - dermoscopy used in some but not all cases. 
EXCLUDE but contact authors
Response from author "One of the main issues is that we just don’t know to what
extent dermoscopy was used in that study. We just asked where they used it in a
general sense and not for each case. However for each case GPs and skin clinic
doctors did indicate whether they conducted a whole- or part-body skin examination
(or just lesion specific)
 
Youl 2007a
Reason for exclusion EXCLUDE on index test
Evaluates clinical diagnosis (some lesions had dermoscopy)
 
Zaballos 2013
Reason for exclusion EXCLUDE on study population
They do not have enough benign cases to include as full report. 
 
Zou 2001
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Reason for exclusion EXCLUDE not a primary study
Study uses results from Stolz 1994
EXCLUDE on 2x2 data
Just showing ROC curves
 
Footnotes
AK - actinic keratosis; AUC – area under the curve; BCC - basal cell carcinoma; CAD – computer assisted diagnosis; D+/D- -
disease positive/disease negative; Dx – diagnosis; 7FFM – seven features for melanoma; FPs – false positives; FN – false
negative; FU – follow up; GP – general practitioner; PCP - primary care provider; PPV – positive predictive value; MM - –
malignant melanoma; NPV – negative predictive value; SCC - squamous cell carcinoma; se/sp – sensitivity/specificity; TD –
teledermatology; TN – true negative; TWR – two week rule; VI - visual inspection.
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Summary of findings table
Question: What is the diagnostic accuracy of visual inspection for the detection of cutaneous invasive melanoma andatypical intraepidermal melanocytic variants in adults?
Population: 
 
Adults with lesions suspicious for melanoma, including:
those with limited prior testing (presenting in primary, community or private dermatology settings), and
referred populations (presenting in secondary care or specialist skin cancer clinics).
Index test: 
 
Visual inspection with or without the use of any established algorithms or checklist to aid diagnosis,
including:
in-person evaluations (face-to-face diagnosis), and
image-based evaluations (diagnosis based on assessment of a clinical image).
Target
condition: Cutaneous invasive melanoma and atypical intraepidermal melanocytic variants
Reference
standard: 
Histology with or without long term follow-up
Action: If accurate, positive results ensure melanoma lesions are not missed but are appropriately referred andexcised and those with negative results can be safely reassured and discharged.
  Number of studies Total lesions Total cases
Quantity of evidence 49* 34351 2499
Limitations 
Risk of bias: 
Potential risk for patient selection from case control design (6), inappropriate exclusion criteria (7) or lack of
detail (27/49). All index test interpretation was blinded to reference standard diagnosis. Index test thresholds
not clearly pre-specified (22/28 in-person evaluations; 13/16 image-based). Low risk for reference standard
(42/49); high concern from use of expert diagnosis (6). Blinding of reference standard to visual inspection
diagnosis not reported in any study. High risk for participant flow due to differential verification (11), and
exclusions following recruitment (15); timing of tests was not mentioned in 37.
Applicability of
evidence to
question:
Participants restricted to those with melanocytic lesions only (10), or to those with histopathology results (37)
and included multiple lesions per participant (14). No description of diagnostic thresholds (24 in-person; 13
image-based) or reporting of average or consensus diagnoses (7 in-person; 13 image-based). Clinical
images interpreted blinded to clinical information (11/16). Little information given concerning the expertise of
the histopathologist (40/49).
FINDINGS: 
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Question: What is the diagnostic accuracy of visual inspection for the detection of cutaneous invasive melanoma andatypical intraepidermal melanocytic variants in adults?
Thirty-seven studies (providing 39 datasets) reporting accuracy data for the primary target condition were separated a priori
into in-person (n=28) and image-based (n=11) evaluations. Subsequent analysis confirmed differences in accuracy
according to the different approaches to diagnosis (P<0.001). Attempts to analyse studies by degree of prior testing were
hampered by a lack of relevant information provided in the study publications and by the inclusion of lesions selected for
biopsy or excision. Of the 28 in-person evaluations, only 17 could be clearly placed on the clinical pathway, and 11 were
considered not to have provided sufficient information to allow the pathway to be identified (coded ‘unclear’ on pathway).
The findings presented are based on results for in-person evaluations that could be clearly placed on the clinical pathway.
Test: In-person visual inspection using any or no algorithm at any threshold 
Data: Number of datasets Total lesions Total melanomas
All in-person evaluations 28 25604 1748
Studies clearly placed on the clinical pathway 17 14700 622
Place on pathway: Participants with limited prior testing (all lesions) 
Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
3 1339 55 92% (26, 100) 80% (74, 85)
Numbers in a
cohort of 1000
lesions** 
TP FP FN TN PPV NPV
At a
prevalence of
4%
37
[10; 40]
195
[252; 147]
3
[30; 0]
765
[708; 813]
16% [4; 21]
100%
[96; 100]
At a
prevalence of
9%
83
[24; 90]
185
[239; 139]
7
[66; 0]
725
[671; 771]
31%
[9; 39]
99%
[91; 100]
At a
prevalence of
16%
148
[42; 160]
171
[221; 129]
12
[118; 0]
669
[619; 711]
46%
[16; 55]
98%
[84; 100]
Place on pathway: Participants with limited prior testing (only lesions selected for excision)
Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
2 4228 160 90% (70, 97) 81% (67, 90)
Numbers in a
cohort of 1000
lesions** 
TP FP FN TN PPV NPV
At a
prevalence of
4%
36
[28; 39]
180
[312; 96]
4
[12; 1]
780
[648; 864]
17%
[8; 29]
99%
[98; 100]
At a
prevalence of
9%
81
[63; 88]
170
[296; 91]
9
[27; 2]
740
[614; 819]
32%
[18; 49]
99%
[96; 100]
At a
prevalence of
16%
144
[112; 156]
157
[273; 84]
16
[48; 4]
683
[567; 756]
48%
[29; 65]
98%
[92; 99]
Place on pathway: Referred participants (all lesions)
Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
2 3494 61 75% (49, 90) 99% (95, 100)
Numbers in a
cohort of 1000
lesions** 
TP FP FN TN PPV NPV
At a
prevalence of
4%
30
[20; 36]
13
[51; 4]
10
[20; 4]
947
[909; 956]
69%
[28; 90]
99%
[98; 100]
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Question: What is the diagnostic accuracy of visual inspection for the detection of cutaneous invasive melanoma andatypical intraepidermal melanocytic variants in adults?
At a
prevalence of
9%
67
[44; 81]
13
[48; 4]
23
[46; 9]
897
[862; 906]
84%
[48; 96]
98%
[95; 99]
At a
prevalence of
16%
119
[78; 144]
12
[45; 3]
41
[82; 16]
828
[795; 837]
91%
[64; 98]
95%
[91; 98]
Referred participants (only lesions selected for excision)
Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
8 5331 258 77% (62, 87) 96% (90, 98)
Numbers in a
cohort of 1000
lesions** 
TP FP FN TN PPV NPV
At a
prevalence of
4%
31
[25; 35]
41
[99; 16]
9
[15; 5]
919
[861; 944]
43%
[20; 68]
99%
[98; 99]
At a
prevalence of
9%
69
[56; 78]
39
[94; 15]
21
[34; 12]
871
[816; 895]
64%
[37; 84]
98%
[96; 99]
At a
prevalence of
16%
123
[99; 139]
36
[87; 14]
37
[61; 21]
804
[753; 826]
77%
[53; 91]
96%
[92; 98]
Referred participants with equivocal lesions (only lesions selected for excision)
Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
2 930 88 85% (56, 96) 89% (79, 95)
Numbers in a
cohort of 1000
lesions** 
TP FP FN TN PPV NPV
At a
prevalence of
4%
34
[22; 38]
101
[197; 48]
6
[18; 2]
859
[763; 912]
25%
[10; 44]
99%
[98; 100]
At a
prevalence of
9%
76
[50; 86]
96
[187; 46]
14
[40; 4]
814
[723; 865]
44%
[21; 66]
98%
[95; 100]
At a
prevalence of
16%
136
[89; 154]
88
[172; 42]
24
[71; 6]
752
[668; 798]
61%
[34; 79]
97%
[90; 99]
Footnotes
*37 of the 49 included studies (reporting on 39 cohorts of lesions) provide data for the primary target condition (defined as
detection of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants) and are the main focus of this
'Summary of findings' table; the summary of methodological quality is based on the full sample of 49 studies.
** Number of true positives (TP), false positives (FP), false negatives (FN), true negatives (TN) for a hypothetical cohort of
1000 lesions have been estimated at the median and interquartile ranges of prevalence (25th and 75th percentiles), at
average sensitivity and specificity and using the lower and upper limits of the 95% confidence intervals, denoted in square
brackets [lower limit; upper limit].
Additional tables 
1 Primary analyses for detection of invasive melanoma or melanocytic intraepidermal variants by position on
the clinical pathway
a. In-person evaluations (n=28)
Position on pathwayDatasetsLesions (cancers)Sensitivity
(95% CI)
VarianceSpecificity
(95% CI)
Variance
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a. In-person evaluations (n=28)
Position on pathwayDatasetsLesions (cancers)Sensitivity
(95% CI)
VarianceSpecificity
(95% CI)
Variance
Participants with limited prior testing (unselected on reference standard)
Clear 3
1339 (55)
92.4
(26.2, 99.8)
6.26
79.7
(73.7, 84.7)
0.07
Participants with limited prior testing (selected for excision)
Clear 2 
(ind)
4228 (160)
90.1
(70.0, 97.3)
0.53
81.3
(67.5, 90.0)
0.25
 
Unclear 1 353 (38)
78.9
(62.7, 90.4)
-
94.0
(90.7, 96.3)
-
Combined 3 4581 (198) 87.2
(73.2, 94.4)
0.45 87.1
(74.6, 94.0)
0.51
Referred participants (unselected on reference standard)
Clear 2
3494 (61)
74.6
(48.9,90.0)
0.14
98.6 
(94.7,99.6)
0.77
Referred participants (selected for excision)
Clear 8
5331 (258)
76.7
(61.7, 87.1)
0.78
95.7
(89.7, 98.3)
1.73
Unclear
9 9611 (1015)
82.8
(74.4, 88.9)
0.34
89.2
(71.1, 96.5)
3.21
Combined 17 14942
(1273)
79.7
(71.7, 85.8)
0.59 93.0
(85.4, 96.8)
2.59
Referred participants with equivocal lesions (selected for excision)
Clear 2 
(ind)
930 (88)
84.7
(55.5, 96.1)
0.93
89.5
(79.5, 95.0)
0.27
Unclear
1 318 (73)
61.4
(49.0, 72.9)
-
87.3
(82.5, 91.2)
-
Combined 3 1248 (161) 76.4
(48.4, 91.8)
1.03 88.8
(81.8, 93.3)
0.21
b. Image-based evaluations (n=11)
Position on pathwayDatasetsLesions (cancers)Sensitivity
(95% CI)
VarianceSpecificity
(95% CI)
Variance
Participants with limited prior testing (selected for excision)
Clear 1 50 (9) 22.2
(2.8, 60.0)
- 70.7
(54.4, 83.9)
-
 
Unclear
1 463 (29) 20.7
(8.0, 39.7)
- 96.8
(94.6, 98.2)
-
Combined 2 513 (38) 21.4
(10.0, 40.1)
0 90.9
(60.7, 98.1)
1.50
Referred participants (unselected on reference standard)
Clear 1 134 (31) 74.2
(55.4, 88.1)
- 82.5
(73.8, 89.3)
1
Referred participants (selected for excision)
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a. In-person evaluations (n=28)
Position on pathwayDatasetsLesions (cancers)Sensitivity
(95% CI)
VarianceSpecificity
(95% CI)
Variance
Unclear 6 293 (96) 60.3
(49.2, 70.5)
0.02 77.0
(63.9, 86.4)
0.40
Referred participants with equivocal lesions (selected for excision)
Unclear 2 303 (98) 61.9
(46.7, 75.0)
0.10 81.8
(75.2, 87.0)
0.01
Footnotes
ind - sensitivity and specificity estimated 'independently' in separate models due to sparse data.
2 Secondary analyses for primary target condition by covariate
Subgroup DatasetsLesions
(cancers)
Diagnostic
odds
ratio (DOR)
(95% CI)
Relative DOR 
(95% CI)
P value
(DOR)
P value 1 (Hierarchical
summary receiver-
operator curves
(HSROC) models)
Differences in-person and image based
In-person 28 25604(1748)
37.5 (21.7,
64.7)
8.54 (2.89, 25.3) <0.001 0.001
Image-based 11 1243 (263) 4.38 (1.79,10.8)
     
Analyses based on in-person evaluations only (n=28):
Study setting
Primary/Community/Private 6 5920 (253) 27.6 (6.95,109)
     
Secondary 10 10419(1019)
39.0 (13.8,
110)
     
Specialist clinic 12 9265 (476) 44.4 (17.2,115)
Secondary/specialist vs.
primary2: 1.51 (0.32, 7.09)
0.59 0.62
Use of a diagnostic algorithm
No algorithm used 21 19330(1076)
37.3 (18.0,
77.3)
     
Any algorithm used 7 6274 (672) 38.5 (11.3,132) 1.03 (0.25, 4.34) 0.96 0.55
Type of reference standard used
Histology alone 22 20783(1627)
39.1 (19.7,
77.8)
     
Histology plus any other 6 4821 (121) 29.7 (6.60,134) 0.76 (0.14, 4.02) 0.74 0.68
Prevalence
Prevalence ≤0.1 16 21907(811)
63.7 (28.6,
142)
     
Prevalence>0.1 12 3697 (937) 19.6 (8.39,45.8) 0.31 (0.09, 1.00) 0.05 0.06
Footnotes
1 Likelihood ratio test assessing differences in both accuracy and threshold
2 Secondary vs Primary 1.41 (0.25, 7.93), P=0.68; Specialist vs Primary 1.61 (0.30, 8.63), P=0.56; Specialist vs Secondary
1.14 (0.28, 4.68), P=0.85.
3 Visual inspection for detection of melanoma and intraepidermal melanocytic variants - by algorithm
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 Test (threshold)
DatasetsLesions 
(melanomas)
Pooled 
Sensitivity (95% CI)
Pooled
Specificity (95% CI)
Diagnostic odds ratio (DOR)
(95% CI)
In-person evaluations
No algorithm 21 19330 (1076)0.78 (0.68, 0.85) 0.93 (0.88, 0.96) 46.2 (21.9, 97.5)
(A)BCD(E)* 6 *** 5501 (654) 0.83 (0.75, 0.88) 0.88 (0.64, 0.97) 36.6 (7.94, 168)
7point checklist at >=2 1 205 (12) 0.92 (0.62, 1.00) 0.65 (0.58, 0.72) 22.8 (2.08, 176)
7point checklist at >=3 1 205 (12) 0.42 (0.15, 0.72) 0.93 (0.89, 0.96) 11.8 (3.22, 43.3)
7point checklist at >=4 1 205 (12) 0.25 (0.07, 0.57) 0.98 (0.96, 1.00) 31.8 (4.71, 215)
7point checklist (revised) at >=3 1 773 (18) 0.94 (0.73, 1.00) 0.80 (0.77, 0.83)  
new Collas at >=1 1 353 (38) 0.76 (0.60, 0.89) 0.50 (0.44, 0.56) 3.24 (1.49, 7.07)
Image-based evaluations
No algorithm 9 1090 (217) 0.58 (0.43, 0.71) 0.84 (0.76, 0.90) 7.47 (4.12, 13.5)
ABCD(E)** 2 153 (46) 0.53 (0.37, 0.70) 0.71 (0.45, 0.88) 2.87 (0.93, 8.79)
Footnotes
* Combines data from studies using ABCD with threshold not reported (n=2), ABCDE with at least 2 characteristics present
(n=3) and BCD with at least 2 characteristics present (n=1)
** Combines data from studies using ABCD with at least 2 characteristics present (n=1) and ABCDE with at least 2
characteristics present (n=1)
*** Due to non-convergence, the bivariate models were fitted assuming zero correlation between the logit sensitivity and logit
specificity and removing the random effects term for specificity when estimating sensitivity and the random effects term for
sensitivity when estimating specificity.
4 Secondary analyses for detection of melanoma and intraepidermal melanocytic variants by observer
Subgroup DatasetsLesions
(melanomas)
Diagnostic
odds ratio
(DOR)
(95% CI)
Relative
DOR
(RDOR)
(95% CI)
P value
(for RDOR)
P value* (Hierarchical summary
receiver-operator curves
(HSROC) models)
In-person evaluations
Expert consultant 9 3547 29.0 (11.0, 76.2) 1   0.36
Consultant 13 16858 38.4 (16.9, 87.6) 1.32 (0.37,4.71) 0.65
 
Resident/registrar 2 1339 12.9 (1.99, 84.0) 0.45 (0.05,3.67) 0.44
 
Mixed (secondary
care) 2 2704 48.0 (4.54, 507)
1.65 (0.13,
21.4) 0.69
 
GP 3 1236 211 (24.9, 1788) 7.28 (0.69,76.3) 0.09
 
Image-based evaluations
Expert consultant 6 974 20.5 (4.82, 86.9) 1   0.22
Consultant 4 200 3.76 (1.15, 12.3) 0.18 (0.04,0.90) 0.04
 
Mixed (secondary
care) 1 200 10.9 (2.02, 59.2)
0.53 (0.07,
3.97) 0.50
 
Mixed
(secondary/primary
care)
1 40 11.5 (0.94, 142) 0.56 (0.04,7.51) 0.63
 
Mixed (primary care) 2 184 6.60 (1.73, 25.2) 0.32 (0.07,1.40) 0.11
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Footnotes
* Likelihood ratio test assessing differences in both accuracy and threshold
5 Results for studies reporting data for more than one observer
Study 
Algorithm
(diagnostic
approach)
Dis/Non-
dis*;
prevalence
Observer
qualification
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Observer
qualification
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Observer
qualification
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Target condition: Invasive melanoma and/or atypical intraepidermal melanocytic variants
Benelli
2001
ABCDE (i-
b)
12 / 38;
24%
      Dermatologist
(n=65)
50% (21,
79)
50% (33,
67)
Expert
dermatologists
(n=1)
58% (28,
85)
53% (36,
69)
Morton
1998
No
algorithm
(in-p)
Different
lesions per
obs
Registrar
(n=6)
69 / 694; 9%
79% (59,
92)
98% (97,
99)
Senior registrar
(n=2)
31 / 536; 5%
90% (74,
98)
97% (96,
99)
Expert
dermatologists
(n=2)
28 / 641; 4%
91% (82,
97)
99% (97,
99)
Stanganelli
2005
No
algorithm (i-
b)
31 / 103;
23%
GP (n=3) 81% (63,
93)
73% (63,
81)
      Experienced
dermatologists
(n=3)
74% (55,
88)
83% (74,
89)
Target condition: Invasive melanoma alone
Lorentzen
1999
No
algorithm (i-
b)
49 / 183;
21%
      Non-expert
dermatology
residents (n=5)
61% (46,
75)
88% (82,
92)
Experienced
dermatologists
(n=4)
78% (63,
88)
89% (84,
93)
Rao 1997
ABCD (i-b)
21 / 51;
29%
       
Melanoma
Fellow 1 (n=1)
90% (70,
99)
80% (67,
90)
Dermatologist
1 (n=1)
76% (53,
92)
82% (69,
92)
 
Melanoma
Fellow 2 (n=1)
86% (64,
97)
75% (60,
86)
Dermatologist
2 (n=1)
86% (64,
97)
75% (60,
86)
Scope 2008
Ugly
Duckling (i-
b)
5 / 140; 3%
Dermatology
nurse +
medical
photographer
(n=5)
60% (15,
95)
96% (91,
98)
General
dermatologists
(n=13)
80% (28,
99)
86% (79,
91)
Expert
dermatologists
(n=8)
80% (28,
99)
95% (90,
98)
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Study 
Algorithm
(diagnostic
approach)
Dis/Non-
dis*;
prevalence
Observer
qualification
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Observer
qualification
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Observer
qualification
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Target condition: Invasive melanoma and/or atypical intraepidermal melanocytic variants
Westerhoff
2000
No
algorithm (i-
b)
50 / 50;
50%
GP pre-
dermoscopy
training (n=37)
54% (39,
68)
53% (38,
67)
GP post-
dermoscopy
training
(n=37)
62% (47,
75)
54% (39,
68)
     
Footnotes
in-p - in-person; i-b - image-based; obs - observer; GP - general practitioner
*Number of diseased / number of non-diseased (prevalence of disease), for each definition of the target condition
6 Secondary analyses for alternative definitions of the target condition
Subgroup DatasetsParticipants
(cases)
Diagnostic
odds
ratio (DOR)
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
Relative
DOR
(RDOR)
(95% CI)
P value
(RDOR)
P value* (Hierarchical
summary receiver-operator
curves (HSROC) models)
Differences in-person and image-based
Detection of invasive melanoma alone
In-person 7 6857 (208) 62.4 (17.6,222)
86% (68,
94)
91% (81,
96)
4.21 (0.62,
28.6) 0.13 0.27
Image-
based 5 599 (150)
14.8 (3.56,
61.9)
76% (50,
91)
83% (62,
93)
     
Detection of any skin lesion requiring excision
In-person 7 8091 (2187) 20.5 (7.11,59.3)
81% (68,
90)
81% (56,
93)
1.70 (0.24,
12.3) 0.55 0.87
Image-
based 3 547 (138)
11.9 (2.22,
65.3)
75% (49,
90)
79% (38,
96)
     
Footnotes
* Likelihood ratio test assessing differences in both accuracy and threshold
7 Results for studies reporting data for more than one definition of the target condition
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  Detection of invasive melanoma Detection of invasive melanoma or
atypical intraepidermal melanocytic
variants
Detection of any lesion requiring
excision
Study
author
Dis/ non-
dis
(prev)*
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Dis/ non-
dis (prev)*
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Dis/ non-
dis
(prev)*
Sensitivity
(95% CIs)
Specificity
(95% CIs)
In-person
Ek 2005 - - - 23 / 2559;
1% 48% (27, 69) 99% (99, 99)
1754
/828;
68%
98% (97,
98)
13% (11,
15)
McGovern
1992
6 / 186;
3%
100% (54,
100)
89% (83,
93)
11 / 181;
6% 73% (39, 94) 88% (83, 93)
15 / 177;
8%
73% (45,
92)
88% (82,
93)
Stanganelli
2000
- - - 55 / 3317;
2% 67% (53, 79)
99% (99,
100)
98 /
3274; 3%
71% (61,
80)
99% (99,
99)
Steiner
1987
- - - 73 / 245;
23% 59% (47, 70) 87% (83, 91)
93 / 225;
29%
67% (56,
76)
86% (81,
90)
Walter 2012 16 / 757;
2%
94% (70,
100)
80% (77,
83)
18 / 755;
2%
94% (73,
100) 80% (77, 83)
22 / 751;
3%
82% (60,
95)
80% (77,
83)
Image-based
Carli 2002b - - - 10 / 43;
19% 80% (44, 97) 84% (69, 93)
20 / 34;
37%
80% (56,
94)
74% (56,
87)
Rosendahl
2011
- - - 29 / 434;
6% 21% (08, 40) 97% (95, 98)
104 /
359; 22%
76% (67,
84)
85% (81,
88)
Stanganelli
1998
- - - 10 / 20;
33% 40% (12, 74) 75% (51, 91)
14 / 16;
47%
64% (35,
87)
75% (48,
93)
Footnotes
*Number of diseased / number of non-diseased (prevalence of disease), for each definition of the target condition
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Test StudiesParticipants
1 Visual inspection - in-person (MM) 7 6857
2 Visual inspection - image-based (MM) 5 599
3 Visual inspection - in-person (MM+MiS) 28 25604
4 Visual inspection - image-based (MM+MiS) 11 1243
5 Visual inspection - in-person (Any) 7 8091
6 Visual inspection - image-based (Any) 3 547
7 MM2- VI - in-person - no algorithm 21 19330
8 MM2- VI - in-person - no algorithm (alt thresholds) 2 475
9 MM2- VI - in-person - (A)BCD(E) at NR or standard threshold 6 5501
10 MM2-VI - in-person - ABCD at NR 2 3548
11 MM2-VI - in-person - ABCDE at >=1 2 1541
12 MM2-VI - in-person - ABCDE at >=2 3 1761
13 MM2-VI - in-person - ABCDE at >=3 2 1541
14 MM2-VI - in-person - ABCDE at >=4 2 1541
15 MM2-VI - in-person - ABCDE at >=5 2 1541
16 MM2-VI - in-person - BCD at >=1 1 192
17 MM2-VI - in-person - BCD at >=2 1 192
18 MM2-VI - in-person - BCD at >=3 1 192
19 MM2-VI - in-person - 7point at >=2 1 205
20 MM2-VI - in-person - 7point at >=3 1 205
21 MM2-VI - in-person - 7point at >=4 1 205
22 MM2-VI - in-person - 7point(rev) at >=3 1 773
23 MM2-VI - in-person - Collas at >=1 1 353
24 MM2- VI - image-based - no algorithm 9 1090
25 MM2- VI - image-based - no algorithm (alt threshold) 0 0
26 MM2-VI - image-based - ABCD(E) at standard 2 153
27 MM2-VI - image-based - ABCD at >=2 1 103
28 MM2-VI - image-based - ABCD at >=3 1 103
29 MM2-VI - image-based - ABCDE at >=2 1 50
30 MM2-VI - image-based - ABCDE at >=3 1 50
31 MM2- VI - in-person - experience NR 12 16778
32 MM2- VI - in-person - experience High 9 3547
33 MM2- VI - in-person - experience Moderate 1 567
34 MM2- VI - in-person - experience Low 4 2008
35 MM2- VI - in-person - experience Mixed 2 2704
36 MM2- VI - image-based - experience NR 5 663
37 MM2- VI - image-based - experience High 5 540
38 MM2- VI - image-based - experience Low 1 134
39 MM2- VI - image-based - experience Mixed 2 90
40 VI - in-person - Expert consultant (MM+MiS) 9 3547
41 VI - in-person - Consultant (MM+MiS) 12 16778
42 VI - in-person - Resident/registrar (MM+MiS) 2 1236
43 VI - in-person - Mixed qualifications (secondary care) (MM+MiS) 2 2704
44 VI - in-person - GP (MM+MiS) 3 1339
45 MM2- VI - image-based - Expert consultant 4 700
46 MM2- VI - image-based - Consultant 4 200
47 MM2- VI - image-based - Mixed qualifications (secondary care) 1 200
48 MM2- VI - image-based - Mixed qualifications (secondary/primary care)1 40
49 MM2- VI - image-based - Mixed qualifications (primary care) 2 184
50 MM2 - VI - image-based qual not reported 0 0
51 MM2 - Selected on quality - pathway 2 or 3 5 5728
52 MM2 - Selected on quality - pathway 5 9 3556
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Caption
Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right)
Figure 2
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
185 / 256
Caption
Current clinical pathway for people with skin lesions
Figure 3
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Caption
Clinical pathway
Figure 4
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Caption
PRISMA flow diagram.
Figure 5
Caption
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Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 6
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Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 7 (Analysis 7) 
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Caption
Forest plot of in-person evaluations of visual inspection for detection of invasive melanoma and melanocytic intra-epidermal
variants by point on the clinical pathway where they are diagnosed
Figure 8 (Analysis 8) 
Caption
Forest plot of image-based evaluations of visual inspection for detection of invasive melanoma and melanocytic intra-
epidermal variants by point on the clinical pathway where they are diagnosed
Figure 9 (Analysis 7) 
Caption
Summary estimates of accuracy of in-person visual inspection for the detection of invasive melanoma and melanocytic intra-
epidermal variants by point on the clinical pathway where they are diagnosed
(confidence regions are not plotted due to small numbers of studies)
Figure 10 (Analysis 8) 
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Caption
Summary estimates of accuracy of image-based visual inspection for the detection of invasive melanoma and melanocytic
intra-epidermal variants by point on the clinical pathway where they are diagnosed
(confidence regions are not plotted due to small numbers of studies)
Figure 11 (Analysis 2) 
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Caption
Summary ROC comparing in-person and image-based evaluations of visual inspection for detection of invasive melanoma or
atypical intraepidermal melanocytic variants (MM+MiS).
Figure 12 (Analysis 5) 
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Caption
Summary ROC Plot of in-person visual inspection evaluations stratified by study setting for detection of invasive melanoma
and atypical intraepidermal melanocytic variants (MM+MiS)
Figure 13 (Analysis 6) 
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Caption
Summary ROC Plot of in-person visual inspection evaluations stratified by use of a published algorithm for detection of
invasive melanoma and atypical intraepidermal melanocytic variants (MM+MiS)
Figure 14 (Analysis 3) 
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Caption
Summary ROC Plot of in-person visual inspection evaluations stratified by reference standard for detection of invasive
melanoma and atypical intraepidermal melanocytic variants (MM+MiS)
Figure 15 (Analysis 13) 
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Caption
Summary ROC Plot of in-person visual inspection (VI) evaluations stratified by observer experience and qualifications for
detection of invasive melanoma and atypical intraepidermal melanocytic variants (MM+MiS)
Figure 16 (Analysis 9) 
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Caption
Summary ROC comparing in-person and image-based evaluations of visual inspection for detection of invasive melanoma
alone (MM).
Figure 17 (Analysis 10) 
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Caption
Summary ROC comparing in-person and image-based evaluations of visual inspection for detection of any skin lesion
requiring excision (Any)
Sources of support 
Internal sources
No sources of support provided
External sources
NIHR Systematic Review Programme, UK
The National Institute for Health Research (NIHR), UK
The NIHR, UK, is the largest single funder of the Cochrane Skin Group
Feedback 
Appendices 
1 Current content and structure of the Programme Grant
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List of reviews  
Diagnosis of melanoma 
Estimated number of
studies
1. Visual inspection versus visual inspection plus dermoscopy 120
2. Teledermatology 12
3. Mobile phone applications 2
4. Computer-aided diagnosis: dermoscopy-based and spectroscopy-based techniques 37
5. Reflectance confocal microscopy 19
6. High frequency ultrasound 3
7. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination -
Diagnosis of keratinocyte skin cancer (basal cell carcinoma and cutaneous squamous cell
carcinoma)
 
8. Visual inspection ± dermoscopy 22
9. Computer-aided diagnosis: dermoscopy-based and spectroscopy-based techniques 3
10. Optical coherence tomography 6
11. Reflectance confocal microscopy 9
12. High frequency ultrasound 1
13. Exfoliative cytology 5
14. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination -
Staging of melanoma  
15. Ultrasound 25 to 30
16. Computer tomography 5 to 10
17. Positron emission tomography or positron emission tomography-computer tomography 20 to 25
18. Magnetic resonance imaging 5
19. Sentinel lymph node biopsy ± high frequency ultrasound 70
20. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination -
Staging of cutaneous squamous cell carcinoma  
21. Imaging tests review 10 to 15
22. Sentinel lymph node biopsy ± high frequency ultrasound 15 to 20
2 Glossary of terms
Term Definition
Atypical intraepidermal
melanocytic variant
Unusual area of darker pigmentation contained within the epidermis that may progress to an
invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the skin
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the control of
cell growth. BRAF mutations (damaged DNA) occur in around 40% of melanomas, which
can then be treated with particular drugs.
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF mutated
metastatic melanoma.
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a microscope,
measured in mm from the top layer of skin to the bottom of the tumour.
Congenital naevi A type of mole found on infants at birth
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Term Definition
 
Dermoscopy
Whereby a handheld microscope is used to allow more detailed, magnified, examination of
the skin compared to examination by the naked eye alone
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies them
as disease-free.
False positive An individual who is truly disease-free, but whom a diagnostic test classifies them as having
the disease.
Histopathology/Histology The study of tissue, usually obtained by biopsy or excision, for example under a microscope.
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which includes
malignant cells but with no invasive growth. May progress to an invasive melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that travels
around the body to help fight disease; they are located throughout the body often in clusters
(nodal basins).
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as ‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual studies.
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the bloodstream or
the lymphatic system.
Micrometastases Micrometastases are metastases so small that they can only be seen under a microscope.
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour.
Morbidity Detrimental effects on health.
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which reflects the
number of deaths per unit of population in relation to any specific region, age group,
disease, treatment or other classification, usually expressed as deaths per 100, 1000,
10,000 or 100,000 people.
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g. urology,
oncology, pathology, radiology, and nursing). Cancer care in the National Health Service
(NHS) uses this system to ensure that all relevant health professionals are engaged to
discuss the best possible care for that patient.
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the patient’s
prognosis.
Receiver operating
characteristic (ROC) plot
A plot of the sensitivity and 1 minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a range of
binary test results
Receiver operating
characteristic (ROC) analysis
The analysis of a ROC plot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can occur either
at the site of the original tumour or at other sites in the body.
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of a patient in an
evaluation of a diagnostic test
Reflectance confocal
microscopy (RCM)
A microscopic technique using infrared light (either in a handheld device or a static unit) that
can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of individuals with a disease who
have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with benign skin
lesions) who have that absence of disease correctly identified by the study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into internationally
agreed categories.
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Term Definition
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or physical
examination.
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer cells
throughout the body rather than targeting one specific area.
3 Table of acronyms and abbreviations used
Acronym Definition
3PCL three point checklist
7FFM seven features for melanoma
7PCL seven point checklist
ABCD(E) asymmetry, border, colour, differential structures (enlargement)
AHM amelanotic or hypomelanotic melanoma
AK actinic keratosis
AMN atypical melanocytic naevi
AUC area under the curve
BCC basal cell carcinoma
BD Bowen’s disease
BN benign naevi
BNM benign non-melanocytic
BPC between person comparison (of tests)
CAD computer assisted diagnosis
CCS case control study
CD compact disc
CM cutaneous melanoma
CMM cutaneous malignant melanoma
CS case series
CSCC cutaneous squamous cell carcinoma
D- disease negative
D+ disease positive
DF dermatofibroma
Dx diagnosis
ELM epiluminescence microscopy
FN false negative
FP false positive
FU Follow- up
GP general practitioner
H&E haematoxylin and eosin stain
LPLK lichen planus- like keratosis
LS lentigo simplex
MiS melanoma in situ (or lentigo maligna)
MM malignant melanoma
MN melanocytic naevi
MSDSLA multispectral digital skin lesion analysis device
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Acronym Definition
N/A not applicable
NC non comparative
NMLs non melanocytic lesions
NPV negative predictive value
NR not reported
P prospective
PCPs primary care providers
PLC pigmented lesion clinic
PPV positive predictive value
PSL pigmented skin lesion
R retrospective
RCM reflectance confocal microscopy
RCT randomised controlled trial
SCC squamous cell carcinoma
SD standard deviation
SDDI Short term sequential digital dermoscopy imaging
se sensitivity
sp specificity
SK seborrhoeic keratosis
SN Spitz nevi
SSM superficial spreading melanoma
SVS support vector system
TD teledermatology
TN true negative
TWR two week rule
VI visual inspection
WPC within person comparison (of tests)
WPC-algswithin person comparison (of algorithms)
4 Content of algorithms used to assist melanoma diagnosis by visual inspection alone
 
ABCD (Friedman 1985; Rigel 1993; 
Pehamberger 1993)
ABCDE (Carli 1994; Cristofolini 1994; 
Thomas 1998; Benelli 1999; Benelli 2001; 
Abbasi 2004)
BCD (McGovern 1992)
 
Seven-point checklist (
MacKie 1985; MacKie
1990; Keefe 1990)
 
Seven-point checklist (revised) (MacKie 1990; 
Healsmith 1994)
 
A – asymmetry
variable centripetal growth of
melanocytes (Friedman 1985)
“geometrical asymmetry in two
axes of the tumour” (Thomas 1998; 
Benelli 1999; Benelli 2001)
“one half does not match the
other half” (McGovern 1992); not
separately scored in study “because we
believed that asymmetry and border
 
sensory change
(greater awareness of
the lesion or mild itch);
diameter of >=1 cm;
growth of the lesion;
an irregular edge;
irregular pigment with
different shades of
brown and black in the
lesion;
 
MacKie 1990, Mackie 1991, and Healsmith 1994
describe the revised criteria as:
Major signs
Change in size
Change in shape
Change in colour
Minor signs
Inflammation
Crusting or bleeding
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irregularity were linked”
B - irregular borders
irregular shape with notching or
scalloping of border (Friedman 1985)
“edges are ragged, notched, or
blurred (McGovern 1992)
“irregular and notched” (Cristofolini 1994)
“unsharp or ill-defined or angular” (
Thomas 1998)
“ragged or indented” (Benelli 1999, 
Benelli 2001)
C - colour
variable pigmentation, multiple
colours; various of hues of
brown, also black, blue, red and
white (Friedman 1985 )
“pigmentation is not uniform;
shades of tan, brown and black
are present with dashes of red,
white, or blue” (McGovern 1992)
“mottled-haphazard display” (Cristofolini
1994)
“presence of at least two different
colours within the lesion (with the
exception of the usual symmetrical
darkening of the lesion in its
center)” (Thomas 1998; Benelli 2001)
“multiple colours” (Abbasi 2004)
D - diameter equal or superior to 6mm
all studies agree
E - evolution
“changes in pigmentation” (Cristofolini
1994)
“enlargement of the surface (and
not in height) of the lesion;
anamnestic criterion based on the
patient’s description of the natural
history of the lesion” (Thomas 1998)
“elevation, enlargement or change
in the color of the lesion” (Benelli 1999; 
Benelli 2001)
“evolving (with respect to size,
shape, shades of colour, surface
features, or symptoms)” (Abbasi 2004)
McGovern 1992 describes 7 characteristics
as: “increasing size, variegation,
inflammation, irregular outline, greater than
1cm diameter, itch, bleeding”
These are expanded on in MacKie 1990, who
describes the original (1985) criteria as:
sensory change, often described as a
greater awareness of the lesion but also
as a mild itch;
diameter of 1 cm or greater;
growth of the lesion;
an irregular edge;
irregular pigment with different shades of
brown and black in the lesion;
inflammation (a reddish tinge within the
lesion); and
crusting, oozing, or bleeding.
inflammation
crusting, oozing, or
bleeding.
Presence of 3 or more
suggestive of melanoma
Sensory change
Diameter >=7 mm
“a patient with a pigmented lesion with any
one of the major signs should be
considered for referral and that the
presence of any of the minor signs should
be a further stimulus to referral.” (MacKie 1990)
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>=3 criteria should prompt referral (
MacKie 1990)
     
5 Proposed sources of heterogeneity
i. Population characteristics
general versus higher risk populations
patient population: primary/secondary/specialist unit
lesion suspicion: general suspicion/atypical/equivocal/NR
lesion type: any pigmented; melanocytic
inclusion of multiple lesions per participant
ethnicity
ii. Index test characteristics
the nature of and definition of criteria for test positivity
observer experience with the index test
approaches to lesion preparation (e.g. the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
reference standard used
whether histology-reporting meets pathology-reporting guidelines
use of excisional versus diagnostic biopsy
whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
consecutive or random sample of participants recruited
index test interpreted blinded to the reference standard result
index test interpreted blinded to the result of any other index test
presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by
the reference test or by the same reference test with selection dependent on the index test result)
use of an adequate reference standard
overall risk of bias
6 Final search strategies
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
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19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
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65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 "Sensitivity and Specificity"/
111 exp cancer staging/
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112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August, 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
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39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
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85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$
or epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
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28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$).mp. or tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
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74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 "Sensitivity and Specificity"/
120 *cancer staging/
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121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 "skin cancer*"
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#6 nmsc
#7 "squamous cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 "basal cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 "visual inspect*"
#20 "visual exam*"
#21 (clinical or physical) next (exam*)
#22 "3 point"
#23 "three point"
#24 "pattern analys*"
#25 ABDC
#26 menzies
#27 "7 point"
#28 "seven point"
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 "artificial intelligence"
#31 "AI"
#32 "computer assisted"
#33 "computer aided"
#34 AI
#35 "neural network*"
#36 MoleMax
#37 "computer diagnosis"
#38 "image process*"
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#39 "automatic classif*"
#40 SIAscope
#41 "image analysis"
#42 "optical near/2 scan*"
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 "confocal microscopy"
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 "mitotic index"
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 "Mole Detective"
#60 "Spot Check"
#61 mole* near/2 map*
#62 total near/2 body
#63 "exfoliative cytolog*"
#64 "digital analys*"
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatolog*
#67 "optical coherence" next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or
#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or
#63 or #64 or #65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 "CAT SCAN" or "CATSCAN"
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 "magnetic resonance imag*"
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#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 "positron emission tomograph*"
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or "false negative*" or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 "electrical impedance spectroscopy"
#100 "history taking"
#101 "patient history"
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 "ugly duckling" or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 "clinical accuracy"
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 "diagnostic algorithm*"
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 "virtual image*"
#115 "volatile organic compound*"
#116 dog or dogs
#117 VOC
#118 "gene expression analys*"
#119 "reflex transmission imaging"
#120 "thermal imaging"
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111
or #112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
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Search strategy:
S1 (MH "Melanoma") OR (MH "Nevi and Melanomas+")
S2 (MH "Skin Neoplasms+")
S3 (MH "Carcinoma, Basal Cell+")
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH "Keratinocytes")
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or
(seven point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or
DermoScan or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH "Diagnosis, Computer Assisted+")
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH "Sentinel Lymph Node Biopsy")
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
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S44 "Patient history"
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR
S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH "Deoxyglucose+")
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH "Deoxyglucose+")
S72 (MH "Tomography, Emission-Computed+")
S73 (MH "Tomography, X-Ray Computed")
S74 positron emission tomograph*
S75 (MH "Magnetic Resonance Imaging+")
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77
OR S78 OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH "Neoplasm Staging")
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
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S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or "incident light" or "surface
microscop*" or "visual inspect*" or "physical exam*" or 3 point or three point or pattern analy* or ABCDE or menzies or 7
point or seven point or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural
network* or Molemax or image process* or automatic classif* or image analysis or siascope or optical scan* or Aura or
melafind or simsys or molemate or solarscan or vivascope or confocal microscop* or high ultraso* or canine detect* or
cellphone* or mobile* or phone* or smartphone or dermoscan or skinvision or dermlink or spotcheck or spot check or mole
detective or mole map* or total body or exfoliative psychology or digital or image software or optical coherence or
teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos* or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or
physical exam* or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general
practice or confocal microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile
organic or VOC or dog* or gene expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron
emission or computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or
sonograph* or ultraso* or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
7 Full text inclusion criteria
Criterion Inclusion Exclusion
 
Study design
 
For diagnostic and staging reviews
Any study for which a 2×2 contingency table can be
extracted, e.g.
diagnostic case control studies
'cross-sectional' test accuracy study with
retrospective or prospective data collection
studies where estimation of test accuracy was not the
primary objective but test results for both index and
reference standard were available
RCTs of tests or testing strategies where participants
were randomised between index tests and all
undergo a reference standard (i.e. accuracy RCTs)
 
< 5 melanoma cases (diagnosis reviews)
< 10 participants (staging reviews)
Studies developing new criteria for diagnosis
unless a separate 'test set' of images were
used to evaluate the criteria (mainly digital
dermoscopy)
Studies using 'normal' skin as controls
Letters, editorials, comment papers, narrative
reviews
Insufficient data to construct a 2×2 table
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Criterion Inclusion Exclusion
Target
condition
 
Melanoma
Keratinocyte skin cancer (or non-melanoma skin
cancer)
BCC or epithelioma
cSCC
 
Studies exclusively conducted in children
Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
Adults with a skin lesion suspicious for melanoma, BCC,
or cSCC (other terms include pigmented skin
lesion/nevi, melanocytic, keratinocyte, etc.)
Adults at high risk of developing melanoma skin cancer,
BCC, or cSCC
For staging reviews
Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or distant
metastases or both
 
People suspected of other forms of skin cancer
Studies conducted exclusively in children
Index tests For diagnosis
Visual inspection/clinical examination
Dermoscopy/dermatoscopy
Teledermoscpoy
Smartphone/mobile phone applications
Digital dermoscopy/artificial intelligence
Confocal microscopy
Ocular coherence tomography
Exfoliative cytology
High frequency ultrasound
Canine odour detection
DNA expression analysis/gene chip analysis
Other
For staging
CT
PET
PET-CT
MRI
Ultrasound +/fine needle aspiration cytology FNAC
SLNB +/high frequency ultrasound
Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope used)
 
Sentinel lymph biopsy for therapeutic rather
than staging purposes
Tests to determine melanoma thickness
Tests to determine surgical margins/lesion
borders
Tests to improve histopathology diagnose
LND
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Criterion Inclusion Exclusion
Reference
standard
 
For diagnostic studies
Histopathology of the excised lesion
Clinical follow-up of non-excised/benign appearing
lesions with later histopathology if suspicious
Expert diagnosis (studies should not be included if
expert diagnosis is the sole reference standard)
For studies of imaging tests for staging
Histopathology (via LND or SLMB)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging
LND of both SLN+ and SLn participants to identify all
diseased nodes
LND of SLN+ participants and follow-up of SLN
participants to identify a subsequent nodal recurrence in
a previously investigated nodal basin
 
For diagnostic studies
Exclude if any disease positive participants
have diagnosis unconfirmed by histology
Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
Exclude studies of referral accuracy, i.e.
comparing referral decision with expert
diagnosis, unless evaluations of
teledermatology or mobile phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle
aspiration cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography;
PET-CT: positron emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell
carcinoma; SLN+: positive sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy.
8 Quality assessment (based on QUADAS-2)
The QUADAS-2 checklist (Whiting 2011) was tailored to the review topic as follows below.
Patient selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible
to undergo a test should be included in a study, allowing for the intended use of that test within the context of the study. We
considered studies that separately sampled malignant and benign lesions to have used a case-control design; and those that
supplemented a series of suspicious lesions with additional malignant or benign lesions to be at unclear risk of bias
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion
sites, or that excluded lesions on the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at
high risk of bias.
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion
populations, such as melanocytic, nodular, high risk or restrictions by size to be of high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions
to contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We
considered studies that include a high number of lesions in relation to the number of study to be less representative than
studies conducted in a more general population participants (i.e. if the difference between the number of included lesions and
number of included participants is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to
the result of the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that
used the original index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the
reference standard is known; however, studies using previously acquired images could be particularly susceptible to
information bias. For these studies to be at low risk of bias, we required a clear indication that observers were unaware of the
reference standard diagnosis at time of test interpretation. An item was also added to assess the presence of blinding
between interpretations of different algorithms, however this item was not included in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was
not data driven, i.e. was not based on study results. Studies that did not clearly describe the threshold used but that required
clinicians to record a diagnosis or management decision for a lesion were considered to be unclear on this criterion. Studies
reporting accuracy for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported
accuracy for the presence of independently significant lesion characteristics with no separate test set of lesions were
considered at high risk of bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would
be in a clinical practice setting, i.e. in-person or face-to-face with the patient, and by a single observer as opposed to a
consensus decision or average across multiple observers. Image-based studies were considered to be high concern,
although RCM image interpretations where the observer was also supplied with a clinical or dermoscopic image of the lesion
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along with some patient characteristics were considered ‘unclear’.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion
characteristics that were considered to be indicative for melanoma, particularly where established algorithms or checklists
were not used. Studies were considered of low concern if the threshold used was established in a prior study or sufficient
threshold details were presented to allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test
interpreter as ‘experienced’ or ‘expert’ in RCM to have low concern about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion
regardless of level of clinical suspicion of melanoma. In reality, both partial and differential verification bias are likely. Partial
verification bias may occur where histology is the only reference standard used, and only those participants with a certain
degree of suspicion of malignancy based on the result of the index test undergo verification, the others either being excluded
from the study or defined as being disease-negative without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of
suspicious lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with
benign-appearing lesions but instead follow them up for a period of time to determine whether any malignancy subsequently
develops (these would be false-negatives on the index test). We defined an 'adequate' reference standard as: all disease-
positive individuals having a histological reference standard either at the time of application of the index test or after a period
of clinical follow-up; and at least 80% of disease-negative participants have received a histological diagnosis, with up to 20%
undergoing at least three months' follow-up of benign-appearing lesions.
A further challenge is the potential for incorporation bias, i.e. where the result of the index test is used to help determine the
reference standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to
be included on pathology request forms and for the histopathologist to use this diagnosis to help with the pathology
interpretation. Although inclusion of such clinical information on the histopathology request form is theoretically a form of
incorporation bias, blinded interpretation of the histopathology reference standard is not normal practice, and enforcement of
such conditions would significantly limit the generalisability of the study results. For studies evaluating RCM, this item was
divided into two questions, firstly whether the reference standard was blinded to the index test result (RCM), and secondly
whether it was blinded to the clinical diagnosis. Only the response to the first part (i.e. blinding to RCM) was included in our
overall assessment of risk of bias for the reference standard domain.
In judging the applicability of the reference standard to our review question, scored studies as high concern around
applicability if they used expert diagnosis (with no follow-up) as a reference standard in any patient, or did not report
histology interpretation by a dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or
as near to each other in time as possible to avoid changes in lesion over time. For lesions with a histological
reference standard, we have defined a one-month period as an appropriate interval between application of the index
test and the reference standard. For studies using clinical follow-up, a minimum three-month follow-up period has
been defined as at low risk of bias for detecting false-negatives. This interval was chosen based on a study showing
that most false-negative melanomas will be diagnosed within three months of the initial negative index test although
a small number will be diagnosed up to 12 months subsequently (Altamura 2008).
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were
excluded following recruitment.
Comparative domain
A comparative domain was added to the QUADAS-2 checklist for studies comparing the accuracy of RCM and dermoscopy.
Items were included to assess the presence blinding of interpretation between tests, and to specify a maximum of one month
interval between application of index tests, as intervals greater than these may be accompanied by changes in tumour
characteristics. As it would not be normal practice for RCM to be interpreted blinded to the clinical or dermoscopic diagnosis,
the scoring of this item did not contribute to our overall assessment of risk of bias. We also considered whether both tests
were applied and interpreted in a clinically applicable manner.
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues ( Whiting 2011 ).
Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
1) Was a consecutive or random sample of participants or
images enrolled?
Yes – if paper states consecutive or random
No – if paper describes other method of sampling
Unclear – if participant sampling not described
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
2) Was a case-control design avoided? Yes – if consecutive or random or case-control design
clearly not used
No – if study described as case-control or describes
sampling specific numbers of participants with particular
diagnoses
Unclear – if not described
 
3) Did the study avoid inappropriate exclusions, e.g.
'difficult to diagnose' lesions not excluded
lesions not excluded on basis of disagreement between
evaluators
Yes if inappropriate exclusions were avoided
No – if lesions were excluded that might affect test
accuracy, e.g. 'difficult to diagnose' lesions, or where
disagreement between evaluators was observed
Unclear – if not clearly reported but there is suspicion that
difficult to diagnose lesions may have been excluded
 
4) For between-person comparative studies only (i.e. allocating
different tests to different study participants):
A) were the same participant selection criteria used for those
allocated to each test?
B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised
sequence?
C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to
assignment?
For A)
Yes – if same selection criteria were used for each index
test, No – if different selection criteria were used for each
index test, Unclear – if selection criteria per test were not
described, N/A – if only 1 index test was evaluated or all
participants received all tests
For B)
Yes – if adequate randomisation procedures are
described, No – if inadequate randomisation procedures
are described, Unclear – if the method of allocation to
groups is not described (a description of 'random' or
'randomised' is insufficient), N/A – if only 1 index test
was evaluated or all participants received all tests
For C)
Yes – if appropriate methods of allocation concealment
are described, No – if appropriate methods of allocation
concealment are not described, Unclear – if the method
of allocation concealment is not described (sufficient
detail to allow a definite judgement is required), N/A – if
only 1 index test was evaluated
 
Could the selection of participants have introduced bias?
For non-comparative and within-person-comparative studies
If answers to all of questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For between-person comparative studies
If answers to all of questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
 
For non-comparative and within-person-comparative
studies
Risk is low1.
Risk is high2.
Risk unclear3.
For between-person comparative studies
Risk is low1.
Risk is high2.
Risk unclear3.
PARTICIPANT SELECTION (1) CONCERNS REGARDING APPLICABILITY
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
 
1) Are the included participants and chosen study setting
appropriate to answer the review question, i.e. are the study
results generalisable?
This item is not asking whether exclusion of certain
participant groups might bias the study's results (as in Risk
of Bias above), but is asking whether the chosen study
participants and setting are appropriate to answer our review
question. Because we are looking to establish test accuracy
in both primary presentation and referred participants, a
study could be appropriate for 1 setting and not for the other,
or it could be unclear as to whether the study can
appropriately answer either question
For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a
skin lesion or B) referred participants, and respond to the
questions in either A) or B) accordingly. If the study gives
insufficient details, please respond Unclear to both parts of
the question
 
A) For studies that will contribute to the analysis of
participants with a primary presentation of a skin lesion (i.e.
test naive)
Yes – if participants included in the study appear to be
generally representative of those who might present in a
usual practice setting
No – if study participants appear to be unrepresentative of
usual practice, e.g. in terms of severity of disease,
demographic features, presence of differential diagnosis or
comorbidity, setting of the study, and previous testing
protocols
Unclear – if insufficient details are provided to determine
the generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e. who have already undergone some form of
testing)
Yes – if study participants appear to be representative of
those who might be referred for further investigation. If the
study focuses only on those with equivocal lesions, for
example, we would suggest that this is not representative of
the wider referred population
No – if study participants appear to be unrepresentative of
usual practice, e.g. if a particularly high proportion of
participants have been self-referred or referred for cosmetic
reasons. Other factors to consider include severity of
disease, demographic features, presence of differential
diagnosis or comorbidity, setting of the study, and previous
testing protocols
Unclear – if insufficient details are provided to determine
the generalisability of study participants
2) Did the study avoid including participants with multiple
lesions?
Yes – if the difference between the number of included
lesions and number of included participants is less than 5%
No – if the difference between the number of included
lesions and number of included participants is greater than
5%
Unclear – if it is not possible to assess
 
Is there concern that the included participants do not match the
review question?
If the answer to question 1) or 2) 'Yes':1.
If the answer to question 1) or 2) 'No':2.
If the answer to question 1) or 2) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
INDEX TEST (2) RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted
without knowledge of the results of the reference standard?
Yes – if index test described as interpreted without
knowledge of reference standard result or, for prospective
studies, if index test is always conducted and interpreted
prior to the reference standard
No – if index test described as interpreted in knowledge of
reference standard result
Unclear – if index test blinding is not described
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
2) Was the diagnostic threshold at which the test was
considered positive (i.e. melanoma present) prespecified?
Yes – if threshold was prespecified (i.e. prior to analysing
study results)
No – if threshold was not prespecified
Unclear – if not possible to tell whether or not diagnostic
threshold was prespecified
3) For within-person comparisons of index tests or testing
strategies (i.e. > 1 index test applied per participant): was each
index test result interpreted without knowledge of the results of
other index tests or testing strategies?
Yes – if all index tests were described as interpreted
without knowledge of the results of the others
No – if the index tests were described as interpreted in the
knowledge of the results of the others
Unclear – if it is not possible to tell whether knowledge of
other index tests could have influenced test interpretation
N/A – if only 1 index test was evaluated
 
Could the conduct or interpretation of the index test have
introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1) and 2) 'Yes':1.
If answers to either questions 1) or 2) 'No':2.
If answers to either questions 1) or 2) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), for any index test and 3)1.
'Yes':
If answers to any 1 of questions 1) or 2) for any index test or2.
3) 'No':
If answers to any 1 of questions 1) or 2) for any index test or3.
3) 'Unclear':
 
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
INDEX TEST (2) CONCERN ABOUT APPLICABILITY
 
1) Was the diagnostic threshold to determine presence or
absence of disease established in a previously published
study?
E.g. previously evaluated/established
algorithm/checklist used
lesion characteristics indicative of melanoma used
objective (usually numerical) threshold used
Yes – if a previously evaluated/established tool to aid
diagnosis of melanoma was used or if the diagnostic
threshold used was established in a previously published
study
No – if an unfamiliar/new tool to aid diagnosis of melanoma
was used, if no particular algorithm was used, or if the
objective threshold reported was chosen based on results
in the current study
Unclear – if insufficient information was reported
 
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold
is described in sufficient detail. This item applies equally to
studies using pattern recognition and those using checklists or
algorithms to aid test interpretation
Yes – If the criteria for diagnosis of melanoma were
reported in sufficient detail to allow replication
No – if the criteria for diagnosis of melanoma were not
reported in sufficient detail to allow replication
Unclear – If some but not sufficient information on criteria
for diagnosis to allow replication were provided
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
3) Was the test interpretation carried out by an experienced
examiner?
Yes – if the test was interpreted by 1 or more speciality-
accredited dermatologists, or by examiners of any clinical
background with special interest in dermatology and with
any formal training in the use of the test
No – if the test was not interpreted by an experienced
examiner (see above)
Unclear – if the experience of the examiner(s) was not
reported in sufficient detail to judge or if examiners were
described as 'Expert' with no further detail given
N/A – if system-based diagnosis, i.e. no observer
interpretation
 
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to questions 1), 2), or 3) 'No':2.
If answers to questions 1), 2), or 3) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
REFERENCE STANDARD (3) RISK OF BIAS
 
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive – 1 or more of the following:
histological confirmation of melanoma following biopsy or
lesion excision
clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to
a histological diagnosis of melanoma
B) Disease-negative – 1 or more of the following:
histological confirmation of absence of melanoma following
biopsy or lesion excision in at least 80% of disease-negative
participants
clinical follow-up of benign-appearing lesions for a minimum
of 3 months following the index test in up to 20% of disease-
negative participants
 
A) Disease-positive
Yes – if all participants with a final diagnosis of melanoma
underwent 1 of the listed reference standards
No – If a final diagnosis of melanoma for any participant
was reached without histopathology
Unclear – if the method of final diagnosis was not reported
for any participant with a final diagnosis of melanoma or if
the length of clinical follow-up used was not clear or if a
clinical follow-up reference standard was reported in
combination with a participant-based analysis and it was
not possible to determine whether the detection of a
malignant lesion during follow-up is the same lesion that
originally tested negative on the index test
B) Disease-negative
Yes – If at least 80% of benign diagnoses were reached by
histology and up to 20% were reached by clinical follow-up
for a minimum of 3 months following the index test
No – if more than 20% of benign diagnoses were reached
by clinical follow-up for a minimum of 3 months following
the index test or if clinical follow-up period was less than 3
months
Unclear – if the method of final diagnosis was not reported
for any participant with benign or non-melanoma diagnosis
 
2) Were the reference standard results interpreted without
knowledge of the results of the index test?
Please score this item for all studies even though
histopathology interpretation is usually conducted with
knowledge of the clinical diagnosis (from visual inspection or
dermoscopy or both). We will deal with this by not including the
response to this item in the 'Risk of bias' assessment for these
tests. For reviews of all other tests, this item will be retained
Yes – if the reference standard diagnosis was reached
blinded to the index test result
No – if the reference standard diagnosis was reached with
knowledge of the index test result
Unclear – if blinded reference test interpretation was not
clearly reported
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
 
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
If answer to question 1) 'Yes':1.
If answer to question 1) 'No':2.
If answer to question 1) 'Unclear':3.
For all other tests
If answers to questions 1) and 2) 'Yes':1.
If answers to questions 1) or 2) 'No':2.
If answers to questions 1) or 2) 'Unclear':3.
 
For visual inspection/dermoscopy evaluations
Risk is low1.
Risk is high2.
Risk is unclear3.
For all other tests
Risk is low1.
Risk is high2.
Risk is unclear3.
REFERENCE STANDARD (3) CONCERN ABOUT APPLICABILITY
1) Are index test results presented separately for each
component of the target condition (i.e. separate results
presented for those with invasive melanoma, melanoma in situ,
lentigo maligna, severe dysplasia, BCC, and cSCC)?
Yes – if index test results for each component of the target
condition can be disaggregated
No – if index test results for the different components of the
target condition cannot be disaggregated
Unclear – if not clearly reported
 
2) Expert opinion (with no histological confirmation) was not
used as a reference standard
'Expert opinion' means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
Yes – if expert opinion was not used as a reference
standard for any participant
No – if expert opinion was used as a reference standard for
any participant
Unclear – if not clearly reported
3) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes – if histology interpretation was reported to be carried
out by an experienced histopathologist or
dermatopathologist
No – if histology interpretation was reported to be carried
out by a less experienced histopathologist
Unclear – if the experience/qualifications of the pathologist
were not reported
 
Is there concern that the target condition as defined by the
reference standard does not match the review question?
If answers to all questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
***For teledermatology studies only
If answers to all questions 1) and 3) 'Yes':1.
If answers to questions 1) or 3) 'No':2.
If answers to questions 1) or 3) 'Unclear':3.
Concern is low1.
Concern is high2.
Concern is unclear3.
***For teledermatology studies only
Concern is low1.
Concern is high2.
Concern is unclear3.
FLOW AND TIMING (4): RISK OF BIAS
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
 
1) Was there an appropriate interval between index test and
reference standard?
A) For histopathological reference standard, was the interval
between index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of
borderline/benign-appearing lesions, was there at least 3
months' follow-up following application of index test(s)?
 
A)
Yes – if study reports ≤ 1 month between index and
reference standard
No – if study reports > 1 month between index and
reference standard
Unclear – if study does not report interval between index
and reference standard
B)
Yes – if study reports ≥ 3 months' follow-up
No – if study reports < 3 months' follow-up
Unclear – if study does not report the length of clinical
follow-up
2) Did all participants receive the same reference standard? Yes – if all participants underwent the same reference
standard
No – if more than 1 reference standard was used
Unclear – if not clearly reported
3) Were all participants included in the analysis? Yes – if all participants were included in the analysis
No – if some participants were excluded from the analysis
Unclear– if not clearly reported
 
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes – if study reports ≤ 1 month between index tests
No – if study reports > 1 month between index tests
Unclear – if study does not report the interval between
index tests
 
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma.
9 Summary study details – in-person evaluations
Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MEL)
 
Exclusions
2 – Limited prior testing          
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MEL)
 
Exclusions
 
Grimaldi
2009
Pathway -
clear
MM+MiS
WPC
P-CS
Italy
Primary
Cutaneous PSL
requiring
confirmation of
diagnosis by
teledermatology.
197/235  
VI (no
algorithm)
Dermoscopy
(no
algorithm)
In-person
(Single)
Subjective
impression
(‘suspicious
for
malignancy’)
 
GP (n=13)
Assumed to be
Low (Expertise
NR; simple
protocols for
diagnosis
provided for
study purposes)
 
Histology/Clinical
FU (6 months)
MM+MiS 5;
BCC 0; Benign
230 (NR)
20%
NR
 
Menzies
2009
Pathway -
clear
MM+MiS
Any
WPC
P-CS
Australia
Primary
PSL that would
be biopsied or
referred on after
routine naked
eye examination
NR/374 VI (no
algorithm)
Dermoscopy
(no
algorithm)
In-person
(Single)
Subjective
impression
(‘correct
diagnosis of
melanoma’)
 
GP (n=62)
Assumed to be
Low (trained for
study; required
history of
excision or
referral of at
least 10
pigmented skin
lesions over the
previous 12-
month period
but no prior
dermoscopy
use)
 
Histology/Clinical
FU (3-6
months)/Expert
dx
MM+MiS 32;
BD 2; Benign
323; Unknown 9
4%
6 BCC and 2
BD excluded
by authors,
43 excluded
as both VI +
Dermoscopic
diagnoses
not available
 
Walter
2012
Pathway -
clear
MM
MM+MiS
Any
BPC
RCT
UK
Primary
Any suspicious
PSL that could
not immediately
be diagnosed as
benign
654/792
(control
arm
only)
 
VI (7-point)
Siascope (iv
arm)
In-person
(Single)
7PCL: >= 3  
GP (n=28)
Nurse
practitioner
(n=2)
Low (excluded
if specialist
dermatology
training)
 
Histology/Clinical
FU (3-6
months)/Expert
dx
Control group
only:
MM 16; MiS 2
BCC 4; SK 20;
DF 2; lentigo 5;
‘benign’ 686;
unknown 10
6%
19 (5 due to
violation of
recruitment
criteria or
discontinued
protocol; 1
died; 4 did
not attend
for
dermatology
assessment;
2 missing
histology; 7
not clearly
accounted
for)
3 – Limited prior testing (selected for excision)      
 
Collas
1999
Pathway –
unclear
MM+MiS
 
NC
P-CS
France
Mixed
(Private/Hospital)
PSL undergoing
excision by
dermatologists
in private
practice, and by
hospital
dermatologists
353 /
353
 
VI (1. no
algorithm; 2.
own new
algorithm)
In-person
1. subjective
impression
2. >=1 of 3
characteristics
present
 
Dermatologist
(n=NR; exp NR)
Single observer
 
Histology
MM+MiS 38
BN 249; Other
pigmented 55
38/353; 11%
None
reported
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MEL)
 
Exclusions
 
Gachon
2005
Pathway –
clear
NC
P-CS
France
Private
Melanocytic skin
lesions removed
for any reason
NR /
4036
 
VI (no
algorithm)
In-person;
Single
Subjective
impression
(‘considered
suspicious’)
Dermatologists
(135/200)
Exp. NR
 
Histology
MM 113; MiS 36
BN 3887
149/4036; 4%
NR
 
McGovern
1992
Pathway –
clear
WPC-algs
P-CS
US
Community
(Army Medical
Center
DermClinic)
PSL (>10mm)
excised to rule
out dysplasia,
lentigo maligna
or malignant
melanoma
179 /
237
 
VI (7-point;
(A)BCD)
In-person;
Single
7-point: >=2,
>=3, >=4
characteristics
present
(A)BCD: >=1,
>=2, >=3
characteristics
present
NR (presume
dermatologist)
Exp. NR
 
Histology
MM 6; MiS 6
BCC 4; SK 32;
BN 138; AK 6;
Other 45
12/205; 6%
32 lesions
unaccounted
for; 13
excluded
due to lesion
size of 8 mm
or less. 192
evaluated for
ABCD and
3-point; 205
evaluated for
7 point
4 - Referred for further assessment      
 
Barzegari
2005
Pathway –
clear
MM+MiS
WPC
NR-CS
Iran
Secondary
PSL <=15mm
diameter
referred to
dermatology
clinic for
diagnostic
evaluation or
cosmetic
reasons
91 / 122 VI (no
algorithm)
In-person
(consensus
diagnosis of
2)
Melanoma
likely /
melanoma
possible
Mixed (n=2; 1
attending
dermatologist
and a third year
dermatology
resident)
Histology
MM 3; MiS 3
SK 2; AK 1; BN
106; DF 7
6/122; 5%
None
reported
 
Stanganelli
2000
Pathway –
clear
MM+MiS
Any
WPC
R-CS
Italy
Specialist clinic
PSL referred by
dermatologists
and general
practitioners
either for pre-
surgical
assessment or
consultation
NR /
3372
VI (ABCD)
Dermoscopy
(no
algorithm)
In-person
(Single)
NR
Subjective
impression
NR (assumed
dermatologist -
described as
one of the co-
authors; n=1)
Histology /
Registry FU
MM+MiS 55
BCC 43; Benign
3274
55/3372; 2%
None
reported
5 - Referred for further assessment (selected for excision)
 
Benelli
1999
Pathway –
unclear
MM+MiS
WPC
P-CS
Italy
Secondary
All PSL
observed and
excised at the
Dermatologic
Surgery
Department
NR /
401
 
1. VI
(ABCDE)
2.
Dermoscopy
(7FFM)
In-person
1. >/=1
characteristic
present; >/=2
characteristics
present; >/=3
characteristics
present; >/=4
characteristics
present; all 5
characteristics
present
2. Score >=2
 
Dermatologist
(n=2; exp NR)
Consensus of 2
 
Histology
MM 54; MiS 6
BCC 1
BN 337; LS 5;
SK 1
60/401; 15%
None
reported
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MEL)
 
Exclusions
 
Bono 2002
Pathway –
clear
MM+MiS
WPC
P-CS
Italy
Specialist clinic
PSL with a more
or less important
suspicion for
MM on VI and/or
dermoscopy
298 /
313
VI (no
algorithm)
Dermoscopy
(no
algorithm)
In-person
VI - subjective
impression
Dermoscopy -
>=1
characteristic
present
Surgical
oncologist (n=4;
high)
Single observer
Histology
MM 55; MiS 11
BCC 6; 8 SK; 3
SN; BN 230
66/313; 21%
None
reported
 
Bono
2002b
Pathway –
clear
MM+MiS
WPC
P-CS
Italy
Specialist clinic
PSL <=6mm
requiring
surgical biopsy
for diagnosis
based on clinical
or dermoscopic
suspicion of MM
157 /
161
VI (no
algorithm)
Dermoscopy
(no
algorithm)
In-person
VI - subjective
impression
Dermoscopy -
>=1
characteristic
present
Surgical
oncologist (n=2;
high)
Single observer
Histology
MM 10; MiS 3
BCC 2; SK 4; SN
5; BN 124
13/161; 8%
None
reported
 
Bono 2006
Pathway –
clear
MM+MiS
 
WPC
R-CS
Italy
Specialist clinic
PSL <=3mm
undergoing
excision due to
a more or less
important
suspicion for
MM on VI and/or
dermoscopy
204 /
206
VI (no
algorithm)
Dermoscopy
(Menzies)
In-person
VI - subjective
impression
Dermoscopy -
NR
NR; assumed
surgical
oncologist as
per Bono 2002; 
Bono 2002b
(n=4; exp NR)
Single observer
Histology
MM 19; MiS 4
SN 3; BN 169;
Other 11
23/206; 11%
None
reported
 
Carli 2002
Pathway –
unclear
MM+MiS
WPC
R-CS
Italy
Secondary
Clinically
equivocal and
suspicious PSL
subjected to
excisional
biopsy at the
Institute of
Dermatology
NR /
256
 
1. VI (no
algorithm)
2.
Dermoscopy
(pattern)
In-person
(Dermoscopy
– image-
based)
Subjective
impression
 
Dermatologist
(n=2; High exp
– “extensive
experience in
both clinical and
dermoscopic
diagnosis”)
Consensus of 2
Histology
MM 40; MiS 14
BCC 5
BN 177; SN 16;
SK 4
54/256; 21%
None
reported
 
Cristofolini
1994
Pathway –
unclear
MM+MiS
WPC
P-CS
Italy
Secondary
Patients with
PSL presenting
during a
campaign for
the early
diagnosis of
cutaneous
melanoma at
the Dermatology
Department
NR /
220
 
1. VI
(ABCDE)
2.
Dermoscopy
(pattern)
In-person
1. ≥2
characteristics
present
2. >=1
characteristic
present
 
Dermatologist
(n=4; High exp -
dermatologists
had all been
trained in the
recognition of
pigmented
lesions)
Unclear
observer
interpretation
 
Histology
MM+MiS 33
BCC 0
BN 181; SK 4; 2
thrombosed
angioma
33/220; 15%
None
reported
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MEL)
 
Exclusions
 
Cristofolini
1997
Pathway –
unclear
MM+MiS
 
WPC (algs)
NR-CS
Italy
Secondary
Patients with
small and flat
common and
atypical PSL
recruited during
a health
campaign for
the early
diagnosis of
melanoma; all
underwent skin
biopsy.
176 /
176
 
VI (ABCD)
In-person
NR  
Dermatologist
(n=3; High
experience)
Consensus of 3
 
Histology
MM+MiS 35
BN 141
35/176; 20%
None
reported
 
Ek 2005
Pathway –
clear
MM+MiS
Any
 
NC
P-CS
Australia
Specialist clinic
Lesions excised
for which
malignancy
could not be
excluded
1223 /
2582
VI (no
algorithm)
In-person
Subjective
impression
Plastic surgeon
(n=4 or 5;
mixed
experience; 3
consultants, 1
plastic surgery
trainee (usually
1st year, on 6
month rotation)
and a clinical
assistant)
Unclear
Histology
MM+MiS 23
BCC 1214; SCC
517; BD 188; SK
63; 577 other
benign (including
330 solar
keratosis)
23/2582; 1%
Incomplete
or incorrectly
entered
proformas
were
excluded –
79 patients
with 96
lesions
 
Green
1991
Pathway –
clear
MM+MiS
NC
NR-CS
Australia
Secondary
PSL for excision 81 / 89 VI (no
algorithm)
In-person
Subjective
impression
NR (n=NR; exp
NR "in the
majority of
cases a
surgeon or a
dermatologist")
Single observer
Histology
MM+MiS 5
BCC 2; SK 7; BN
54; Other 2
5/70; 7%
19/89
lesions
excluded
(number of
participants
not reported)
due to
incomplete
clinical and
histology
records.
 
Langley
2001
Pathway –
unclear
MM+MiS
NC
P-CS
US
Specialist clinic
Patients with
lesions
scheduled for
excision at the
pigmented
lesion clinic to
either remove
atypical nevi or
to rule out
melanoma or for
cosmetic
reasons
NR / 38  
VI (no
algorithm)
In-person
NR  
NR (presume
dermatologist;
n=NR; exp NR)
Unclear
 
Histology
MM 3; MiS 3
BN 32
6/38; 16%
None
reported
 
Morales
Callaghan
2008
Pathway –
unclear
MM+MiS
WPC
P-CS
Spain
Secondary
Randomly
selected
melanocytic
lesions;
melanocytic on
both clinical and
dermoscopic
criteria
166 /
200
 
1. VI (no
algorithm)
2.
Dermoscopy
(no
algorithm)
In-person
NR  
Dermatologist
(n=2; high exp –
“experience in
dermoscopy”)
Consensus of 2
 
Histology
MM+MiS 6
BN 184; SN 1;
Other 9
6/200; 3%
None
reported
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MEL)
 
Exclusions
 
Morton
1998a
(high exp),
Morton
1998b
(mod exp)
and
Morton
1998c (low
exp)
Pathway –
clear
MM+MiS
 
NC
R-CS
UK
Specialist clinic
Patients referred
by their GP to
the clinic
NR /
1999
VI (no
algorithm)
In-person
NR Dermatologist
(n=2; high);
Dermatology
senior registrar
(n=1;
moderate);
Dermatology
registrar (n=1;
low)
SIngle observer
per lesion
Histology
MM 104; MiS 24
Benign 1871
High exp:
69/763; 9%
Moderate exp:
31/567; 5%
Low exp: 28/669;
4%
None
reported
 
Thomas
1998
Pathway –
unclear
MM+MiS
 
NC
CCS
France
Secondary
All cases of
melanoma and
a nonselected
consecutive
group of ‘non-
melanoma’ PSL
NR /
1140
 
VI (ABCDE)
In-person
>=1
characteristic
present
>=2
characteristics
present
>=3
characteristics
present
>=4
characteristics
present
all 5
characteristics
present
 
Dermatologist
(n=2; High exp -
described as
'trained
dermatologists')
Single observer
 
Histology
MM+MiS 460
BCC 8
BN 638; SN 2;
Other 13
460/1140; 40%
None
reported
 
Unlu 2014
Pathway –
unclear
MM+MiS
WPC (algs)
R-CS
Turkey
Specialist clinic
Melanocytic
lesions excised
at Department
of Dermatology
Pigmented
Lesion Clinic
115 /
115
 
1. VI (no
algorithm)
2.
Dermoscopy
(7-point; 3-
point; CASH;
ABCD)
In-person
1. subjective
impression
2. score >=3;
>=2
characteristics
present; score
>=8; score
>5.44
 
NR (presume
dermatologist;
n=1 for VI; n=3
for dermoscopy;
Exp NR for VI)
Single observer
(VI); consensus
of 3
(dermoscopy)
 
Histology
MM+MiS 24
BN 91
24/115; 21%`
None
reported
 
Zaumseil
1983
Pathway –
unclear
MM+MiS
NC
NR-CS
Germany
Secondary
Skin lesions
undergoing
excision
NR /
7063
 
VI (no
algorithm)
In-person
Subjective
impression
 
NR (n=NR; exp
NR)
Single observer
 
Histology
MM+MiS 337
Not melanoma
6726 (dx listed
only for FPs)
337/7063; 5%
None
reported
5* - Equivocal referred for further assessment (selected for excision)
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MEL)
 
Exclusions
 
Dummer
1993
Pathway –
clear
MM+MiS
WPC
P-CS
Germany
Patients with
melanocytic skin
lesions difficult
to diagnose
clinically
NR /
771
VI (no
algorithm)
Dermoscopy
(pattern)
In-person (I-
B for
dermoscopy)
NR NR assume
Dermatologist
(assumed)
(n=2; exp NR)
Single observer
Histology
MM 19; MiS 4
SK 4; BN 706;
Benign NML 32;
Other 6
23/771; 3%
53 non-
melanocytic
lesions not
included in
the final
analysis (no
melanomas
present in
this group)
 
Soyer
1995
Pathway –
clear
MM+MiS
WPC
NR-CS
Austria
PSL difficult to
diagnose on
clinical grounds
alone
NR /
159
VI (no
algorithm)
Dermoscopy
(pattern)
In-person
NR Dermatologist
(n=2; exp High;
"the
examination
was performed
by a
dermatologist
expert in
dermoscopy")
Single observer
 
Histology
MM 50; MiS 15
BCC 3; SK 18;
AK 4; BN 61;
Other 7
65/159; 41%
None
reported
 
Steiner
1987
Pathway –
unclear
MM+MiS
 
P-CS
Austria
Specialist clinic
 
Small (< 10 mm)
diagnostically
equivocal PSL;
no absolute
agreement on
clinical
diagnosis
among
investigating
clinicians at a
pigmented
lesion clinic.
NR /
318
 
1. VI (no
algorithm)
2.
Dermoscopy
(pattern)
In-person
Subjective
impression
 
Dermatologists
(n=3; High exp -
"experienced
dermatologists")
Consensus
diagnosis of 3
observers
 
Histology
MM 49; MiS 24
BCC 20
BN 143; SK 20;
lentigo simplex
and nevoid
lentigo 19; Other
15
73/318; 23%
None
reported
NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS – melanoma in
situ (or lentigo maligna); BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex; SK –
seborrheic keratosis; SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BNM – benign non-melanocytic; BD – Bowen’s
disease; DF – dermatofibroma; FU – follow-up; R –retrospective; P – prospective; CS – case series; CCS – case control study;
WPC – within person comparison (of tests); BPC – between person comparison (of tests); NC – non comparative; exp -
experience; GP - general practitioner; VI - visual inspection; RCT - randomised controlled trial; SCC - squamous cell carcinoma;
dx - diagnosis; AHM - atypical melanocytic naevi; ELM - epiluminescence microscopy.
10 Summary QUADAS - in-person evaluations
  STUDIES CLEARLY PLACED ON CLINICAL
PATHWAY
STUDIES NOT CLEARLY PLACED ON CLINICAL
PATHWAY
 
Pathway
Risk of Bias Concerns about
applicability
Risk of Bias Concerns about applicability
2 – Limited prior testing
Studies N=3; Grimaldi 2009 ; Menzies 2009 ; Walter
2012
N=0
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Participant
selection
Low (3/3) High (2/3);
Unclear (1/3).
Inclusion of
multiple lesions
per participant (Grimaldi
2009; Walter 2012
); patient
numbers not
reported (Menzies 2009).
   
Index test Low (1/3);
Unclear (2/3).
Lack of clear
pre-
specification of
threshold (Grimaldi
2009; Menzies 2009)
Low (1/3); High
(2/3). Lack of
description of
diagnostic
threshold (Grimaldi 2009; 
Menzies 2009).
Non-expert test
interpretation (Menzies
2009; Walter 2012); not
clear in Grimaldi 2009.
   
Reference
standard
 
High (3/3). <80% of
disease negative
participants had
histological or clinical
follow up reference
standard
High (2/3);
Unclear (1/3).
Expert diagnosis
as reference
standard (Menzies 2009; 
Walter 2012); unclear
histopathologist expertise
(3/3).
   
Flow and
timing
High (3/3).
Mixed
reference
standards
(3/3);
participant
exclusions (Menzies
2009; Walter 2012); all
unclear on index to
reference interval.
     
3 – Limited prior testing (selected for excision)
Studies N=2; Gachon 2005 ; McGovern 1992 N=1; Collas 1999
Participant
selection
Low (1/2); Unclear
(1/2). Unclear
exclusion criteria (1/2;
Gachon 2005).
High (2/2). Restriction to
melanocytic (1/2;
Gachon 2005) or primarily
excised lesions (2/2);
multiple lesions per
participant (1/2;
McGovern 1992); no.
patients not reported (1/2;
Gachon 2005)
Unclear (1/1). Participant
sampling not described;
exclusion criteria not reported
High (1/1). Excised only
included
Index test  
Unclear (1/2); High
(1/2). Lack of clear pre-
specification of the
threshold (1/2;
Gachon 2005) or
testing of multiple
thresholds (1/2;
McGovern 1992)
High (1/2); Unclear (1/2).
Lack of threshold detail
(1/2; Gachon 2005);
unclear description of
observer expertise (2/2)
Low (1/1) Unclear (1/1). Observer
expertise not described
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Reference
standard
Low (2/2) Low (1/2); Unclear (1/2).
Lack of description of
histopathology expertise
(1/2; Gachon 2005)
Low (1/1). Unclear (1/1). Histology
expertise not described
(histologically analysed by
different private and hospital
pathologists and reviewed by
one of the authors).
Flow and
timing
High (1/2); Unclear
(1/2). Participant
exclusions (1/2;
McGovern 1992);
unclear reference
interval (2/2).
  Low (1/1)  
 
4 - Referred for further assessment
Studies N=2; Barzegari 2005 ; Stanganelli 2000  
N=0
Participant
selection
Low (2/2) High (2/2). Included
excisions for cosmetic
reasons (1/2; Barzegari
2005), or multiple lesions
per participant (2/2).
   
Index test Low (1/2);
Unclear (1/2).
Lack of clear
pre-
specification
of the
threshold (Barzegari
2005)
High (1/2); Unclear (1/2).
Consensus result (1/2;
Barzegari 2005);
insufficient threshold
detail (1/2; Barzegari
2005); observer expertise
not clear (2/2).
   
Reference
standard
Low (1/2);
High (1/2).
<80% of
disease
negative
participants
had
histological
or clinical
follow up
reference
standard (Stanganelli
2000)
Unclear (2/2). Lack of
description of
histopathology expertise
(2/2)
   
Flow and
timing
High (1/2); Unclear
(1/2). Unclear
reference interval (2/2);
use of different
reference standards
(1/2; Stanganelli 2000)
     
5 - Referred for further assessment (selected for excision)
Studies N=6; Bono 2002 ; Bono 2002b ; Bono 2006 ; Ek
2005 ; Green 1991 ; Morton 1998a ; Morton
1998b ; Morton 1998c *)
N=9; Benelli 1999 ; Carli 2002b ; Cristofolini 1994 ; 
Cristofolini 1997 ; Langley 2001 ; Morales Callaghan 2008 ; 
Thomas 1998 ; Unlu 2014 ; Zaumseil 1983
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Participant
selection
Low (2/6); High (2/6);
Unclear (2/6).
Inappropriate (2/6;
Bono 2002; Ek 2005)
or unclear (2/6;
Gachon, Morton)
exclusions;
consecutive
recruitment not
reported (1/6; Gachon)
High (6/6).
Unrepresentative (6/6)
participants; all excised.
Multiple lesions per
participant (2/6; Ek 2005; 
Green 1991) or
number of
participants not
reported (Morton 1998)
High (4/9); Unclear
(5/9). Inappropriate
exclusions (4/9) due to
restriction to
melanocytic only (Morales
Callaghan 2008; Unlu 2014
), disagreement on
histology (Zaumseil 1983). Use
of case control type design
(1/9; Thomas 1998). Unclear
participant sampling (6/9;
Benelli 1999; Carli 2002b, 
Cristofolini 1994, Cristofolini
1997, Langley 2001; Zaumseil
1983).
High (9/9). Inclusion of only
excised lesions (9/9). Multiple
lesions per participant (2/9;
Langley 2001, Morales
Callaghan 2008); number of
participants not reported (6/9;
Benelli 1999, Carli 2002b, 
Cristofolini 1994, Cristofolini
1997, Thomas 1998, 
Zaumseil 1983)
Index test Low (3/6); Unclear
(3/6). Pre-
specification of
threshold not
reported (Ek 2005; 
Green 1991; Morton
1998)
High (6/6). All clinically
applicable application of
test. No threshold details
(6/6). Observer
experience unclear (3/6;
Bono 2006; Ek 2005; 
Green 1991).
Low (2/9); High (2/9), Unclear
(5/9). Threshold not
prespecified (2/9; Benelli 1999, 
Thomas 1998) or not clear
whether prespecified (Carli
2002b, Cristofolini 1997, 
Langley 2001, Morales
Callaghan 2008, Unlu 2014).
Low (1/9);High (7/9), Unclear
(1/9). Test application not
clinically applicable (4/9;
Benelli 1999; Carli 2002b; 
Cristofolini 1997; Morales
Callaghan 2008) or
not clear (Cristofolini 1994; 
Langley 2001). No threshold
detail (5/9; Carli 2002b; 
Langley 2001; Morales
Callaghan 2008; Unlu 2014; 
Zaumseil 1983)
Reference
standard
Low (5/6); High (1/6).
Inadequate reference
standard (1/6; Green
1991)
Low (1/6); High (1/6);
Unclear (4/6). Expert
diagnosis used (1/6;
Green 1991). Lack of
description of
histopathology expertise
(5/6; all except Morton
1998)
Low (9/9) Low (2/9); High (1/9); Unclear
(6/9). Use of expert diagnosis
(1/9; Langley 2001).
Histopathology expertise not
reported (7/9; Benelli 1999; 
Carli 2002b; Cristofolini 1994;
Cristofolini 1997; Langley
2001; Morales Callaghan
2008; Zaumseil 1983)
Flow and
timing
High (2/6); Unclear
(4/6). Index to
reference interval not
reported (5/6; Bono
2002; Bonon 2002b;
Bono 2006; Green
1991; Morton 1998).
Participant exclusions
due to incomplete data
(2/6; Green 1991; Ek
2005)
  Low (3/9);Unclear (6/9). Interval
to reference standard not
reported (6/9; Benelli 1999; 
Cristofolini 1994; Langley 2001;
Thomas 1998; Unlu 2014; 
Zaumseil 1983)
 
5* - Equivocal referred for further assessment (selected for excision)
Studies N=2; Dummer 1993 ; Soyer 1995  
N=1; Steiner 1987
Participant
selection
Unclear (2/2). Unclear
sampling methods
(2/2); Unclear
exclusions (1/2; Soyer
1995)
High (1/2); Unclear (1/2).
Participants not
representative (1/2;
Dummer 1993) or unclear
(1/2; Soyer 1995).
Number of participants
not reported (2/2)
Unclear (1/1). Participant
sampling not described;
exclusion criteria not reported
High (1/1). Restricted to small
<10mm pigmented skin
lesions; all excised
Index test Unclear (2/2). Pre-
specification of
threshold not reported
(2/2)
High (2/2). No threshold
details (2/2). Observer
experience unclear (1/2;
Dummer 1993)
Unclear (1/1). Pre-specification
of threshold not reported.
High (1/1). Consensus
decision reported and no
threshold detail.
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Reference
standard
Low (2/2) Unclear (2/2). Lack of
description of
histopathology expertise
(2/2)
Low (1/1). Unclear (1/1). Histology
expertise not described
Flow and
timing
High (1/2), Unclear
(1/2). Participant
exclusions (1/2;
Dummer 1993). Index
to reference interval
not reported (2/2)
  Low (1/1).  
11 Summary study details – image-based evaluations
Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion
criteria
No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual. (n)
Experience
 
Reference
standard
Final
diagnoses
Prevalence
(MM+MiS)
 
Exclusions
3 – Limited prior testing (with selection on reference standard)      
 
Bourne
2012
Pathway -
clear
 
WPC-tests
R-CS
Australia
Primary
All skin lesions
excised to
exclude skin
cancer (and 3
examples
common
lesions
assessed as
clearly benign
and not
biopsied)
46 / 50  
VI (no
algorithm)
Dermoscopy
(3-point;
Menzies;
BLINCK
(excluded))
Image-
based
(blinded)
NR  
GP (n=3)
Clinical nurse (n=1)
Mixed experience
“varying levels of
dermatoscopic
experience”
Average
 
Histology /
Clinical FU
/ Expert dx
MM 1; MiS
8
BCC 6; SK
5; BN 11;
Other 19
9/45; 20%
5 non-
pigmented
specimens
(not further
identified) in
the set of 50
were
excluded
from
dermoscopic
evaluations
 
Rosendahl
2011
Pathway –
unclear
NC
R-CS
Australia
Primary
PSL submitted
for histology
from the
primary care
skin cancer
practice of one
author
389 /
463
 
1. VI (no
algorithm)
2.
Dermoscopy
(pattern)
1. subjective
impression
2. both
characteristics
present
 
Dermatologist (n=1)
Image-based; High
experience (confirmed
by author); Single
observer
 
Histology
MM 9; MiS
20
BCC 72;
SCC 5
BN 217;
BD 18; AK
14*; BNM
140
*
considered
malignant
by study
authors
29/463; 6%
3 poor quality
images
excluded
4 - Referred for further assessment      
 
Stanganelli
2005
Pathway -
clear
MM+MiS
WPC
R-CS
Italy
Specialist
clinic
Melanocytic
lesions
referred to
Skin Cancer
Unit for clinical
and
dermoscopic
evaluation.
NR /
477
VI (no
algorithm)
Dermsocopy
(no
algorithm)
Image-
based
(Average)
NR Dermatologist (n=3);
GP (n=3)
Dermatologists - High
experience (“2 years
dermoscopy
experience”);
experience NR for
GPs, assumed Low
Histology /
Registry
FU
MM+MiS
31
BN 103
31/134;
23%
None
reported
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion
criteria
No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual. (n)
Experience
 
Reference
standard
Final
diagnoses
Prevalence
(MM+MiS)
 
Exclusions
5 - Referred for further assessment (with selection on reference standard)      
 
Benelli 2001
Pathway –
unclear
WPC
R-CS
Italy
Training
images
Slides of PSL
selected for
evaluation
during a
training course
on
dermoscopy.
Lesions not
located on
head, palms or
soles
NR / 49  
1. VI
(ABCDE)
2.
Dermoscopy
(7FFM)
1. >=3 & >=2
2. >=2
 
Expert author (n=1);
Dermatologists (n=65)
Image-based; Single
author - High
experience; Average
result for
dermatologist group;
experience NR
 
Histology
MM 10,
MiS 2
BCC 2
BN 25, SN
5, SK 3,
Other 2 (1
missing)
12/50; 24%
None
reported
 
Carli 2002b
Pathway –
unclear
WPC
R-CS
Italy
Secondary
Clinically
suspicious or
equivocal PSL
undergoing
excision for
diagnostic
purposes; all
<= 14mm
diameter
NR / 57  
1. VI (NR)
2.
Dermoscopy
(NR)
NR  
Dermatologists (n=2)
Image-based; high
experience ('with
experience in the field
of PSL'); consensus of
2
 
Histology
MM 6, MiS
5
BCC 10
BN 31, SK
1; Other 4
11/57; 19%
4 ‘not
evaluables’
excluded
(1MM, 3
benign)
 
Dolianitis
2005
Pathway –
unclear
WPC
CCS
Multi-
centre
Training
images
Melanocytic
skin lesions
selected from
a collection of
dermoscopic
images
belonging to
one author.
NR / 40  
1. VI (no
algorithm)
2.
Dermoscopy
(Pattern
analysis;
Menzies
Criteria; 7
point;
ABCD)
1. subjective
impression
2. subjective
impression;
NR; NR;
>4.75
 
Dermatologists(n=16);
dermatology trainees
(n=16); GPs (n=35)
Image-based; mixed
experience (“range of
experience levels with
assessment of skin
lesions”); average
result
 
Histology
(n=39);
Expert
diagnosis
(n=1)
MM 18,
MiS 2
BN 12; SN
3; Other 4
20/20; 50%
None
reported;
poor quality
images
exclusion
criterion
 
Pizzichetta
2004
Pathway –
unclear
WPC
R-CS
US/Italy
Secondary
Clinical and⁄or
dermoscopic
hypomelanotic
(extent of
pigmentation
<=30%) and
amelanotic
skin lesions
151 /
151
 
1. VI (no
algorithm)
2.
Dermoscopy
(pattern)
subjective
impression
 
NR (presume
dermatologist; n=1)
Image-based;
experience NR; single
observer
 
Histology
AHM 34,
MiS 5
BCC 25,
SCC 5
BN 47, SN
5, SK 8,
Other 18
39/108;
36%
(analysed)
23 lesions
excluded due
to image
quality;
further 43
lesions were
not available
for evaluation
by clinical
images
("mainly
benign
melanocytic
lesions").
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion
criteria
No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual. (n)
Experience
 
Reference
standard
Final
diagnoses
Prevalence
(MM+MiS)
 
Exclusions
 
Stanganelli
1998
Pathway –
unclear
WPC
R-CS
Italy
Training
images
PSL images
selected from
computerised
files of the skin
cancer clinic.
NR / 30  
1. VI (no
algorithm)
2.
Dermoscopy
(no
algorithm)
NR  
Dermatologists (n=20)
Image-based;
experience NR
(“experience in ELM
but (with) no formal
training”); average
 
Histology
MM+MiS
10
BCC 4
BN 10, SK
3, Other 3
10/30; 33%
None
reported
 
Winkelmann
2016
Pathway –
unclear
WPC
CCS
Unclear
Training
images
Selected
images
previously
analysed by
MSDSLA
NR / 12  
1. VI (no
algorithm)
2.
Dermoscopy
(no
algorithm)
NR  
Dermatologists (n=70)
Image-based;
experience NR;
average
 
Histology
MM 3; MiS
2
BN 7
5/12; 42%
None
reported
5* - Equivocal referred for further assessment (with
selection on reference standard)
       
 
Carli 2003b
Pathway –
unclear
 
WPC
R-CS
Italy
Secondary
Clinically
difficult to
diagnose or
equivocal
melanocytic
lesions
randomly
selected from
image
database; all
melanomas
<1mm
thickness.
NR /
200
 
1. VI (no
algorithm)
2.
Dermoscopy
(own choice)
subjective
impression
 
Dermatology registrar
(n=2); dermatologists
(senior experts n=2;
practicing
dermatologists n=4)
Classed as High
experience (both
dermatologists and
registrars “formally
trained in
dermoscopy”);
Average result
 
Histology
MM 40;
MiS 24
BN 136
64/200;
32%
None
reported
 
de Giorgi
2012
Pathway –
unclear
 
WPC
R-CS
Italy
Secondary
Pigmented
melanocytic
skin lesions <=
6mm diameter
excised at
dermatology
department
NR /
103
 
VI (ABCD)
1. >=2
characteristics
present
2. >=3
characteristics
present
 
Dermatologists (n=3)
High experience
(“more than 5 years of
practice in
dermoscopy”);
consensus of 3
 
Histology
MM 16;
MiS 18
BN 69
34/103;
33%
None
reported
NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS –
melanoma in situ (or lentigo maligna); BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; LS –
lentigo simplex; SK – seborrhoeic keratosis; SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s
disease; DF – dermatofibroma; FU – follow-up; R –retrospective; P – prospective; CS – case series; CCS – case control
study; WPC – within person comparison (of tests); BPC – between person comparison (of tests); NC – non comparative; GP
- general practitioner; VI - visual inspection; RCT - randomised controlled trial; SCC - squamous cell carcinoma; dx -
diagnosis; ELM – epiluminescence microscopy; BLINCK - Benign Lonely irregular Nervous Change Known Clues; BNM -
benign non-melanocytic; AHM - amelanotic ⁄ hypomelanotic melanoma; MSDSLA - multispectral digital skin lesion analysis
device.
12 Summary QUADAS - image-based evaluations
  STUDIES CLEARLY PLACED ON
CLINICAL PATHWAY
STUDIES NOT CLEARLY PLACED ON CLINICAL PATHWAY
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Pathway Risk of Bias Concerns about
applicability
Risk of Bias Concerns about applicability
3 – Limited prior testing (with selection on reference standard)
Studies N=1; Bourne 2012 N=1; Rosendahl 2011
Participant
selection
Unclear
(1/1).
Unclear
exclusion
criteria (
Bourne 2012).
High (1/1). Restriction
to primarily excised
lesions (1/1)
Low (1/1). High (1/1). Includes excised lesions
only; multiple lesions per participant.
Index test  
Unclear
(1/1)
Lack of
clear
pre-
specification
of the
threshold
(Bourne 2012).
High (1/1).
Blinded image
interpretation
and average
observer
result
presented (Bourne
2012); lack of
threshold
detail (Bourne 2012);
unclear description of
observer expertise
Unclear (1/1). No clear pre-
specification of threshold.
High (1/1). Image-based study; no
threshold detail.
Reference
standard
Low (1/1) High (1/1) Use
of expert
diagnosis as
reference (Bourne
2012); lack of
description of
histopathology
expertise (Bourne
2012)
Low (1/1). Unclear (1/1). Histopathology
experience not reported.
Flow and
timing
High
(1/1)
Use of
different
reference
standards
(Bourne 2012
);
participant
exclusions
(Bourne 2012).
  High (1/1). Exclusions on image
quality Unclear interval between
index and reference.
 
4 - Referred for further assessment
Studies  
N=1; Stanganelli 2005
 
N=0
Participant
selection
Unclear
(1/1).
Unclear
participant
sampling
across
all
items
(Stanganelli
2005)
High (1/1).
Sample
restricted
to
melanocytic
lesions (Stanganelli
2005). Patient
numbers not
reported,
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Index test Unclear
(1/1).
Lack
of
clear
pre-
specification
of
the
threshold
(Stanganelli
2005)
High (1/1).
Average
result
presented
(Stanganelli 2005
);
insufficient
threshold
detail (Stanganelli
2005).
   
Reference
standard
Low (1/1) Unclear
(1/1).
Unclear
use of
expert
diagnosis
as
reference
standard (
Stanganelli 2005).
Unclear
histopathology
expertise
   
Flow and
timing
High
(1/1)
Use
of
different
reference
standards
(Stanganelli
2005); unclear
reference
interval.
     
5 - Referred for further assessment (with selection on reference standard)
Studies N=0 N=6; Benelli 2001 ; Carli 2002b ; Dolianitis 2005 ; Pizzichetta 2004 ; 
Stanganelli 1998 ; Winkelmann 2016
Participant
selection
    High (3/6), Unclear (3/6). Case
control type design used (3/3;
Dolianitis 2005; Stanganelli
1998, Winkelmann 2016)
or unclear design (Benelli 2001; 
Pizzichetta 2004). Unclear
participant sampling (5/6; Benelli
2001, Carli 2002b, Pizzichetta
2004, Stanganelli 1998, 
Winkelmann 2016), design
unclear (1/6), exclusion criteria
not clearly reported (5/6; Benelli
2001, Carli 2002b, Dolianitis
2005, Stanganelli 1998, 
Winkelmann 2016).
High (6/6). Excised only included (6/6),
amelanotic/ hypomelanotic lesions only
(1/6; Pizzichetta 2004). Number
participants not reported (5/6; Benelli
2001, Carli 2002b, Dolianitis 2005, 
Stanganelli 1998, Winkelmann 2016)
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Index test     Low (1/6); Unclear (5/6). No
clear pre-specification of
threshold
(5/6; Carli 2002b, Dolianitis
2005, Pizzichetta 2004, 
Stanganelli 1998, Winkelmann
2016).
High (6/6). Image-based evaluations
(6/6), blinded to all other information
(5/6; Benelli 2001, Carli 2002b, 
Dolianitis 2005, Stanganelli 1998, 
Winkelmann 2016), with consensus
(1/6; Carli 2002b) or average result
(4/6; Benelli 2001, Dolianitis 2005, 
Stanganelli 1998, Winkelmann 2016)
reported. Threshold not clearly
specified (5/6; Carli 2002b, Dolianitis
2005, Pizzichetta 2004, Stanganelli
1998, Winkelmann 2016). Observer
expertise not reported (4/6; Dolianitis
2005; Pizzichetta 2004; Stanganelli
1998; Winkelmann 2016)
Reference
standard
    Low (6/6) High (1/6); Unclear (5/6). Use of expert
observer diagnosis (1/6; Dolianitis
2005); expertise of histopathologist not
described (6/6).
Flow and
timing
    Low (1/6); High (2/6); Unclear
(3/6). Lesions excluded from
analysis (reason not reported)
(2/6; Dolianitis 2005; 
Pizzichetta 2004); different
reference standards used (1/6;
Dolianitis 2005). Index to
reference interval not reported
(5/6; Benelli 2001, Dolianitis
2005, Pizzichetta 2004, 
Stanganelli 1998, Winkelmann
2016).
 
5* - Equivocal referred for further assessment (with selection on reference standard)
Studies N=0 N=2; Carli 2003b ; de Giorgi 2012
Participant
selection
    High (2/2). Exclusion of difficult
to diagnose, including peculiar
lesions (1/2; Carli 2003b),
histology disagreement (1/2; de
Giorgi 2012).
High (2/2). Restriction to melanocytic
only (2/2), excised only (2/2). Patient
numbers not reported (2/2)
Index test     High (1/2), Unclear (1/2). Multiple
thresholds tested (1/2; de
Giorgi 2012); no clear threshold
specification (1/2; Carli 2003b).
High (2/2). Image-based evaluations
(2/2), blinded to all other information
(1/2; Carli 2003b), with consensus (1/2;
de Giorgi 2012) or average result (1/2;
Carli 2003b) reported. Threshold not
described (1/2; Carli 2003b)
Reference
standard
    Low (2/2) Low (2/2)
Flow and
timing
    Unclear (2/2). Index to reference
interval not reported (2/2).
 
13 Summary study details – detection of invasive melanoma alone
Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer
qual. (n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MM+MiS)
 
Exclusions
In-person          
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer
qual. (n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MM+MiS)
 
Exclusions
Bono 1996WPC-tests
Unclear
Italy
Specialist
clinic
Pigmented skin
lesions at the
Instituto
Nazionale
Tumori of Milan
45 / 54 VI (no
algorithm)
Single
observer
Subjective
impression
Plastic
surgeon
 
Histology plus
other (31% of
benign had
expert dx)
MM: 18
BN: 25
18/43; 42%
Only 43
lesions had
complete
clinical and
histological
information.
11 lesions not
surgically
removed had
only clinical
diagnosis
(benign) and
were not
included in
the final
accuracy
analysis
Green
1994
NC
NR-CS
Australia
Secondary
Pigmented
lesions for
excision
129 /
164
VI (no
algorithm)
Single
observer
Subjective
impression;
clinical dx
recorded
NR  
Histology
MM 18; MiS 3
BN 128; misc
pigmented
lesions including
SK, BCC,
lentigines 15
18/164; 11%
 
Kopf 1975 NC
R-CS
US
Specialist
clinic
All lesions
subject to biopsy
at the Oncology
Section of the
Skin and Cancer
Unit.
NR /
5538
VI (no
algorithm)
Single
observer
No details;
'clinical
diagnosis'
Oncologist  
Histology
MM 99
Other dx listed
only for false
positives
99/5538; 2%
 
Krahn
1998
WPC-tests
P-CS
Germany
Secondary
Excised
pigmented skin
lesions
80 / 80 VI (no
algorithm)
Single
observer
no details Dermatologist
(assumed)
 
Histology
MM 39
BN 40; SN 1
39/80; 49%
 
 
McGovern
1992
Pathway –
clear
Pathway -
clear
WPC-algs
P-CS
US
Community
PSL (>10mm)
excised to rule
out dysplasia,
lentigo maligna
or malignant
melanoma
179 /
237
 
VI (7-point;
(A)BCD)
In-person;
Single
7-point: >=2,
>=3, >=4
characteristics
present
(A)BCD: >=1,
>=2, >=3
characteristics
present
NR (presume
dermatologist)
experience.
NR
 
Histology
MM 6; MiS 6
BCC 4; SK 32;
BN 138; AK 6;
Other 45
6/211; 3%
32 lesions
unaccounted
for; 13
excluded due
to lesion size
of 8mm or
less. 192
evaluated for
ABCD and 3-
point; 205
evaluated for
7 point
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer
qual. (n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MM+MiS)
 
Exclusions
 
Viglizzo
2004
WPC-tests
NR-CS
Italy
Specialist
clinic
Pigmented skin
lesions
examined at the
Dermoscopy
Service and
undergoing
excisions; high
and medium risk
on dermoscopy
were selected
for excision and
2x2 can be
estimated only
for melanocytic
subgroup.
NR / 79 VI (no
algorithm)
Single
observer
 
No details
Dermatologist
(assumed)
 
Histology
Melanoma
(invasive): 11;
Melanoma (in
situ): 1
Melanocytic
lesion: 57
11/67 16%
 
 
Walter
2012
Pathway -
clear
MM
MM+MiS
Any
BPC
RCT
UK
Primary
Any suspicious
PSL that could
not immediately
be diagnosed as
benign
654/792
(control
arm
only)
 
VI (7-point)
Siascope (iv
arm)
In-person
(Single)
NR  
GP (n=28)
Nurse
practictioner.
(n=2)
Low
(excluded if
specialist
dermatology
training)
 
Histology/Clinical
FU(3-6
months)/Expert
dx
Control group
only:
MM 16; MiS 2
BCC 4; SK 20;
DF 2; lentigo 5;
‘benign’ 686;
unknown 10
16/773 2%
19 (5 due to
violation of
recruitment
criteria or
discontinued
protocol; 1
died; 4 did
not attend for
dermatology
assessment;
2 missing
histology; 7
not clearly
accounted
for)
Image-based      
Lorentzen
1999
WPC-tests
P-CS
Denmark
Secondary
Patients with
lesions
suspicious for
CMM referred to
outpatients clinic
232 /
232
 
VI (no
algorithm)
[Dermoscopy]
Single
observer
Subjective
impression;
clinical
diagnosis
Dermatologist  
Histology
MM 49
'malignant
melanoma'
BCC 16, SK
12; BN: 137
Other: 18
(including SN,
BD, and others)
49/232; 21%
Poor quality
index test
image 10
cases
excluded
Rao 1997 WPC-algs
(tests)
R-CS
US
Private
Patients with
atypical
melanocytic
lesions or
suspected early
malignant
melanoma
63 / 72  
VI (ABCD)
[Dermoscopy]
Single
observer
Diagnosis of
melanoma
Dermatology
registrar
 
Histology
MM 21
Atypical
melanocytic
nevus 51
21/72; 29%
None
#164d Visual inspection for the diagnosis of cutaneous melanoma in adults
244 / 256
Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer
qual. (n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MM+MiS)
 
Exclusions
Scope
2008
NC
R-CS
New
Zealand
Industry
image
database
Images of
pigmented skin
lesions selected
from a database
of standardised
patient images
provided by a
New
Zealand–based
teledermatology
company
(MoleMap);
images were
selected on the
basis that (1) at
least 8 clinically
atypical nevi
were apparent
on the back; (2)
most of the
lesions on the
back and all of
the atypical nevi
had close-up
clinical digital
images; (3) 1-
year follow-up
images (close-
up clinical and
dermoscopic
images) were
available to
show that
lesions
considered to be
benign were in
fact biologically
indolent by
revealing no
change; and (4)
the image quality
of both the
overview and the
close-up images
were acceptable
12 / 145  
VI (Ugly
duckling)
Single
observer
Lesion id as
'completely
different'
or somewhat
different from
the other
moles; (Bx)
decision.
Dermatologist  
Histology or FU
MM 5 'malignant
melanoma'
BN: 140
5/145; 3%
Unacceptable
image quality
Troyanova
2003
BPC/WPC-
tests
R-CCS
NR
Training
images
(source
NR)
Images of
pigmented skin
lesions selected
for a
dermoscopy
training study
NR / 50  
VI (no
algorithm)
[Dermoscopy]
Single
observer
Subjective
impression;
dx of
melanoma
Dermatologist  
Histology
MM: 25
'Benign': 25
25/50; 50%
NR
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients
/
lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer
qual. (n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MM+MiS)
 
Exclusions
Westerhoff
2000
WPC-tests
R-CCS
Australia
Training
images
(Specialist
unit)
Clinically
atypical
pigmented skin
lesions; 50
invasive
melanomas and
50
nonmelanomas
randomly
selected from
the Sydney
Melanoma Unit
pigmented skin
lesions (PSL)
image database.
NR /
100
VI (no
algorithm)
[Dermoscopy]
Single
observer
Subjective
impression;
dx of
melanoma
GP  
Histology or FU
MM 50
'Benign':50
50/100; 50%
None
NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS –
melanoma in situ (or lentigo maligna); BCC – basal cell carcinoma; SK – seborrhoeic keratosis; SN – Spitz nevi; AK – actinic
keratosis; BN – benign naevi; BD – Bowen’s disease; DF – dermatofibroma; FU – follow-up; R –retrospective; P –
prospective; CS – case series; CCS – case control study; WPC – within person comparison (of tests); BPC – between
person comparison (of tests); NC – non comparative; VI - visual inspection; RCT - randomised controlled trial; FU - follow-
up; Bx - biopsy; CMM - cutaneous malignant melanoma.
14 Summary study details – detection of any skin lesion requiring excision
Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion
criteria
No.
patients
/ lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MM+MiS)
 
Exclusions
In person          
 
Argenziano
2006
Any
RCT
Italy, Spain
Primary
Patients asking
for screening
or exhibiting
one or more
skin tumours
as seen during
routine
physical
examination
(patient-finding
screening).
Participating
PCPs
randomised to
either visual
inspection
alone or visual
inspection plus
dermoscopy;
only excised
lesions can be
included for
each arm.
NR / 85 VI (ABCD)
Dermoscopy
(3-point
checklist)
In person
(single
observer)
Subjective
impression ;
dx of
malignancy
GPs (n=37)
All trained in
ABCD rule
Histology
MM+MiS 6
BCC 37; SCC 10
Benign 32
53/85; 62%
Only those
patients who
were
considered to
have lesions
suggestive of
skin cancer
had histology
and could be
included; rest
had expert
diagnosis
(making full
dataset
ineligible for
this review)
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion
criteria
No.
patients
/ lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MM+MiS)
 
Exclusions
 
Chang
2013
Any
NC
R-CS
Taiwan
Secondary
Potentially
malignant
biopsied or
excised skin
lesions
(nontumour
specimens
excluded)
676 /
769
VI (no
algorithm)
In person
(single
observer)
Subjective
impression;
definitely
malignant
 
Dermatologists;
n= 25
Board-certified
 
Histology
MM 4; MiS 4
BCC: 110; cSCC:
20
'Benign'
diagnoses: 595
152/769; 20%
Poor quality
index test
image mis-
registered or
poor quality
images
(unfocused
or containing
a motion
artifact)
 
Ek 2005
Pathway –
clear
MM+MiS
Any
 
NC
P-CS
Australia
Specialist
clinic
Lesions
excised for
which
malignancy
could not be
excluded
1223 /
2582
VI (no
algorithm)
In person
Subjective
impression
Plastic surgeon
(n=4 or 5; mixed
experience; 3
consultants, 1
plastic surgery
trainee (usually
1st year, on 6
month rotation)
and a clinical
assistant)
Unclear
Histology
MM+MiS 23
BCC 1214; SCC
517; BD 188; SK
63; 577 other
benign (including
330 solar
keratosis)
1754/2582; 68%
Incomplete or
incorrectly
entered
proformas
were
excluded –
79 patients
with 96
lesions
 
McGovern
1992
Pathway –
clear
WPC-algs
P-CS
US
Community
PSL (>10mm)
excised to rule
out dysplasia,
lentigo maligna
or malignant
melanoma
179 /
237
 
VI (7-point;
(A)BCD)
In person;
Single
7-point: >=2,
>=3, >=4
characteristics
present
(A)BCD: >=1,
>=2, >=3
characteristics
present
NR (presume
dermatologist)
experience. NR
 
Histology
MM 6; MiS 6
BCC 4; SK 32;
BN 138; AK 6;
Other 45
15/192; 8%
32 lesions
unaccounted
for; 13
excluded due
to lesion size
of 8mm or
less. 192
evaluated for
ABCD and 3-
point; 205
evaluated for
7 point
 
Stanganelli
2000
Pathway –
clear
MM+MiS
Any
WPC
R-CS
Italy
Specialist
clinic
PSL referred
by
dermatologists
and general
practitioners
either for pre-
surgical
assessment or
consultation
NR /
3372
VI (ABCD)
Dermoscopy
(no
algorithm)
In person
(Single)
NR
Subjective
impression
NR (assumed
dermatologist -
described as
one of the co-
authors; n=1)
Histology /
Registry FU
MM+MiS 55
BCC 43; Benign
3274
98/3372; 3%
None
reported
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion
criteria
No.
patients
/ lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MM+MiS)
 
Exclusions
 
Steiner
1987
Pathway –
unclear
MM+MiS
P-CS
Austria
Specialist
clinic
 
Small (< 10
mm)
diagnostically
equivocal PSL;
no absolute
agreement on
clinical
diagnosis
among
investigating
clinicians at a
pigmented
lesion clinic.
NR /
318
 
1. VI (no
algorithm)
2.
Dermoscopy
(pattern)
In person
Subjective
impression
 
Dermatologists
(n=3; High
experience -
"experienced
dermatologists")
Consensus
diagnosis of 3
observers
 
Histology
MM 49; MiS 24
BCC 20
BN 143; SK 20;
lentigo simplex
and nevoid
lentigo 19; Other
15
93/318; 29%
None
reported
 
Walter
2012
Pathway -
clear
MM
MM+MiS
Any
BPC
RCT
UK
Primary
Any suspicious
PSL that could
not
immediately be
diagnosed as
benign
654/792
(control
arm
only)
 
VI (7-point)
Siascope (iv
arm)
In person
(Single)
NR  
GP (n=28)
Nurse
practitioner
(n=2)
Low (excluded if
specialist
dermatology
training)
 
Histology/Clinical
FU(3-6
months)/Expert
dx
Control group
only:
MM 16; MiS 2
BCC 4; SK 20;
DF 2; lentigo 5;
‘benign’ 686;
unknown 10
22/773; 3%
19 (5 due to
violation of
recruitment
criteria or
discontinued
protocol; 1
died; 4 did
not attend for
dermatology
assessment;
2 missing
histology; 7
not clearly
accounted
for)
Image-based      
 
Carli
2002b
Pathway –
unclear
WPC
R-CS
Italy
Secondary
Clinically
suspicious or
equivocal PSL
undergoing
excision for
diagnostic
purposes; all
<= 14mm
diameter
NR / 57  
1. VI (NR)
2.
Dermoscopy
(NR)
NR  
Dermatologists
(n=2)
Image-based;
high experience
('with
experience in
the field of
PSL');
consensus of 2
 
Histology
MM 6, MiS 5
BCC 10
BN 31, SK 1;
Other 4
20/54; 37%
4 ‘not
evaluables’
excluded (1
MM, 3
benign)
 
Rosendahl
2011
Pathway –
unclear
NC
R-CS
Australia
Primary
PSL submitted
for histology
from the
primary care
skin cancer
practice of one
author
389 /
463
 
1. VI (no
algorithm)
2.
Dermoscopy
(pattern)
1. subjective
impression
2. both
characteristics
present
 
Dermatologist
(n=1)
Image-based;
High experience
(confirmed by
author); Single
observer
 
Histology
MM 9; MiS 20
BCC 72; SCC 5
BN 217; BD 18;
AK 14*; BNM
140
* considered
malignant by
study authors
104/463; 22%
3 poor quality
images
excluded
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion
criteria
No.
patients
/ lesions
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(MM+MiS)
 
Exclusions
 
Stanganelli
1998
Pathway –
unclear
WPC
R-CS
Italy
Training
images
PSL images
selected from
computerised
files of the skin
cancer clinic.
NR / 30  
1. VI (no
algorithm)
2.
Dermoscopy
(no
algorithm)
NR  
Dermatologists
(n=20)
Image-based;
experience NR
(“experience in
ELM but (with)
no formal
training”);
average
 
Histology
MM+MiS 10
BCC 4
BN 10, SK 3,
Other 3
14/30; 47%
None
reported
NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS –
melanoma in situ (or lentigo maligna); BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; SK –
seborrheic keratosis; SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF –
dermatofibroma; FU – follow-up; R –retrospective; P – prospective; CS – case series; CCS – case control study; WPC –
within person comparison (of tests); BPC – between person comparison (of tests); NC – non comparative; GP - general
practitioner; VI - visual inspection; RCT - randomised controlled trial; SCC - squamous cell carcinoma; dx - diagnosis; ELM
– epiluminescence microscopy; PCP - primary care practitioner; WPC-algs - within person comparison of algorithms.
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